WO2025214344A1 - Kras inhibitor and pharmaceutical use thereof - Google Patents

Abstract

The present invention relates to a KRAS inhibitor and a pharmaceutical use thereof. In particular, the present invention relates to a KRAS inhibitor having the structure of formula (I), a preparation method therefor, a pharmaceutical composition containing same, a use thereof as a KRAS inhibitor, and a use thereof in the treatment of KRAS-related cancers or tumors. Each substituent in formula (I) is as defined in the description.

Description

A KRAS inhibitor and its pharmaceutical application Technical Field

The present invention belongs to the field of drug synthesis, and particularly relates to a KRAS inhibitor and its pharmaceutical application.

Background Art

The RAS gene family, which includes HRAS, KRAS, and NRAS, is a proto-oncogene that is frequently mutated in tumors. RAS proteins are mutated in 20-30% of human tumors. Aberrantly activated RAS proteins lead to malignant phenotypes in tumor cells, including dysregulation of cell growth and programmed cell death, increased invasiveness, and neoangiogenesis. Due to the high affinity of RAS for GTP/GDP and the lack of a clear drug binding pocket, the development of drugs targeting RAS proteins remains an unresolved issue.

Under physiological conditions, RAS proteins function as molecular switches, maintaining a dynamic equilibrium between an inactive, GDP-bound state and an activated, GTP-bound state. On the one hand, under stimulation by exogenous growth factors (such as EGFR and FGFR), guanine nucleotide exchange factors (GEFs) catalyze the conversion of RAS proteins from an inactive, GDP-bound form to an activated, GTP-bound form, thereby binding to downstream effector proteins and activating downstream signaling pathways. On the other hand, through the inherent GTPase activity of RAS proteins and the catalytic action of GTPase-activating proteins (GAPs), RAS reverts to its inactive, GDP-bound form.

Missense mutations in RAS proteins often lead to abnormal RAS activation, with mutations at amino acid positions glycine 12 (G12), glycine 13 (G13), and glutamine 61 (Q61) being the most common. These mutations disrupt the dynamic equilibrium of the GDP/GTP-bound state of RAS, causing the RAS protein to be more frequently in the activated GTP-bound state, leading to sustained activation of RAS downstream signaling pathways.

In human tumors, KRAS mutations are the most common mutation subtype of the RAS family. Studies have found that KRAS mutations are found in approximately 71% of pancreatic cancers, approximately 35% of small intestinal cancers, approximately 35% of colorectal cancers, approximately 26% of biliary tract cancers, approximately 17% of endometrial cancers, and approximately 19% of lung cancers. Among them, G12D/G12V/G12C/G13D mutations are the most common KRAS mutation type in pancreatic cancer, lung cancer, and colorectal cancer. In addition, recent studies suggest that targeting KRAS wild-type (KRAS WT)-dependent tumors may also bring certain therapeutic benefits.

However, due to the lack of a clear drug-binding pocket on the KRAS protein, the development of KRAS inhibitors has been challenging. Recent studies have discovered a previously undiscovered drug-binding pocket in the GDP-bound state of the mutant KRAS G12C protein. Based on these new findings, covalent inhibitors targeting KRAS G12C have become a hot topic in the development of KRAS inhibitors and have made some clinical progress. However, in addition to the G12C mutation, targeting other activating KRAS mutations remains an urgent task, including mutations such as KRAS G12D/G12V/G13D. On the other hand, studies have found that there is a certain probability of drug resistance after treatment with KRAS G12C inhibitors, and that abnormal KRAS activation may be restored through mutations such as KRAS G12D/G12R/G12V/G12W/G13D.

Therefore, it is necessary to continue to develop safe and effective pan-KRAS inhibitors to treat more patients with KRAS mutations/KRAS-dependent tumors and to overcome resistance to KRAS G12C inhibitors.

Summary of the Invention

The present invention aims to provide a KRAS inhibitor and its pharmaceutical application. The compounds of the present invention have a strong inhibitory effect on KRAS and can be widely used in the preparation of drugs for treating and/or preventing KRAS-related cancers or tumors, thus potentially leading to the development of a new generation of KRAS inhibitors.

The first aspect of the present invention provides a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:

in, is a double bond or a single bond;

Y ₁ is O, S, N, N (R _9a ), CH ₂ , CH, CH ₂ CH ₂ or CH=CH; Y ₂ is O, S, N, N (R _9b ), CH ₂ , CH, CH ₂ CH ₂ or CH=CH; Y ₃ is O, S, N, N (R _9c ), CH ₂ , CH, CH ₂ CH ₂ or CH=CH;

_Z1 is N or C( _R10a ); _Z2 is N or C( _R10b );

Ring A is selected from the following structures:

_R1 is selected from _C3-12 cycloalkyl, _C1-10 alkyl substituted with 3-12 membered heterocyclyl and 5-10 membered heteroaryl, _R2 is selected from hydrogen, _C1-10 alkyl, _C2-10 alkenyl, _C2-10 alkynyl, C3-12 cycloalkyl and _3-12 membered heterocyclyl, or, _R1 and _R2 together with the nitrogen atom to which they are directly attached form a 4-12 membered heterocyclyl, said 4-12 membered heterocyclyl being optionally fused to a 5-10 membered heteroaryl, said group being optionally further substituted with one or more radicals selected from deuterium, halogen, cyano, _C1-10 alkyl, _C2-10 alkenyl, _C2-10 alkynyl, C3-12 cycloalkyl, _3-12 membered heterocyclyl, _C6-10 aryl, 5-10 membered heteroaryl, =O, =S, _-C0-8 alkyl- _SF5 , -C _-Co- 8alkyl-S(O)(═NR ₁₂ )R ₁₃ , -Co _- 8alkyl-N═S(O)R ₁₃ R ₁₄ , -Co _- 8alkyl-N═SR ₁₃ R ₁₄ , -Co _- 8alkyl-OS(O) ₂ R ₁₅ , -Co _- 8alkyl-S(O) _r R ₁₅ , -Co _- 8alkyl-OR ₁₆ , -Co _- 8alkyl-C(O)OR ₁₆ , -Co _- 8alkyl-C(O)SR ₁₆ , -Co _- 8alkyl-SC(O)R ₁₇ , -Co _- 8alkyl-C(O)R ₁₇ , -Co _- 8alkyl-OC(O)R ₁₇ , -Co _- 8alkyl-P(O)(R ₁₇ ) ₂ , -Co _- 8alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C(＝NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(＝NR ₁₉ )R ₁₇ , -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, ＝O, ＝S, -C _0-8 alkyl-SF ₅ , -C _-Co- 8alkyl-S(O)(═NR ₁₂ )R ₁₃ , -Co _- 8alkyl-N═S(O)R ₁₃ R ₁₄ , -Co _- 8alkyl-N═SR ₁₃ R ₁₄ , -Co _- 8alkyl-OS(O) ₂ R ₁₅ , -Co _- 8alkyl-S(O) _r R ₁₅ , -Co _- 8alkyl-OR ₁₆ , -Co _- 8alkyl-C(O)OR ₁₆ , -Co _- 8alkyl-C(O)SR ₁₆ , -Co _- 8alkyl-SC(O)R ₁₇ , -Co _- 8alkyl-C(O)R ₁₇ , -Co _- 8alkyl-OC(O)R ₁₇ , -Co _- 8alkyl-P(O)(R ₁₇ ) ₂ , -Co _- 8alkyl-NR ₁₈ R ₁₉ , _-C0-8alkyl -C(= _NR18 ) _R17 , _-C0-8alkyl -N( _R18 )-C(= _NR19 ) _R17 , _-C0-8alkyl -C(O) _{NR18R19 and -C0-8alkyl} -N( _R18 )-C(O) _R17 ;

each R ₃ and each R ₄ are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -Co _0-8 alkyl-SF ₅ , -Co _0-8 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -Co _0-8 alkyl-N═S(O)R ₁₃ R ₁₄ , -Co _0-8 alkyl-N═SR ₁₃ R ₁₄ , -Co _0-8 alkyl-OS(O) ₂ R ₁₅ , -Co _0-8 alkyl-S(O) _r R ₁₅ , -Co _0-8 alkyl-OR ₁₆ , -Co _0-8 alkyl-C(O)OR ₁₈ )R 17 , -C _0-8 alkyl-C(O)SR ₁₆ , -C _0-8 alkyl-SC(O)R ₁₇ , -C _0-8 alkyl-C(O)R ₁₇ , -C _0-8 alkyl-OC(O)R ₁₇ , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ , or R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, ＝O, ＝S, -Co _0-8 alkyl-SF ₅ , -Co _0-8 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -Co _0-8 alkyl-N＝S(O)R ₁₃ R ₁₄ , -Co _0-8 alkyl-N＝SR ₁₃ R ₁₄ , -Co _0-8 alkyl-OS(O) ₂ R ₁₅ , -C ₁₈ ) _{R 17} , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , _{-C 0-8} alkyl-C(═NR 18 )R ₁₇ , -C _0-8 alkyl-N( _{R 18 ) -C(═NR 19 )R 17 , -C 0-8 alkyl - C} (O _{) NR 18 R 19 and -C 0-8 alkyl-} substituted by a substituent of _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ ;

R ₅ is selected from -NR _11a R _11b , C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, C _2-10 alkenyl, C _1-10 alkylene, C _2-10 alkynyl, C _3-12 cycloalkyl, _3-12 membered heterocyclyl, C _6-10 aryl, C _6-10 aryl and 3-12 membered heterocyclyl, 5-10 membered heteroaryl, ＝O, ＝S, -C _0-8 alkyl-SF ₅ , -C _0-8 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -C _0-8 alkyl-N＝S(O)R ₁₃ R ₁₄ , -C _{17 、-C 0-8 alkyl-C(O)R 17 、} -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ 、-C _0-8 alkyl-NR _{18 R 19} 、-C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ 、-C _0-8 alkyl-N═SR 13 R ₁₄ 、-C _0-8 alkyl-OS(O) 2 R ₁₅ 、-C _0-8 alkyl-S(O) r R ₁₅ 、-C _0-8 alkyl-OR 16 、-C _0-8 alkyl-C(O)OR ₁₆ 、-C _0-8 alkyl-C(O) _{SR 16} 、-C _0-8 alkyl-SC(O _{)R 17 、} -C _0-8 alkyl-C(O)R ₁₇ 、-C _0-8 alkyl-OC(O _{)R 17 、 wherein the alkyl radical is a C 0-8 alkyl radical , ... ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​} 18 )R ₁₇ , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR 18 R ₁₉ , -C _0-8 alkyl-C(═NR 18 ) _{R 17} , -C _0-8 alkyl-N═SR ₁₃ R ₁₄ , -C _0-8 alkyl-OS(O) 2 R 15 , -C _0-8 alkyl-S(O) r R ₁₅ , -C _0-8 alkyl-OR 16 , -C _0-8 alkyl-C(O)OR ₁₆ , -C 0-8 alkyl-C(O)SR ₁₆ , -C _0-8 alkyl-SC(O)R ₁₇ , -C _0-8 alkyl-C(O)R ₁₇ , -C _0-8 alkyl-OC(O)R ₁₇ , -C _0-8 alkyl-P(O)(R 17 ) 2 , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C 0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ ;

each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -Co _0-8 alkyl-SF ₅ , -Co _0-8 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -Co _0-8 alkyl-N═S(O)R ₁₃ R ₁₄ , -Co _0-8 alkyl-N═SR ₁₃ R ₁₄ , -Co _0-8 alkyl-OS(O) ₂ R ₁₅ , -Co _0-8 alkyl-S(O) _r R ₁₅ , -Co _0-8 alkyl-OR ₁₆ , -C _0-8 alkyl-C(O)OR ₁₆ , -C _0-8 alkyl-C(O)SR ₁₆ , -C _0-8 alkyl-SC(O)R ₁₇ , -C _0-8 alkyl-C(O)R ₁₇ , -C _0-8 alkyl-OC(O)R ₁₇ , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ ;

R ₇ is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -C _0-8 alkyl-SF ₅ , -C _0-8 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -C _0-8 alkyl-N═S(O)R ₁₃ R ₁₄ , -C _0-8 alkyl-N═SR ₁₃ R ₁₄ , -C _0-8 alkyl-OS(O) ₂ R ₁₅ , -C _0-8 alkyl-S(O) _r R ₁₅ , -C _0-8 alkyl-OR ₁₆ , -C -C _0-8 alkyl-C(O)OR ₁₆ , -C _0-8 alkyl-C(O)SR ₁₆ , -C _0-8 alkyl-SC(O)R ₁₇ , -C _0-8 alkyl-C(O)R ₁₇ , -C _0-8 alkyl-OC(O)R ₁₇ , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ ;

Each R ₈ is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, cyano-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -Co _0-8 alkyl-SF ₅ , _{-Co 0-8 alkyl} -S(O)(═NR ₁₂ )R ₁₃ , -Co _0-8 alkyl-N═S(O)R ₁₃ R ₁₄ , -Co _0-8 alkyl-N═SR ₁₃ R ₁₄ , -Co _0-8 alkyl-OS(O) ₂ R ₁₅ , -Co _0-8 alkyl-S(O) _r R ₁₅ 18 )R ₁₇ , -C _0-8 alkyl-C(═NR _{18 )} R ₁₇ , -C _0-8 alkyl-N ₍ R ₁₈ )-C _{( ═NR 19} )R _{17 ,} -C _0-8 alkyl-C ₍ O _{) NR 18 R 19 and -C 0-8 alkyl} - _N ( _{R 18 ) -C} (O _{) R 17} ;

R _9a , R _9b and R _9c are each independently selected from hydrogen, cyano, C _1-10 alkyl, C _2-10 alkenyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -Co _0-8 alkyl-S(O) _r R ₁₅ , -Co _0-8 alkyl-OR ₁₆ , -Co _0-8 alkyl-C(O)OR ₁₆ , -Co _0-8 alkyl-C(O)SR ₁₆ , -Co _0-8 alkyl-C(O)R ₁₇ , -Co _0-8 alkyl-OC(O)R ₁₇ , -Co _0-8 alkyl-NR ₁₈ R ₁₉ , -Co _0-8 alkyl-C(O)NR ₁₈ R ₁₉ and -Co _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ , the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, _3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, ＝O, ＝S, -Co _-8 alkyl-SF ₅ , -Co _-8 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -Co _-8 alkyl-N＝S(O)R ₁₃ R ₁₄ , -Co _-8 alkyl-N＝SR ₁₃ R ₁₄ , -Co _-8 alkyl-OS(O) ₂ R ₁₅ , -Co _-8 alkyl-S(O) _r R ₁₅ 18 )R ₁₇ , -C _0-8 alkyl-C( _{═NR 18 )} R ₁₇ , -C _0-8 alkyl-N ₍ R ₁₈ )-C _{( ═NR 19} )R _{17 ,} -C _0-8 alkyl-C ₍ O _{) NR 18 R 19 and -C 0-8} alkyl- _N ( _{R 18 ) -C} (O _{) R} substituted by a substituent of ₁₇ ;

R _10a and R _10b are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -Co _0-8 alkyl-SF ₅ , -Co _0-8 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -Co _0-8 alkyl-N═S(O)R ₁₃ R ₁₄ , -Co _0-8 alkyl-N═SR ₁₃ R ₁₄ , -Co _0-8 alkyl-OS(O) ₂ R ₁₅ , -Co _0-8 alkyl-S(O) _r R ₁₅ , -Co _0-8 alkyl-OR ₁₆ , -Co _0-8 alkyl-C(O)OR ₁₆ , -C _0-8 alkyl-C(O)SR ₁₆ , -C _0-8 alkyl-SC(O)R ₁₇ , -C _0-8 alkyl-C(O)R ₁₇ , -C _0-8 alkyl-OC(O)R ₁₇ , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ , and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ , the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, _3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, ＝O, ＝S, _{-Co 0-8 alkyl} -SF ₅ , -Co _0-8 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -Co _0-8 alkyl-N＝S(O)R ₁₃ R ₁₄ , -Co _0-8 alkyl-N＝SR ₁₃ R ₁₄ , -Co _0-8 alkyl-OS(O) ₂ R ₁₅ , -Co _0-8 alkyl-S(O) _r R ₁₅ , -Co ₁₈ )R ₁₇ , -Co _0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -Co _0-8 alkyl-N ₍ R ₁₈ )-C(═NR ₁₉ )R _{17 , -Co 0-8} alkyl-C _{( O ) NR 18 R 19 and -Co 0-8 alkyl - N} ( _{R 18} )-C ₍ O _{) R} substituted by a substituent of ₁₇ ;

R _11a and R _11b are each independently selected from hydrogen, deuterium, hydroxyl, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C _1-10 alkanoyl, and the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, hydroxyl, ═O, C _1-10 alkyl, C _2-10 alkenyl, C 2-10 alkynyl, C _1-10 alkylene, halogen-substituted C _1-10 alkylene, deuterium-substituted C _1-10 alkylene, _{halogen-substituted C 1-10 alkyl} , deuterium-substituted C substituted with a substituent selected _from the group consisting of a C _1-10 alkyl group, a C _1-10 alkoxy group, a C _3-12 cycloalkyl group, a C _3-12 cycloalkyloxy group, a 3-12 membered heterocyclyl group, a 3-12 membered heterocyclyloxy group, a C _6-10 aryl group, a C 6-10 aryloxy group, a 5-10 membered heteroaryl group, a _5-10 membered heteroaryloxy group, an amino group, a mono-C _1-10 alkylamino group, a di-C _1-10 alkylamino group, and a C _1-10 alkanoyl group;

Alternatively, R _11a and R _11b together with the nitrogen atom to which they are directly attached form a 4-10 membered heterocyclyl or 5-10 membered heteroaryl, wherein the 4-10 membered heterocyclyl or 5-10 membered heteroaryl is optionally further substituted by one or more groups selected from deuterium, halogen, hydroxy, =O, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _1-10 alkylene, halogen-substituted C _1-10 alkylene, deuterium-substituted C _1-10 alkylene, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, _{C 1-10} alkoxy, C _3-12 cycloalkyl, C _3-12 cycloalkyloxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, C _6-10 aryl, C _6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, mono-C substituted by _{C 1-10} alkylamino, diC _1-10 alkylamino and C _1-10 alkanoyl substituents;

Each R ₁₂ is independently selected from hydrogen, deuterium, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-10 cycloalkyl, 3-10 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -C _0-8 alkyl-S(O) _r R ₁₅ , -C _0-8 alkyl-C(O)OR ₁₆ , -C _0-8 alkyl-C(O)R ₁₇ and -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, _halogen -substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C ₁₈ )R 19, -C _0-8 alkyl-C(═NR _{18 ) R 17} , -C _0-8 alkyl-N ₍ R ₁₈ )-C ₍ ═NR ₁₉ )R _{17 ,} -C _0-8 alkyl-C ₍ O _{) NR 18 R 19 , and -C 0-8 alkyl} -N( _{R 18} ) _-C ( _O ) _R substituted by a substituent of ₁₇ ;

Each R ₁₃ and each R ₁₄ are independently selected from hydrogen, deuterium, hydroxy, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-10 cycloalkyl, 3-10 membered heterocyclyl, C _6-10 aryl and 5-10 membered heteroaryl, or, R ₁₃ and R ₁₄ together with the sulfur atom to which they are directly attached form a 3-10 membered heterocyclyl, which is optionally further substituted by one or more groups selected from deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _3-10 cycloalkyl, 3-10 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -C _0-8 alkyl-S(O) _r R ₁₅ , -C _{-C 0-8} alkyl-OR ₁₆ , -C _0-8 alkyl-C(O)OR ₁₆ , -C _0-8 alkyl-C(O)R ₁₇ , -C _0-8 alkyl-OC(O)R ₁₇ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ ;

each R ₁₅ is independently selected from hydrogen, deuterium, hydroxy, C _1-10 alkyl, C _2-10 alkenyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, and -NR ₁₈ R ₁₉ , each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, hydroxy, ═O, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _1-10 alkoxy, C _3-12 cycloalkyl, C _3-12 cycloalkyloxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, C _6-10 aryl, C _6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, and -NR ₁₈ R ₁₉ ;

each R ₁₆ is independently selected from hydrogen, deuterium, C _1-10 alkyl, C _2-10 alkenyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, and 5-10 membered heteroaryl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, hydroxy, =0, cyano, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _1-10 alkoxy, C _3-12 cycloalkyl, C _3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 _{membered heterocyclyloxy, C 6-10 aryl} , C _6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, and -NR ₁₈ R ₁₉ ;

Each R ₁₇ is independently selected from hydrogen, deuterium, hydroxy, C _1-10 alkyl, C _1-10 alkoxy, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, C _3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocycloxy, C _6-10 aryl, C _6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR ₁₈ R ₁₉ , and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxy, =O, cyano, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _1-10 alkoxy, C _3-12 cycloalkyl, C _3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocycloxy, C substituted by a substituent selected from the group consisting of C _6-10 aryl, C _6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, and -NR ₁₈ R ₁₉ ;

Each R ₁₈ and each R ₁₉ are independently selected from hydrogen, deuterium, hydroxyl, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C _1-10 alkanoyl, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =0, C _1-10 alkyl, C _{2-10 alkenyl, C 2-10 alkynyl} , halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _1-10 alkoxy, C _3-12 cycloalkyl, C substituted with a substituent selected from the group consisting of a _3-12 -membered cycloalkoxy group, a 3-12-membered heterocyclyl group, a _3-12 -membered heterocyclyloxy group, a C _6-10 aryl group, a C 6-10 aryloxy group, a 5-10-membered heteroaryl group, a 5-10-membered heteroaryloxy group, an amino group, a mono-C _1-10 alkylamino group, a di-C _1-10 alkylamino group, and a C _1-10 alkanoyl group;

Alternatively, R ₁₈ and R ₁₉ , together with the nitrogen atom to which they are directly attached, form a 4-10 membered heterocyclyl or 5-10 membered heteroaryl, which is optionally further substituted with one or more substituents selected from deuterium, halogen, hydroxy, ═O, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _1-10 alkoxy, C _3-12 cycloalkyl, C _3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, C _6-10 aryl, C _6-10 aryloxy, 5-10 membered heteroaryl, _5-10 membered heteroaryloxy, amino, mono-C _1-10 alkylamino, di-C _1-10 alkylamino, and C _1-10 alkanoyl;

m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3, 4, 5 or 6; o is 0, 1 or 2;

and each r is independently 0, 1 or 2.

As a preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, _R1 is selected from _C3-6 cycloalkyl, _C1-4 alkyl substituted with 3-6 membered heterocyclyl and 5-8 membered heteroaryl, _R2 is selected from hydrogen, _C1-4 alkyl, _C2-4 alkenyl, _C2-4 alkynyl, _C3-6 cycloalkyl and _3-6 membered heterocyclyl, or, _R1 and _R2 together with the nitrogen atom to which they are directly connected form a 4-12 membered heterocyclyl, the 4-12 membered heterocyclyl is optionally fused to a 5-10 membered heteroaryl, and the above groups are optionally further substituted with one or more groups selected from deuterium, halogen, cyano, _C1-4 alkyl, _C2-4 alkenyl, _C2-4 alkynyl, C3-6 cycloalkyl, _3-6 membered heterocyclyl, _C6-8 aryl, 5-8 membered heteroaryl, =O, =S, -C _-Co-4 alkyl- _SF5 , -Co _-4 alkyl-S(O)(= _NR12 ) _R13 , -Co _-4 alkyl-N=S(O) _R13R14 , -Co _{- 4} alkyl-N= _SR13R14 , -Co _-4 alkyl-OS(O) _2R15 , -Co _{- 4} alkyl- _S (O) _rR15 , -Co _{- 4} alkyl- _OR16 , -Co _-4 alkyl-C(O) _OR16 , -Co _{-4 alkyl} -C(O) _SR16 , -Co- ₄ alkyl-SC(O) _R17 , -Co- ₄ alkyl-C(O) _R17 , -Co- ₄ alkyl-OC(O) _R17 , -Co _-4 alkyl-P(O)( _R17 ) ₂ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(＝NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(＝NR ₁₉ )R ₁₇ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ substituents, the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -C _0-4 alkyl-SF ₅ , -C -C _0-4 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -C _0-4 alkyl-N═S(O)R ₁₃ R ₁₄ , -C _0-4 alkyl-N═SR ₁₃ R ₁₄ , -C _0-4 alkyl-OS(O) ₂ R ₁₅ , -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C _0-4 alkyl-C(O)OR ₁₆ , _{-C 0-4 alkyl} -C(O)SR ₁₆ , -C _0-4 alkyl-SC(O)R ₁₇ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , _-C0-4alkyl -C(= _NR18 ) _R17 , _-C0-4alkyl -N( _R18 )-C(= _NR19 ) _R17 , _-C0-4alkyl -C(O) _NR18R19 and _-C0-4alkyl -N( _R18 )-C(O) _{R17 ;}

each R ₃ and each R ₄ are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -Co _0-4 alkyl-SF ₅ , -Co _0-4 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -Co _0-4 alkyl-N═S(O)R ₁₃ R ₁₄ , -Co _0-4 alkyl-N═SR ₁₃ R ₁₄ , -Co _0-4 alkyl-OS(O) ₂ R ₁₅ , -Co _0-4 alkyl-S(O) _r R ₁₅ , -Co _0-4 alkyl-OR ₁₆ , -Co _0-4 alkyl-C(O)OR ₁₆ , -Co -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-SC(O)R ₁₇ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ , or R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 membered cycloalkyl or 4-6 membered heterocyclyl, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -Co _0-4 alkyl-SF ₅ , -Co _0-4 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -Co _0-4 alkyl-N＝S(O)R ₁₃ R ₁₄ , -Co _{0-4 alkyl} -N＝SR ₁₃ R ₁₄ , -Co _0-4 alkyl-OS(O) ₂ R ₁₅ , -Co _0-4 alkyl-S(O) _r R ₁₅ 18 )R ₁₇ , -C _0-4 alkyl-C( _{═NR 18} )R ₁₇ , _{-C 0-4 alkyl} -N ₍ R ₁₈ )-C ₍ ═NR _{19 )R 17 , -C 0-4 alkyl - C ( O} ) _{NR 18 R 19 and -C 0-4 alkyl - N} ( _{R 18 )} -C(O) _R substituted by a substituent of ₁₇ ;

R ₅ is selected from -NR _11a R _11b , C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-8 aryl and 5-8 membered heteroaryl, the above groups independently optionally further substituted by one or more selected from deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, C _2-4 alkenyl, C _1-4 alkylene, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, ＝O, ＝S, -C _0-4 alkyl-SF ₅ , -C _0-4 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -C _0-4 alkyl-N＝S(O)R ₁₃ R ₁₄ , -C _0-4 alkyl-N＝SR ₁₃ R ₁₄ , -C _0-4 alkyl-OS(O) ₂ R ₁₅ , -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-SC(O)R ₁₇ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ are substituted independently by one or more substituents selected from deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C 2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -C _0-4 alkyl-SF ₅ , -C _0-4 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -C _0-4 alkyl-N＝S(O)R ₁₃ R ₁₄ , -C _0-4 alkyl-N＝SR ₁₃ R ₁₄ , -C _{-C 0-4} alkyl-OS(O) ₂ R ₁₅ , -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-SC(O)R ₁₇ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C substituted by a substituent selected from -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ ;

Each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -C _0-4 alkyl-SF ₅ , -C _0-4 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -C _0-4 alkyl-N═S(O)R ₁₃ R ₁₄ , -C _0-4 alkyl-N═SR ₁₃ R ₁₄ , -C _0-4 alkyl-OS(O) ₂ R ₁₅ , -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-SC(O)R ₁₇ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ ;

R ₇ is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -C _0-4 alkyl-SF ₅ , -C _0-4 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -C _0-4 alkyl-N═S(O)R ₁₃ R ₁₄ , -C _0-4 alkyl-N═SR ₁₃ R ₁₄ , -C _0-4 alkyl-OS(O) ₂ R ₁₅ , -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-SC(O)R ₁₇ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ ;

each R ₈ is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _{3- 6} cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -Co _0-4 alkyl-SF ₅ , -Co _0-4 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -Co _0-4 alkyl-N＝S(O)R ₁₃ R ₁₄ , -Co _0-4 alkyl-N＝SR ₁₃ R ₁₄ , -Co _0-4 alkyl-OS(O) ₂ R ₁₅ , -Co _0-4 alkyl-S(O) _r R ₁₅ , -Co _0-4 alkyl-OR ₁₆ , -Co _-4 alkyl-C(O)OR ₁₆ , -Co _-4 alkyl-C(O)SR ₁₆ , -Co _-4 alkyl-SC(O)R ₁₇ , -Co _-4 alkyl-C(O)R ₁₇ , -Co _-4 alkyl-OC(O)R ₁₇ , -Co _-4 alkyl-P(O)(R ₁₇ ) ₂ , -Co _-4 alkyl-NR ₁₈ R ₁₉ , -Co _-4 alkyl-C(═NR ₁₈ )R ₁₇ , -Co _-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -Co _-4 alkyl-C(O)NR ₁₈ R ₁₉ and -Co _-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ ;

R _11a and R _11b are each independently selected from hydrogen, deuterium, hydroxyl, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C _1-10 alkanoyl, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, ═O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _{1-4 alkylene, halogen-substituted C 1-4 alkyl} , deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C substituted by _a C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino and C _1-4 alkanoyl substituents;

Alternatively, R _11a and R _11b together with the nitrogen atom to which they are directly attached form a 4-6 membered heterocyclyl or 5-8 membered heteroaryl, wherein the 4-6 membered heterocyclyl or 5-8 membered heteroaryl is optionally further substituted by one or more groups selected from deuterium, halogen, hydroxy, =O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino and C substituted with _1-4 alkanoyl substituents;

wherein R ₁₂ , R ₁₃ , R ₁₄ , R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as defined for the compound of formula (I).

As a preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R _9a , R _9b and R _9c are each independently selected from hydrogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C ₁₈ )-C(O)R ₁₇ , wherein the _above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -C _0-4 alkyl-SF ₅ , -C _0-4 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -C _0-4 alkyl-N＝S(O)R ₁₃ R ₁₄ , -C _0-4 alkyl-N＝SR ₁₃ R ₁₄ , -C _0-4 alkyl-OS(O) ₂ R ₁₅ , -C _{-C 0-4} alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-SC(O)R ₁₇ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C 0-4 alkyl substituted by a substituent of _0-4- alkyl-N(R ₁₈ )-C(O)R ₁₇ ;

R _10a and R _10b are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -Co _0-4 alkyl-SF ₅ , -Co _0-4 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -Co _0-4 alkyl-N═S(O)R ₁₃ R ₁₄ , -Co _0-4 alkyl-N═SR ₁₃ R ₁₄ , -Co _0-4 alkyl-OS(O) ₂ R ₁₅ , -Co _0-4 alkyl-S(O) _r R ₁₅ , -Co _0-4 alkyl-OR ₁₆ , -Co _0-4 alkyl-C(O)OR ₁₆ , -Co -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-SC(O)R ₁₇ , -C _0-4 alkyl-C(O)R ₁₇ , _{-C 0-4 alkyl} -OC(O)R ₁₇ , -C _0-4 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ , the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, nitro, azido, C _{1- 4-} membered heteroaryl, ═O, ═S, —C _{0-4- alkyl} -SF 5 , —C _{0-4- alkyl} -S(O)(═NR ₁₂ )R 13 , —C 0-4-alkyl-N═S(O)R ₁₃ R 14 , —C _0-4- alkyl-N═SR ₁₃ R ₁₄ , —C _0-4- alkyl-OS(O) ₂ R ₁₅ , —C _0-4- alkyl-S(O) _{r R 15} , —C _{0-4 -} alkyl-OR ₁₆ , —C _{0-4 -alkyl-C(O)OR 16 , —C 0-4- alkyl - C ( O ) SR 18} )R ₁₉ , -C _0-4 alkyl-C ₍ ═NR ₁₈ )R _{17 ,} -C _0-4 alkyl-C ₍ O _{) NR 18 R 19 , and -C 0-4 alkyl - N} ( _{R 18} ) _-C (O _{) R 17 ;}

wherein R ₁₂ , R ₁₃ , R ₁₄ , R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R _9a , R _9b and R _9c are each independently selected from hydrogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ , and the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -S(O)(＝NR ₁₂ )R ₁₃ , -N＝S(O)R ₁₃ R ₁₄ , -N＝SR ₁₃ R 14 , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R _{17 ,} -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(＝NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

R _10a and R _10b are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -S(O)(═NR ₁₂ )R ₁₃ , -N═S(O)R ₁₃ R 14 , -N═SR ₁₃ R ₁₄ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O) _{R 17 ,} -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(═NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ , the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ , -S(O)(═NR ₁₂ )R ₁₃ , -N═S(O)R ₁₃ R ₁₄ , -N═SR ₁₃ R ₁₄ , -OS(O) ₂ R _{R 15} , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(═NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

wherein R ₁₂ , R ₁₃ , R ₁₄ , R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, R _9a , R _9b and R _9c are each independently selected from hydrogen and C _1-4 alkyl, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl and 3-6 membered heterocyclyl;

R _10a and R _10b are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl and C _3-6 cycloalkyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium _- substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S and -SF ₅ .

As a preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R ₁₂ is independently selected from hydrogen, deuterium, C _1-4 alkyl, C _2-4 alkenyl, C 2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)R ₁₇ and -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C the alkyl group is substituted by a substituent selected from _{: -C 0-4} alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ ;

Each R ₁₃ and each R ₁₄ are independently selected from hydrogen, deuterium, hydroxy, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl and 5-8 membered heteroaryl, or, R ₁₃ and R ₁₄ together with the sulfur atom to which they are directly attached form a 3-6 membered heterocyclyl, which is optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ ;

each R ₁₅ is independently selected from hydrogen, deuterium, hydroxy, C _1-4 alkyl, C _2-4 alkenyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, and -NR ₁₈ R ₁₉ , each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, hydroxy, ═O, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 _membered heterocyclyloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, and -NR ₁₈ R ₁₉ ;

each R ₁₆ is independently selected from hydrogen, deuterium, C _1-4 alkyl, C _2-4 alkenyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, and 5-8 membered heteroaryl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, hydroxy, =0, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, and -NR ₁₈ R ₁₉ ;

Each R ₁₇ is independently selected from hydrogen, deuterium, hydroxy, C _1-4 alkyl, C _1-4 alkoxy, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, C _3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocycloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR ₁₈ R ₁₉ , and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxy, =O, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted _{C 1-4 alkyl} , C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocycloxy, C _6-8 aryl _, C substituted by _{a 6-8} membered aryloxy group, a 5-8 membered heteroaryl group, a 5-8 membered heteroaryloxy group, and a substituent selected from -NR ₁₈ R ₁₉ ;

Each R ₁₈ and each R ₁₉ are independently selected from hydrogen, deuterium, hydroxyl, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C _1-10 alkanoyl, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =0, C _1-4 alkyl, C 2-4 alkenyl, C _2-4 alkynyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, _3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C substituted by a C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino and C _1-4 alkanoyl substituents _;

Alternatively, R ₁₈ and R ₁₉ , together with the nitrogen atom to which they are directly attached, form a 4-6 membered heterocyclyl or 5-8 membered heteroaryl, which is optionally further substituted with one or more substituents selected from deuterium, halogen, hydroxy, ═O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkoxy, 3-6 membered heterocyclyl, _3-6 membered heterocyclyloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino, and C _1-4 alkanoyl;

and each r is independently 0, 1 or 2.

As a preferred embodiment, among the compounds of formula (I), stereoisomers thereof or pharmaceutically acceptable salts thereof, the compounds of formula (I) are compounds of formula (IIa), formula (IIb), formula (IIc), formula (IId), formula (IIe) or formula (IIf):

Wherein, each ring A is independently selected from the following structures:

each R ₁ is independently selected from C _3-6 cycloalkyl, C _1-4 alkyl substituted with 3-6 membered heterocyclyl and 5-8 membered heteroaryl, each R ₂ is independently selected from hydrogen, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl and _3-6 membered heterocyclyl, or, R ₁ and R ₂ together with the nitrogen atom to which they are directly attached form a 4-12 membered heterocyclyl, said 4-12 membered heterocyclyl being optionally fused to a 5-10 membered heteroaryl, which is optionally further substituted with one or more radicals selected from deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -S(O)(=NR ₁₂ )R _{13 18} )R ₁₇ , -C(＝NR ₁₈ ) _{R 17} , -C(＝NR _{19 )} R _{17 ,} -C(O) _{NR 18} R _{19 and} -N( _{R 18 )} -C(O) _{R 17 are} optionally substituted _{by one or more} substituents selected from deuterium, _{halogen , cyano , C 1-4} membered alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -S(O)(＝NR ₁₂ )R ₁₃ , -N＝S(O)R ₁₃ R ₁₄ , -N＝SR ₁₃ R ₁₄ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(═NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R ₃ and each R ₄ are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -S(O)(═NR ₁₂ )R ₁₃ , -N═S(O)R ₁₃ R ₁₄ , -N═SR ₁₃ R ₁₄ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R _{R 19} , -C(＝NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(＝NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(＝CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, the above groups being independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -S(O)(＝NR ₁₂ )R _{18 ) -C ( ═NR 19 ) R 17} , -C ₍ O _{) NR 18 R 19 and -N ( R 18 ) -C ( O ) R 17 ;}

each R ₅ is independently selected from -NR _11a R _11b , C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-8 aryl or 5-8 membered heteroaryl, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _1-4 alkylene, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -S(O)(＝NR ₁₂ )R ₁₃ , -N＝S(O)R ₁₃ R ₁₄ , -N＝SR ₁₃ R ₁₄ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ 17 、-C(O)OR ₁₆ 、-C(O)SR ₁₆ 、-SC(O)R ₁₇ 、-C(O)R ₁₇ 、-OC(O)R ₁₇ 、-P(O)(R ₁₇ ) ₂ 、-NR ₁₈ R ₁₉ 、-C(＝NR ₁₈ )R ₁₇ 、-N(R ₁₈ )-C(＝NR ₁₉ )R ₁₇ 、-C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ substituents, the above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene, C ₁₇ 、-P(O)(R 17 ) ₂ 、-NR 18 R ₁₉ 、-C(＝NR ₁₈ )R ₁₇ 、-N(R ₁₈ ) _{R 18} 、-P(O) ₍ R _{18 ) 、} -NR _{18 R 19 、} -C _{( ＝NR 18 ) R 18 、} -N _{( R 18 ) R 18} )-C(═NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -S(O)(═NR ₁₂ )R ₁₃ , -N═S(O)R ₁₃ R ₁₄ , -N═SR ₁₃ R 14 , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O) _{R 17 ,} -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(＝NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(＝NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -S(O)(═NR ₁₂ )R ₁₃ , -N═S(O)R ₁₃ R ₁₄ , -N═SR ₁₃ R 14 , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O) _{R 17 ,} -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(＝NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(＝NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R ₈ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -S(O)(═NR ₁₂ )R ₁₃ , -N═S(O)R ₁₃ R ₁₄ , -N═SR ₁₃ R ₁₄ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(＝NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(＝NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _11a and each R _11b are independently selected from hydrogen, deuterium, hydroxyl, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C _1-10 alkanoyl, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =0, C _1-4 alkyl, C 2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene _{, halogen-substituted C 1-4 alkyl} , deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C substituted with a C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino, and C _1-4 alkanoyl substituent;

Alternatively, R _11a and R _11b together with the nitrogen atom to which they are directly attached form a 4-6 membered heterocyclyl, which is optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, hydroxy, ═O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen _{-substituted C 1-4 alkylene} , deuterium-substituted C _1-4 alkylene, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C 6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino, and C _1-4 alkanoyl;

wherein R ₁₂ , R ₁₃ , R ₁₄ , R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r, m, n and o are as defined for the compound of formula (I).

As a preferred embodiment, among the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, the compound of formula (I) is a compound of formula (IIIa), formula (IIIb), formula (IIIc), formula (IIId), formula (IIIe) or formula (IIIf):

Wherein, each ring A is independently selected from the following structures:

Each R ₁ is independently selected from C _3-6 cycloalkyl, 3-6 membered heterocyclyl and C _1-4 alkyl substituted with 5-8 membered heteroaryl, each R ₂ is independently selected from hydrogen, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl and _3-6 membered heterocyclyl, or, R ₁ and R ₂ together with the nitrogen atom to which they are directly attached form a 4-12 membered heterocyclyl, said 4-12 membered heterocyclyl optionally being fused to a 5-10 membered heteroaryl, said groups optionally being further substituted with one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , which may be further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C 2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -S(O)(＝NR ₁₂ )R ₁₃ , -N＝S(O)R ₁₃ R ₁₄ , -N＝SR ₁₃ R ₁₄ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(═NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ 18 )R ₁₇ , -C(＝NR ₁₈ )R 17 , -C(＝NR 19 )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ are substituted by a substituent selected from the group consisting of: -S(O)(＝NR ₁₂ ) _{R 13} , -N＝S(O)R 13 R ₁₄ , -N＝SR ₁₃ R ₁₄ , -OS(O) 2 R 15 , -S(O) r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR 16 , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(＝NR ₁₈ )R ₁₇ , -N(R 18 )-C(＝NR 19 )R 17 , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R ₅ is independently selected from -NR _11a R _11b , C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-8 aryl or 5-8 membered heteroaryl, which are independently optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _1-4 alkylene, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , which are independently optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -S(O)(＝NR ₁₂ )R ₁₃ , -N＝S(O)R ₁₃ R ₁₄ , -N＝SR ₁₃ R ₁₄ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(═NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R _8a and each R _8b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _11a and each R _11b are independently selected from hydrogen, deuterium, hydroxyl, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C _1-10 alkanoyl, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =0, C _1-4 alkyl, C 2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene _{, halogen-substituted C 1-4 alkyl} , deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C substituted with a C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino, and C _1-4 alkanoyl substituent;

Alternatively, R _11a and R _11b together with the nitrogen atom to which they are directly attached form a 4-6 membered heterocyclyl, which is optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, hydroxy, ═O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen _{-substituted C 1-4 alkylene} , deuterium-substituted C _1-4 alkylene, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C 6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino, and C _1-4 alkanoyl;

wherein R ₁₂ , R ₁₃ , R ₁₄ , R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r, m and n are as defined for the compound of formula (I).

As a further preferred embodiment, among the compounds of formula (I), stereoisomers thereof or pharmaceutically acceptable salts thereof, the compounds of formula (I) are compounds of formula (IVa1), formula (IVb1), formula (IVc1), formula (IVd1), formula (IVe1) or formula (IVf1):

Wherein, each ring A is independently selected from the following structures:

Each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C 6-8 aryl and _3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c and the part to which they are directly attached together form a C _3-4 cycloalkyl or 3-4 membered heterocyclyl, R _5b or R _5c are otherwise defined as above, or, R _5a and R _5b and the carbon atom to which they are directly attached together form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(＝CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ;

each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R _8a and each R _8b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each s is independently 0 or 1;

wherein R ₁₂ , R ₁₃ , R ₁₄ , R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r and n are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, ＝O, ＝S, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , which are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

each R _5a and R _5b together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl group, which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, ＝O, ＝S, -SF ₅ , -OR ₁₆ , -C(O)OR ₁₆ , and -NR ₁₈ R ₁₉ ;

Each R _5c is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

Each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which _{they are directly attached form a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(＝CH ₂ ), which are independently optionally further substituted with one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ is substituted by a substituent;

Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C ₍ ═CH ₂ ), which groups are independently optionally further substituted with one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -NR ₁₈ R ₁₉ ;

wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano and C _1-4 alkyl, and the above groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl and deuterium-substituted C _1-4 alkyl;

each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl and -C(O)R ₁₇ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted _{C 1-4} alkyl, ═O, ═S and -OR ₁₆ ;

each R _5a and R _5b together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl group, which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl and deuterium-substituted C _1-4 alkyl;

Each R _5c is independently selected from hydrogen, deuterium, halogen, cyano and C _1-4 alkyl;

each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl and -SR ₁₅ , or R _5d and R _5e together with the carbon atom to which they are directly attached form C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _{1-4 alkyl and deuterium-substituted C 1-4 alkyl} ;

each R _5f and each R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _6-8 aryl, and C _6-8 aryl and 3-6 membered heterocyclyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ , and -OC(O)R ₁₇ ;

wherein R ₁₅ , R ₁₆ and R ₁₇ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers, or pharmaceutically acceptable salts thereof, each R _1a and each R _1b are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, and methyl, and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, and trideuteriomethyl;

each R _1c is independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl, and -C(O)R _17a , which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriummethyl, ═O, ═S, and hydroxy;

each R _5a and R _5b together with the carbon atom to which they are directly attached form a cyclopropyl or cyclobutyl group, which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl;

Each R _5c is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl and isopropyl;

each R _5d and each R _5e are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl and -S-CH ₃ , or R _5d and R _5e together with the carbon atom to which they are directly attached form C(=CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl;

Each R _5f and each R _5g are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, phenyl and The above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuteriomethyl, -OR _16a , -C(O)OR _16a and -OC(O)R _17a ;

R _16a is selected from pyrimidinyl, pyridyl, phenyl, amino and dimethylamino;

R _17a is selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino,

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , which are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

each R _5a and R _5b together with the carbon atom to which they are directly attached form C(═CH ₂ ), which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, ═O, ═S, —SF ₅ , —OR ₁₆ , —C(O)OR ₁₆ , and —NR ₁₈ R ₁₉ ;

each R _5c is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

each R _5d and each R _5e is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form a 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C ₍ ═CH ₂ ), which groups are independently optionally further substituted with one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -NR ₁₈ R ₁₉ ;

wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers, or pharmaceutically acceptable salts thereof, each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, and C _1-4 alkyl, and the above groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, and deuterium-substituted C _1-4 alkyl;

each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, and -C(O)R ₁₇ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted _{C 1-4 alkyl} , ═O, ═S, and -OR ₁₆ ;

Each R _5a and R _5b together with the carbon atom to which they are directly attached form C(=CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl and deuterium-substituted C _1-4 alkyl;

Each R _5c is independently selected from hydrogen, deuterium, halogen, cyano and C _1-4 alkyl;

each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl and -SR ₁₅ , or R _5d and R _5e together with the carbon atom to which they are directly attached form C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _{1-4 alkyl and deuterium-substituted C 1-4 alkyl} ;

each R _5f and each R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _6-8 aryl, and C _6-8 aryl and 3-6 membered heterocyclyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ , and -OC(O)R ₁₇ ;

wherein R ₁₅ , R ₁₆ and R ₁₇ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers, or pharmaceutically acceptable salts thereof, each R _1a and each R _1b are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, and methyl, and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, and trideuteriomethyl;

each R _1c is independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl, and -C(O)R _17a , which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriummethyl, ═O, ═S, and hydroxy;

Each R _5a and R _5b together with the carbon atom to which they are directly attached form C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl;

Each R _5c is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl and isopropyl;

each R _5d and each R _5e are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl and -S-CH ₃ , or R _5d and R _5e together with the carbon atom to which they are directly attached form C(=CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl;

Each R _5f and each R _5g are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, phenyl and The above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuteriomethyl, -OR _16a , -C(O)OR _16a and -OC(O)R _17a ;

R _16a is selected from pyrimidinyl, pyridyl, phenyl, amino and dimethylamino;

R _17a is selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino,

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , which are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

each R _5a and R _5c together with the portion to which they are directly attached form a C _3-4 cycloalkyl group, which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, ＝O, ＝S, -SF ₅ , -OR ₁₆ , -C(O)OR ₁₆ , and -NR ₁₈ R ₁₉ ;

each R _5b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

Each of R _5d and R _5e is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ is substituted by a substituent;

Each of R _5f and R _5g is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -NR ₁₈ R ₁₉ ;

wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano and C _1-4 alkyl, and the above groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl and deuterium-substituted C _1-4 alkyl;

each R _1c is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl and -C(O)R ₁₇ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, ═O, ═S and -OR ₁₆ ;

Each R _5a and R _5c together with the part to which they are directly attached form a C _3-4 cycloalkyl group, which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl and deuterium-substituted C _1-4 alkyl;

Each R _5b is independently selected from hydrogen, deuterium, halogen, cyano and C _1-4 alkyl;

each of R _5d and R _5e is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl and -SR ₁₅ , or R _5d and R _5e together with the carbon atom to which they are directly attached form C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl and deuterium-substituted C _1-4 alkyl;

each R _5f and R _5g is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _6-8 aryl and _{C 6-8} aryl and 3-6 membered heterocyclyl, and the above groups are independently optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -OC(O)R ₁₇ ;

wherein R ₁₅ , R ₁₆ and R ₁₇ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers, or pharmaceutically acceptable salts thereof, each R _1a and each R _1b are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, and methyl, and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, and trideuteriomethyl;

each R _1c is independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl, and -C(O)R _17a , which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriummethyl, ═O, ═S, and hydroxy;

each R _5a and R _5c together with the moiety to which they are directly attached form a cyclopropyl or cyclobutyl group, which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl;

Each R _5b is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl and isopropyl;

each R _5d and R _5e is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl and -S-CH ₃ , or R _5d and R _5e together with the carbon atom to which they are directly attached form C(=CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl;

Each R _5f and each R _5g are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, phenyl and The above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuteriomethyl, -OR _16a , -C(O)OR _16a and -OC(O)R _17a ;

R _16a is selected from pyrimidinyl, pyridyl, phenyl, amino and dimethylamino;

R _17a is selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino,

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, in the compound of formula (IVa1), R _1a and R _1b are each independently selected from deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

R _1c is selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -NR ₁₈ R ₁₉ and -C(O)R ₁₇ , which are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, _{C 2-4 alkynyl} , C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ ;

R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _{6-8 aryl, C 6-8 aryl} and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

R _5d and R _5e are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), the above groups being independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a _3-6 -membered cycloalkyl group, a 3-6-membered heterocyclyl group, -OR ₁₆ , -NR ₁₈ R ₁₉ and -C(O)OR ₁₆ substituent;

R _5f and R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), the above groups being independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from the group consisting of a _3-6 -membered cycloalkyl group, a 3-6-membered heterocyclyl group, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -NR ₁₈ R ₁₉ ;

wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, in the compound of formula (IVa1), R _1a and R _1b are each independently selected from deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl and 3-6 membered heterocyclyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

R _1c is selected from hydrogen, deuterium, cyano, C _1-4 alkyl and -C(O)R ₁₇ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, ═O, ═S and -OR ₁₆ ;

R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl and C _3-6 cycloalkyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

R _5d and R _5e are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -C(O)OR ₁₆ ;

R _5f and R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5f and R _5g together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -NR ₁₈ R ₁₉ ;

wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, in the compound of formula (IVa1), R _1a and R _1b are each independently selected from deuterium, fluorine and chlorine;

R _1c is selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl and -C(O)R _17a , which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriummethyl, ═O, ═S and hydroxy;

R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, C _1-4 alkyl and C _3-6 cycloalkyl, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, hydroxyl and amino;

R _5d and R _5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH ₃ , phenyl and The above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, -OR _16a and -C(O)OR _16a ;

R _5f and R _5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH ₃ , phenyl and Alternatively, R _5f and R _5g together with the carbon atom to which they are directly attached form a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, -OR _16a , -C(O)OR _16a and -OC(O)R _17a ;

R _16a is selected from pyrimidinyl, pyridyl, phenyl, amino and dimethylamino;

R _17a is selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino,

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, in the compound of formula (IVa1), R _1a and R _1b are each independently hydrogen;

R _1c is -C(O)R ₁₇ , which is optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, _{C 1-4} alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _{6-8 aryl, C 6-8 aryl} and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

R _5d and R _5e are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ;

R _5f and R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), the above groups being independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ;

wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, in the compound of formula (IVa1), R _1a and R _1b are each independently hydrogen;

R _1c is -C(O)R ₁₇ , which is optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, ═O, ═S, and -OR _{16 ;}

R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl and C _3-6 cycloalkyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

R _5d and R _5e are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -C(O)OR ₁₆ ;

R _5f and R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5f and R _5g together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -NR ₁₈ R ₁₉ ;

wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, in the compound of formula (IVa1), R _1a and R _1b are each independently hydrogen;

R _1c is -C(O)R _17a , which is optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, ═O, ═S, and hydroxy;

R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, C _1-4 alkyl and C _3-6 cycloalkyl, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, hydroxyl and amino;

R _5d and R _5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH ₃ , phenyl and The above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, -OR _16a and -C(O)OR _16a ;

R _5f and R _5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH ₃ , phenyl and Alternatively, R _5f and R _5g together with the carbon atom to which they are directly attached form a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, -OR _16a , -C(O)OR _16a and -OC(O)R _17a ;

R _16a is selected from pyrimidinyl, pyridyl, phenyl, amino and dimethylamino;

R _17a is selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino,

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, in the compound of formula (IVa1), R _1a and R _1b are each independently hydrogen; R _1c is hydrogen;

R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _{6-8 aryl, C 6-8 aryl} and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

R _5d and R _5e are each independently selected from hydrogen, C _1-4 alkyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl and -S(O) _r R ₁₅ , the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

R _5f and R _5g are each independently selected from hydrogen, C _1-4 alkyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl and -S(O) _r R ₁₅ , the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; provided that R _5d and R _5f are not H at the same time;

wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, in the compound of formula (IVa1), R _1a and R _1b are each independently hydrogen; R _1c is hydrogen;

R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl and C _3-6 cycloalkyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

R _5d and R _5e are each independently selected from hydrogen, C _6-8 aryl and 3-6 membered heterocyclyl, and -S-CH ₃ , wherein the above groups are independently optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -C(O)OR ₁₆ ;

R _5f and R _5g are each independently selected from hydrogen, C _1-4 alkyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl and -S-CH ₃ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -NR ₁₈ R ₁₉ ; provided that R _5d and R _5f are not H at the same time; wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as defined in the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, in the compound of formula (IVa1), R _1a and R _1b are each independently hydrogen; R _1c is hydrogen;

R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl and cyclobutyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, hydroxyl and amino;

R _5d and R _5e are each independently selected from hydrogen or -S-CH ₃ ;

R _5f and R _5g are each independently selected from hydrogen, -CH ₂ -OC(O)R _17a and The above groups are independently optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl and trideuteriomethyl; provided that R _5d and R _5f are not H at the same time;

R _17a is selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino,

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, in the compound of formula (IVb1), formula (IVc1), formula (IVd1), formula (IVe1) or formula (IVf1), each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C substituted by a _6-8 membered aryl group, a 5-8 membered heteroaryl group, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ;

Each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -NR ₁₈ R ₁₉ and -C(O)R ₁₇ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5a , each R _5b and each R _5c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR _{18 R 19} , and the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C substituted by a _6-8 membered aryl group, a 5-8 membered heteroaryl group, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ;

wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, in the compound of formula (IVb1), formula (IVc1), formula (IVd1), formula (IVe1) or formula (IVf1), each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl and 3-6 membered heterocyclyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl and -C(O)R ₁₇ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted _{C 1-4} alkyl, ═O, ═S and -OR ₁₆ ;

each R _5a , each R _5b , and each R _5c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, and C _3-6 cycloalkyl, which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , and -NR ₁₈ R _{19 ;}

each R _5d and each R _5e is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -C(O)OR ₁₆ ;

Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -NR ₁₈ R ₁₉ is substituted by a substituent;

wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, in the compound of formula (IVb1), formula (IVc1), formula (IVd1), formula (IVe1) or formula (IVf1), each R _1a and each R _1b are independently selected from hydrogen, deuterium, fluorine and chlorine;

each R _1c is independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl, and -C(O)R _17a , which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriummethyl, ═O, ═S, and hydroxy;

each R _5a , each R _5b , and each R _5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, C _1-4 alkyl, and C _3-6 cycloalkyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, hydroxyl, and amino;

Each R _5d and each R _5e are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH ₃ , phenyl and The above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, -OR _16a and -C(O)OR _16a ;

Each R _5f and each R _5g are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH ₃ , phenyl and Alternatively, R _5f and R _5g together with the carbon atom to which they are directly attached form a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, -OR _16a , -C(O)OR _16a and -OC(O)R _17a ;

R _16a is selected from pyrimidinyl, pyridyl, phenyl, amino and dimethylamino;

R _17a is selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino,

As a further preferred embodiment, among the compounds of formula (I), stereoisomers thereof or pharmaceutically acceptable salts thereof, the compounds of formula (I) are compounds of formula (IVa2), formula (IVb2), formula (IVc2), formula (IVd2), formula (IVe2) or formula (IVf2):

Wherein, each ring A is independently selected from the following structures:

each R _1a , each R _1b , and each R _1c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ , and -NR ₁₈ R ₁₉ , which are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C 6-8 aryl and _3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c and the part to which they are directly attached together form a C _3-4 cycloalkyl or 3-4 membered heterocyclyl, R _5b or R _5c are otherwise defined as above, or, R _5a and R _5b and the carbon atom to which they are directly attached together form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ;

each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R _8a and each R _8b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each s is independently 0 or 1;

wherein R ₁₂ , R ₁₃ , R ₁₄ , R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r and n are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a , each R _1b and each R _1c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, ＝O, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

wherein R ₁₆ , R ₁₈ and R ₁₉ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a , each R _1b and each R _1c are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino, and the above groups are optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino.

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a , each R _1b and each R _1c are independently hydrogen. As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c together with the part to which they are directly connected form a C _3-4 cycloalkyl or 3-4 membered heterocyclyl, R _5b or R 5c is another definition as described above, or, R _5a and R _5b together with the carbon atom to which they are directly connected form C(＝CH ₂ ), R _5c is defined as described above, _and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen, C substituted by a C _1-4 alkyl group, a deuterium-substituted C _1-4 alkyl group, a C _3-6 cycloalkyl group, a 3-6 membered heterocyclic group, -OR ₁₆ and -NR ₁₈ R ₁₉ substituent;

each R _5d and each R _5e are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5d and R _5e, together with the carbon atom to which they are directly attached, form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R _5f and each R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5f and R _5g , together with the carbon atom to which they are directly attached, form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino; or, R _5a and one of R _5b or R _5c together with the part to which they are directly attached form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine or azetidinyl group, and R _5b or R _5c are otherwise defined as above; or, R _5a and R _5b together with the carbon atom to which they are directly attached form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino;

each R _5d and each R _5e is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxy, amino and dimethylamino; or, R _5d and R _5e, taken together with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino;

Each R _5f and each R _5g are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxy, amino and dimethylamino; or, R _5f and R _5g , together with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(=CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino.

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium and fluorine;

each R _5d and each R _5e are each independently hydrogen;

Each R _5f and each R _5g are independently hydrogen. As a further preferred embodiment, the compound of formula (I), its stereoisomers, or pharmaceutically acceptable salts thereof, wherein the compound of formula (I) is a compound of formula (IVa3), formula (IVb3), formula (IVc3), formula (IVd3), formula (IVe3), or formula (IVf3):

Wherein, each ring A is independently selected from the following structures:

Each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C 6-8 aryl and _3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c and the part to which they are directly attached together form a C _3-4 cycloalkyl or 3-4 membered heterocyclyl, R _5b or R _5c are otherwise defined as above, or, R _5a and R _5b and the carbon atom to which they are directly attached together form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ;

each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R _8a and each R _8b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each s is independently 0 or 1; each t is independently 0, 1 or 2;

wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r and n are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _{3- 6} cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

wherein R ₁₆ , R ₁₈ and R ₁₉ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a and each R _1b are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino, and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino;

Each R _1c is independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino, which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino.

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c together with the part to which they are directly connected form a C _3-4 cycloalkyl or 3-4 membered heterocyclyl, R _5b or R 5c is another definition as described above, or, R _5a and R _5b together with the carbon atom to which they are directly connected form C(＝CH ₂ ), R _5c is defined as described above, _and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen, C substituted by a C _1-4 alkyl group, a deuterium-substituted C _1-4 alkyl group, a C _3-6 cycloalkyl group, a 3-6 membered heterocyclic group, -OR ₁₆ and -NR ₁₈ R ₁₉ substituent;

each R _5d and each R _5e are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5d and R _5e, together with the carbon atom to which they are directly attached, form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R _5f and each R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5f and R _5g , together with the carbon atom to which they are directly attached, form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino; or, R _5a and one of R _5b or R _5c together with the part to which they are directly attached form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine or azetidinyl group, and R _5b or R _5c are otherwise defined as above; or, R _5a and R _5b together with the carbon atom to which they are directly attached form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino;

each R _5d and each R _5e is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxy, amino and dimethylamino; or, R _5d and R _5e, taken together with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino;

Each R _5f and each R _5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxy, amino and dimethylamino; or, R _5f and R _5g , together with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino.

As a further preferred embodiment, among the compounds of formula (I), stereoisomers thereof or pharmaceutically acceptable salts thereof, the compounds of formula (I) are compounds of formula (IVa4), formula (IVb4), formula (IVc4), formula (IVd4), formula (IVe4) or formula (IVf4):

Wherein, each ring A is independently selected from the following structures:

each R _1a is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , the above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R _1b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , the above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C 6-8 aryl and _3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c and the part to which they are directly attached together form a C _3-4 cycloalkyl or 3-4 membered heterocyclyl, R _5b or R _5c are otherwise defined as above, or, R _5a and R _5b and the carbon atom to which they are directly attached together form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ;

each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R _8a and each R _8b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each s is independently 0 or 1;

wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r and n are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

each R _1b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , which are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

wherein R ₁₆ , R ₁₈ and R ₁₉ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino, and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino;

each R _1b is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino, which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino;

Each R _1c is independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino, which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino.

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c together with the part to which they are directly connected form a C _3-4 cycloalkyl or 3-4 membered heterocyclyl, R _5b or R 5c is another definition as described above, or, R _5a and R _5b together with the carbon atom to which they are directly connected form C(＝CH ₂ ), R _5c is defined as described above, _and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen, C substituted by a C _1-4 alkyl group, a deuterium-substituted C _1-4 alkyl group, a C _3-6 cycloalkyl group, a 3-6 membered heterocyclic group, -OR ₁₆ and -NR ₁₈ R ₁₉ substituent;

each R _5d and each R _5e are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5d and R _5e, together with the carbon atom to which they are directly attached, form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R _5f and each R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5f and R _5g , together with the carbon atom to which they are directly attached, form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino; or, R _5a and one of R _5b or R _5c together with the part to which they are directly attached form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine or azetidinyl group, and R _5b or R _5c are otherwise defined as above; or, R _5a and R _5b together with the carbon atom to which they are directly attached form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino;

each R _5d and each R _5e is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxy, amino and dimethylamino; or, R _5d and R _5e, taken together with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino;

Each R _5f and each R _5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxy, amino and dimethylamino; or, R _5f and R _5g , together with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino.

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium and fluorine;

each R _5d and each R _5e are each independently hydrogen;

Each R _5f and each R _5g are each independently hydrogen.

As a further preferred embodiment, among the compounds of formula (I), stereoisomers thereof or pharmaceutically acceptable salts thereof, the compounds of formula (I) are compounds of formula (IVa5), formula (IVb5), formula (IVc5), formula (IVd5), formula (IVe5) or formula (IVf5):

Wherein, each ring A is independently selected from the following structures:

each R _1a is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -NR ₁₈ R ₁₉ , the above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R _1b and each R _1c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -NR ₁₈ R ₁₉ , the above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C 6-8 aryl and _3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c and the part to which they are directly attached together form a C _3-4 cycloalkyl or 3-4 membered heterocyclyl, R _5b or R _5c are otherwise defined as above, or, R _5a and R _5b and the carbon atom to which they are directly attached together form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ;

Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ;

each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R _8a and each R _8b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each s is independently 0 or 1;

wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r and n are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)NR ₁₈ R ₁₉ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

each R _1b and each R _1c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)NR ₁₈ R ₁₉ and -NR ₁₈ R ₁₉ , which are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

wherein R ₁₆ , R ₁₈ and R ₁₉ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, -C(O)NR ₁₈ R ₁₉ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino;

each R _1b and each R _1c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, -C(O)NR ₁₈ R ₁₉ and -NR ₁₈ R ₁₉ , which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino;

R ₁₈ and R ₁₉ are each independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine and azetidinyl.

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c together with the part to which they are directly connected form a C _3-4 cycloalkyl or 3-4 membered heterocyclyl, R _5b or R 5c is another definition as described above, or, R _5a and R _5b together with the carbon atom to which they are directly connected form C(＝CH ₂ ), R _5c is defined as described above, _and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen, C substituted by a C _1-4 alkyl group, a deuterium-substituted C _1-4 alkyl group, a C _3-6 cycloalkyl group, a 3-6 membered heterocyclic group, -OR ₁₆ and -NR ₁₈ R ₁₉ substituent;

each R _5d and each R _5e are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5d and R _5e, together with the carbon atom to which they are directly attached, form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R _5f and each R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5f and R _5g , together with the carbon atom to which they are directly attached, form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino; or, R _5a and one of R _5b or R _5c together with the part to which they are directly attached form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine or azetidinyl group, and R _5b or R _5c are otherwise defined as above; or, R _5a and R _5b together with the carbon atom to which they are directly attached form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino;

each R _5d and each R _5e is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxy, amino and dimethylamino; or, R _5d and R _5e, taken together with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino;

Each R _5f and each R _5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxy, amino and dimethylamino; or, R _5f and R _5g , together with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino.

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _{2-4 alkenyl, C 2-4} alkynyl and C _3-6 cycloalkyl _;

wherein R ₁₆ , R ₁₈ and R ₁₉ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino; or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(＝CH ₂ ), C(O), cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine or azetidinyl group, and the above groups are independently optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl and cyclobutyl.

As a further preferred embodiment, among the compounds of formula (I), stereoisomers thereof or pharmaceutically acceptable salts thereof, the compounds of formula (I) are compounds of formula (IVa6), formula (IVb6), formula (IVc6), formula (IVd6), formula (IVe6) or formula (IVf6):

Wherein, ring A is selected from the following structures:

Each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R _8a and each R _8b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _11a and each R _11b are independently selected from hydrogen, deuterium, hydroxyl, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C _1-10 alkanoyl, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =0, C _1-4 alkyl, C 2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene _{, halogen-substituted C 1-4 alkyl} , deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C substituted with a C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino, and C _1-4 alkanoyl substituent;

Alternatively, R _11a and R _11b together with the nitrogen atom to which they are directly attached form a 4-6 membered heterocyclyl, which is optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, hydroxy, ═O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen _{-substituted C 1-4 alkylene} , deuterium-substituted C _1-4 alkylene, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C 6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino, and C _1-4 alkanoyl;

wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r and n are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _{3- 6} cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

each R _1c is independently selected from hydrogen, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl and -C(O)R ₁₇ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a and each R _1b are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino, and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino;

each R _1c is independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, and -C(O)R _17a , which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino, and dimethylamino;

R _17a is selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino,

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R ₃ and each R ₄ together with the carbon atom to which they are directly attached form a C(＝CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclic group, and the above groups are independently optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, and C _3-6 cycloalkyl.

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R ₃ and each R ₄ together with the carbon atom to which they are directly attached form a C(=CH ₂ ), C(O), cyclopropyl, cyclobutyl, oxirane, oxetanyl, azirane or azetidinyl group, and the above groups are independently optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl and cyclobutyl.

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _11a and each R _11b are independently selected from hydrogen, hydroxyl, C _1-4 alkyl, C _3-6 cycloalkyl and -6-membered heterocyclyl, and the above groups are independently optionally further substituted by one or more substituents selected from deuterium, halogen, hydroxyl, =O, C _1-4 alkyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, 3-6-membered heterocyclyl, 3-6-membered heterocyclyloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino and C _1-4 alkanoyl;

Alternatively, R _11a and R _11b together with the nitrogen atom to which they are directly attached form a 4-6 membered heterocyclic group, which is optionally further substituted by one or more substituents selected from deuterium, halogen, hydroxy, ＝O, C _1-4 alkyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino and C _1-4 alkanoyl.

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _11a and each R _11b are independently selected from hydrogen, hydroxy, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine and azetidinyl, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, hydroxy, =0, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuterium, methylene, monofluoromethylene, difluoromethylene, methoxy, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, amino and dimethylamino;

Alternatively, R _11a and R _11b together with the nitrogen atom to which they are directly attached form an oxirane, oxetanyl, oxolanyl, oxhexyl, aziridine, azetidinyl, azetyl, azetyl, azetyl or azetyl group. The above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, hydroxyl, =0, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, methylene, monofluoromethylene, difluoromethylene, methoxy, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino and dimethylamino.

As a further preferred embodiment, among the compounds of formula (I), stereoisomers thereof or pharmaceutically acceptable salts thereof, the compounds of formula (I) are compounds of formula (IVa7), formula (IVb7), formula (IVc7), formula (IVd7), formula (IVe7) or formula (IVf7):

Wherein, each ring A is independently selected from the following structures:

Each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

each R _8a and each R _8b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

Each R _11a is independently selected from hydrogen, deuterium, hydroxyl, C _1-4 alkyl, C _1-4 alkylene, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl and 5-8 membered heteroaryl, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, _3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C substituted by _{a 6-8} membered aryloxy group, a 5-8 membered heteroaryl group, a 5-8 membered heteroaryloxy group, an amino group, a mono-C _1-4 alkylamino group, a di-C _1-4 alkylamino group, and a C _1-4 alkanoyl group;

Each R _11b is independently selected from hydrogen, deuterium, hydroxyl, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl and 5-8 membered heteroaryl, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, _{C 3-6} cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C substituted by _{a 6-8} membered aryloxy group, a 5-8 membered heteroaryl group, a 5-8 membered heteroaryloxy group, an amino group, a mono-C _1-4 alkylamino group, a di-C _1-4 alkylamino group, and a C _1-4 alkanoyl group;

Each R _11c is independently selected from hydrogen, deuterium, hydroxyl, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl and 5-8 membered heteroaryl, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, _{C 3-6} cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C substituted by _{a 6-8} membered aryloxy group, a 5-8 membered heteroaryl group, a 5-8 membered heteroaryloxy group, an amino group, a mono-C _1-4 alkylamino group, a di-C _1-4 alkylamino group, and a C _1-4 alkanoyl group;

wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r and n are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _{3- 6} cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

each R _1c is independently selected from hydrogen, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl and -C(O)R ₁₇ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -OR ₁₆ and -NR ₁₈ R ₁₉ ;

wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _1a and each R _1b are independently hydrogen;

Each R _1c is independently hydrogen.

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R ₃ and each R ₄ are independently hydrogen or deuterium.

As a further preferred embodiment, in the compound of formula (I), its stereoisomers, or pharmaceutically acceptable salts thereof, each R _11a is independently selected from hydrogen, deuterium, hydroxy, methyl, ethyl, and methylene, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, or hydroxy;

Each R _11b is independently selected from hydrogen, deuterium, hydroxyl, methyl and ethyl, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine or hydroxyl;

Each R _11c is independently selected from hydrogen, deuterium, hydroxy, methyl, ethyl and methylene, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine or hydroxy.

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each Each is independently selected from the following structures:

each R _6a , each R _6b , each R _6c and each R _6d are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ ;

wherein R ₁₆ , R ₁₈ and R ₁₉ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each Each is independently selected from the following structures:

Each R _6a , each R _6b , each R _6c and each R _6d are each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy, amino, monomethylamino and dimethylamino.

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -OC(O)R ₁₇ , -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R ₇ is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy, amino, monomethylamino and dimethylamino.

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _8a and each R _8b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ , -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ;

wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as defined for the compound of formula (I).

As a further preferred embodiment, in the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, each R _8a and each R _8b are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyano-substituted methyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, -SF ₅ , hydroxyl, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy, amino, monomethylamino and dimethylamino.

As the most preferred embodiment, the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof include but are not limited to the following compounds:

The second aspect of the present invention provides a pharmaceutical composition comprising a compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

The third aspect of the present invention also relates to the use of the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof in the preparation of drugs for treating KRAS-related tumors.

As a preferred embodiment, the KRAS-related tumor is a tumor associated with wild-type KRAS, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D or KRAS Q61H.

As a further preferred embodiment, the tumor is cancer.

As a further preferred embodiment, the tumor is adenoma, lymphoma, mesothelioma, lung cancer, esophageal cancer, gastric cancer, pancreatic cancer, liver cancer, bile duct cancer, gallbladder cancer, ampullary cancer, small intestine cancer, colorectal cancer, kidney cancer, testicular cancer, blood cancer, hemangioma, myeloma, chondroma, skull cancer, brain cancer, glioma, uterine cancer, vulvar cancer, vaginal cancer, fallopian tube cancer, bladder cancer, urethral cancer, prostate cancer, adrenal tumor, sarcoma, myxoma, rhabdomyoma, fibroma, lipoma, bronchial cancer, Hodgkin's disease, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, chondrodysplasia, psoriasis or neuroblastoma.

The present invention also relates to the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof, which are used to treat tumors associated with wild-type KRAS, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D or KRAS Q61H.

The present invention also relates to a method for treating KRAS-related tumors, comprising administering the compound of formula (I), its stereoisomers or pharmaceutically acceptable salts thereof to a patient in need thereof.

As a preferred embodiment, the tumor is adenoma, lymphoma, mesothelioma, lung cancer, esophageal cancer, gastric cancer, pancreatic cancer, liver cancer, bile duct cancer, gallbladder cancer, ampullary cancer, small intestine cancer, colorectal cancer, kidney cancer, testicular cancer, blood cancer, hemangioma, myeloma, chondroma, skull cancer, brain cancer, glioma, uterine cancer, vulvar cancer, vaginal cancer, fallopian tube cancer, bladder cancer, urethral cancer, prostate cancer, adrenal tumor, sarcoma, myxoma, rhabdomyoma, fibroma, lipoma, bronchogenic carcinoma, Hodgkin's disease, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, chondrodysplasia, psoriasis or neuroblastoma.

DETAILED DESCRIPTION

After extensive and in-depth research, the inventors of this application have developed, for the first time, a KRAS inhibitor having the structure of Formula (I) below. This series of compounds can be widely used in the preparation of drugs for treating and/or preventing KRAS-related cancers or tumors, and is expected to be developed into a new generation of KRAS inhibitors. This has led to the completion of the present invention.

Detailed Description: Unless otherwise stated or specifically indicated, the following terms used in the specification and claims have the following meanings.

"Alkyl" refers to a straight-chain or branched saturated aliphatic hydrocarbon group, preferably a straight-chain alkyl group and a branched alkyl group having 1 to 10, 1 to 6, or 1 to 4 carbon atoms, including but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl , 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,2-dimethylpentyl, 3,3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylhexyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl or its various branched chain isomers, etc. “C _1-10 alkyl” refers to a straight-chain alkyl group and a branched-chain alkyl group comprising 1 to 10 carbon atoms, “C _1-4 alkyl” refers to a straight-chain alkyl group and a branched-chain alkyl group comprising 1 to 4 carbon atoms, “C _0-8 alkyl” refers to a straight-chain alkyl group and a branched-chain alkyl group comprising 0 to 8 carbon atoms, and “C _0-4 alkyl” refers to a straight-chain alkyl group and a branched-chain alkyl group comprising 0 to 4 carbon atoms.

The alkyl group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, _3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, ＝O, ＝S, -Co _-8 alkyl-SF ₅ , -Co- ₈ alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -Co _-8 alkyl-N＝S(O)R ₁₃ R ₁₄ , -Co- ₈ alkyl-N＝SR ₁₃ R ₁₄ , -Co- ₈ alkyl-OS(O) ₂ R ₁₈ ) _{R 17} , -C _0-8 alkyl-C( _{═NR 18} )R _{17 , -C 0-8} alkyl- _{N (} R _{18 ) -C ( ═NR 19 ) R 17 , -C 0-8 alkyl -} C _{( O ) NR 18 R 19} and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ .

"Alkylene" refers to a group of the formula "=R", where "R" is an "alkyl" as defined above with two hydrogen atoms removed. Preferably, it includes straight-chain alkyl groups of 1 to 10, 1 to 6, or 1 to 4 carbon atoms and branched-chain alkyl groups with two hydrogen atoms removed, including but not limited to methylene (=CH ₂ ), ethylene (=CHCH ₃ ), hexylene (=CH(CH ₂ ) ₄ CH ₃ ), etc. For example, in the following compound: The arrow indicates the methylene group.

The alkylene group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -Co _0-8 alkyl-SF ₅ , -Co _0-8 alkyl-S(O)(═NR ₁₂ )R ₁₃ , _{-Co 0-8 alkyl} -N═S(O)R ₁₃ R ₁₄ , -Co _0-8 alkyl-N═SR ₁₃ R ₁₄ , -Co _0-8 alkyl-OS(O) ₂ R ₁₅ , -Co ₁₈ ) _{R 17} , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C ₍ ═NR 18 )R ₁₇ , -C _0-8 alkyl- _N ( _{R 18 ) -C(═NR 19 )R 17 , -C 0-8 alkyl -} C(O _{) NR 18 R 19 and -C 0-8 alkyl-} substituted by a substituent of _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ .

"Cycloalkyl" or "carbocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic aliphatic hydrocarbon substituent. The partially unsaturated cyclic hydrocarbon refers to a cyclic hydrocarbon that may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system. Cycloalkyl groups are divided into monocyclic cycloalkyl groups and polycyclic cycloalkyl groups. Preferably, the cycloalkyl group includes 3 to 12, 3 to 8 or 3 to 6 carbon atoms. For example, " _{C3-12cycloalkyl} " refers to a cycloalkyl group including 3 to 12 carbon atoms, " _{C3-10cycloalkyl} " refers to a cycloalkyl group including 3 to 10 carbon atoms, " _{C3-8cycloalkyl} " refers to a cycloalkyl group including 3 to 8 carbon atoms, _and " _{C3-6cycloalkyl} " refers to a cycloalkyl group including 3 to 6 carbon atoms, wherein:

Monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, and the like.

Polycyclic cycloalkyl groups include spiro, fused, and bridged cycloalkyl groups. "Spiroalkyl" refers to a polycyclic group in which the rings share a carbon atom (called a spiro atom). These may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Spiroalkyl groups are classified as monospiroalkyl, bispiroalkyl, or polyspiroalkyl groups based on the number of spiro atoms shared between the rings. Spiroalkyl groups include, but are not limited to:

"Fused cycloalkyl" refers to an all-carbon polycyclic group in which each ring shares a pair of adjacent carbon atoms with other rings in the system, wherein one or more rings may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Depending on the number of constituent rings, fused cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Fused cycloalkyl groups include, but are not limited to:

"Bridged cycloalkyl" refers to an all-carbon polycyclic group in which any two rings share two carbon atoms that are not directly connected. These may contain one or more (preferably 1, 2, or 3) double bonds, but no ring has a completely conjugated π electron system. Depending on the number of constituent rings, bridged cycloalkyl groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic. Bridged cycloalkyl groups include, but are not limited to:

The cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, wherein the ring connected to the parent structure is a cycloalkyl, including but not limited to indanyl, tetrahydronaphthyl, benzocycloheptanyl and the like.

The cycloalkyl group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, _3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, ＝O, ＝S, -Co _-8 alkyl-SF ₅ , -Co- ₈ alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -Co _-8 alkyl-N＝S(O)R ₁₃ R ₁₄ , -Co _-8 alkyl-N＝SR ₁₃ R ₁₄ , -Co _-8 alkyl-OS(O) ₂ R ₁₈ ) _{R 17} , -C _0-8 alkyl-C( _{═NR 18} )R _{17 , -C 0-8} alkyl- _{N (} R _{18 ) -C ( ═NR 19 ) R 17 , -C 0-8 alkyl -} C _{( O ) NR 18 R 19} and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ .

"Cycloalkylene" refers to a group of the formula "= _Ra ", wherein " _Ra " is a group obtained by removing two hydrogen atoms from a "cycloalkyl" as defined above. Preferably, the group includes a cycloalkyl group having 3 to 12, 3 to 8, or 3 to 6 carbon atoms, which has two hydrogen atoms removed, including but not limited to cyclopropylene. Cyclobutylene Cyclopentylene etc. For example, in the following compound: The arrow indicates the cyclopropylene group.

The cycloalkylene group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, ＝O, ＝S, -Co- ₈ alkyl-SF ₅ , -Co _{- 8} alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -Co _-8 alkyl-N＝S(O)R ₁₃ R ₁₄ , -Co _-8 alkyl-N＝SR ₁₃ R ₁₄ , -Co _-8 alkyl-OS(O) ₂ R ₁₈ ) _{R 17} , -C _0-8 alkyl-C( _{═NR 18} )R _{17 , -C 0-8} alkyl- _{N (} R _{18 ) -C ( ═NR 19 ) R 17 , -C 0-8 alkyl -} C _{( O ) NR 18 R 19} and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ .

"Heterocyclyl" or "heterocycle" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic aliphatic hydrocarbon substituent, wherein the partially unsaturated cyclic hydrocarbon refers to a cyclic hydrocarbon that may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system, and one or more (preferably 1, 2, 3 or 4) ring atoms in the heterocyclyl are selected from N, O, N·O or S(O) _r (wherein r is an integer of 0, 1 or 2), but does not include the ring portion of -OO-, -OS- or -SS-, and the remaining ring atoms are carbon. Preferably, the heterocyclyl comprises 3 to 12, 3 to 8 or 3 to 6 ring atoms, for example, "3-6 membered heterocyclyl" refers to a heterocyclyl comprising 3 to 6 ring atoms, "3-8 membered heterocyclyl" refers to a heterocyclyl comprising 3 to 8 ring atoms, "4-8 membered heterocyclyl" refers to a heterocyclyl comprising 4 to 8 ring atoms, "4-10 membered heterocyclyl" refers to a heterocyclyl comprising 4 to 10 ring atoms, "5-8 membered heterocyclyl" refers to a heterocyclyl comprising 5 to 8 ring atoms, and "3-12 membered heterocyclyl" refers to a heterocyclyl comprising 3 to 12 ring atoms.

Monocyclic heterocyclyl groups include, but are not limited to, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, oxetanyl, tetrahydrofuranyl, and the like.

Polycyclic heterocyclic groups include spiro rings, fused rings and bridged heterocyclic groups. "Spiro heterocyclic group" refers to a polycyclic heterocyclic group in which one atom (called a spiro atom) is shared between the monocyclic rings, wherein one or more (preferably 1, 2, 3 or 4) ring atoms are selected from N, O, N·O or S(O) _r (wherein r is an integer 0, 1, 2) heteroatoms, and the remaining ring atoms are carbon. These may contain one or more double bonds (preferably 1, 2 or 3), but no ring has a completely conjugated π electron system. Spiro heterocyclic groups are divided into single spiro heterocyclic groups, double spiro heterocyclic groups or multi-spiro heterocyclic groups according to the number of spiro atoms shared between the rings. Spiro heterocyclic groups include but are not limited to:

"Fused heterocyclic group" refers to a polycyclic heterocyclic group in which each ring in the system shares a pair of adjacent atoms with other rings in the system, one or more (preferably 1, 2, 3 or 4) rings may contain one or more (preferably 1, 2 or 3) double bonds, but no ring has a completely conjugated π electron system, wherein one or more (preferably 1, 2, 3 or 4) ring atoms are selected from N, O, N·O or S(O) _r (where r is an integer of 0, 1 or 2) heteroatoms, and the remaining ring atoms are carbon. Depending on the number of constituent rings, fused heterocyclic alkyl groups can be classified as bicyclic, tricyclic, tetracyclic or polycyclic. Fused heterocyclic groups include but are not limited to:

"Bridged heterocyclic group" refers to a polycyclic heterocyclic group in which any two rings share two atoms that are not directly connected. These may contain one or more (preferably 1, 2, or 3) double bonds, but none of the rings has a completely conjugated π electron system, wherein one or more (preferably 1, 2, 3, or 4) ring atoms are selected from N, O, N atoms, or S(O) _r (where r is an integer of 0, 1, or 2), and the remaining ring atoms are carbon. Depending on the number of constituent rings, bridged heterocyclic groups can be classified as bicyclic, tricyclic, tetracyclic, or polycyclic bridged heterocyclic groups. Bridged heterocyclic groups include, but are not limited to:

The heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclyl, including but not limited to:

The heterocyclic group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, _3-12 membered heterocyclic group, C _6-10 aryl, 5-10 membered heteroaryl, ＝O, ＝S, -Co-8 alkyl-SF ₅ , -Co _-8 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -Co _{-8 alkyl} -N＝S(O)R ₁₃ R 14 , -Co- ₈ alkyl-N＝SR ₁₃ R ₁₄ , -Co _{-8 alkyl} -OS(O) ₂ R ₁₈ ) _{R 17} , -C _0-8 alkyl-C( _{═NR 18} )R _{17 , -C 0-8} alkyl- _{N (} R _{18 ) -C ( ═NR 19 ) R 17 , -C 0-8 alkyl -} C _{( O ) NR 18 R 19} and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ .

"Heterocycloalkylene" refers to a group of the formula "=R _b ", wherein "R _b " is a group obtained by removing two hydrogen atoms from a "heterocycloalkyl" as defined above. Preferably, the group includes a group obtained by removing two hydrogen atoms from a heterocycloalkyl group having 3 to 12, 3 to 8, or 3 to 6 carbon atoms, including but not limited to an oxirane group. Aziridinyl etc. For example, in the following compound: The arrow indicates the box containing the oxirane group.

The heterocycloalkylene group may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, ＝O, ＝S, -Co- ₈ alkyl-SF ₅ , -Co _{- 8} alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -Co _-8 alkyl-N＝S(O)R ₁₃ R ₁₄ , -Co _-8 alkyl-N＝SR ₁₃ R ₁₄ , -Co _-8 alkyl-OS(O) ₂ R ₁₅ , -C _0-8 alkyl-S(O) _r R ₁₅ , -C _0-8 alkyl-OR ₁₆ , -C _0-8 alkyl-C(O)OR ₁₆ , -C _0-8 alkyl-C(O)SR ₁₆ , -C _0-8 alkyl-SC(O)R ₁₇ , -C _0-8 alkyl-C(O)R ₁₇ , -C _0-8 alkyl-OC(O)R ₁₇ , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ , _{-C 0-8} alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ .

"Aryl" or "aromatic ring" refers to an all-carbon monocyclic or fused polycyclic (i.e., rings that share adjacent pairs of carbon atoms) group, a polycyclic (i.e., rings with adjacent pairs of carbon atoms) group with a conjugated π electron system, preferably an all-carbon aryl group containing 6-10 or 6-8 carbon atoms, for example, "C _6-10 aryl" refers to an all-carbon aryl group containing 6-10 carbon atoms, including but not limited to phenyl and naphthyl, and "C _6-8 aryl" refers to an all-carbon aryl group containing 6-8 carbon atoms. The aryl ring can be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is the aryl ring, including but not limited to:

"Aryl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, _C1-10 alkyl, halogen-substituted C1-10 alkyl, deuterium-substituted _C1-10 alkyl, C2-10 alkenyl, _C2-10 alkynyl, C3-12 cycloalkyl, _3-12 membered heterocyclyl, C6-10 aryl, 5-10 membered heteroaryl, -Co- ₈ alkyl-SF5, -Co _- 8 alkyl-S(O)( _{=NR12 )R13} , -Co-8 alkyl-N=S(O)R13R14, -Co-8 alkyl-N=SR13R14, -Co _-8 alkyl-OS(O) _2R15 , -Co _-8 alkyl-SF5, -Co _-8 alkyl-S(O)(= _NR12 ) _R13 , -Co _-8 alkyl-N=S(O) _R13R14 , -Co-8 alkyl-N _{= SR13R14} , -Co _-8 alkyl-OS(O) _2R15 , -Co- ₈ alkyl- ₁₈ ) _{R 17} , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C ₍ ═NR 18 )R ₁₇ , -C _0-8 alkyl- _N ( _{R 18 ) -C(═NR 19 )R 17 , -C 0-8 alkyl -} C(O _{) NR 18 R 19 and -C 0-8 alkyl-} substituted by a substituent of _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ .

"Heteroaryl" refers to a heteroaromatic system containing one or more (preferably 1, 2, 3 or 4) heteroatoms, including N, O, N and S(O) _r (wherein r is an integer of 0, 1 or 2), preferably a heteroaromatic system containing 5-10, 5-8 or 5-6 ring atoms, for example, "5-8 membered heteroaryl" refers to a heteroaromatic system containing 5-8 ring atoms, and "5-10 membered heteroaryl" refers to a heteroaromatic system containing 5-10 ring atoms, including but not limited to furanyl, thienyl, pyridyl, pyrrolyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, imidazolyl, tetrazolyl, etc. The heteroaryl ring can be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, including but not limited to:

“Heteroaryl” may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -Co _0-8 alkyl-SF ₅ , -Co _0-8 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -Co _0-8 alkyl-N═S(O)R ₁₃ R ₁₄ , -Co _0-8 alkyl-N═SR ₁₃ R ₁₄ , -Co _0-8 alkyl-OS(O) ₂ R ₁₅ , -C _0-8 alkyl-S(O) _r R ₁₅ , -C _0-8 alkyl-OR ₁₆ , -C _0-8 alkyl-C(O)OR ₁₆ , -C _0-8 alkyl-C(O)SR ₁₆ , -C _0-8 alkyl-SC(O)R ₁₇ , -C _0-8 alkyl-C(O)R ₁₇ , -C _0-8 alkyl-OC(O)R ₁₇ , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ and -C substituted by a substituent of _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ .

"Alkenyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon double bond, preferably a straight-chain or branched alkenyl group containing 2 to 10 or 2 to 4 carbon atoms. For example, " _C2-10 alkenyl" refers to a straight-chain or branched alkenyl group containing 2 to 10 carbon atoms, and " _C2-4 alkenyl" refers to a straight-chain or branched alkenyl group containing 2 to 4 carbon atoms. Examples include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 1-, 2- or 3-butenyl, and the like.

"Alkenyl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, _C1-10 alkyl, halogen-substituted _C1-10 alkyl, deuterium-substituted _C1-10 alkyl, _C2-10 alkenyl, C2-10 alkynyl, _C3-12 cycloalkyl, _3-12 membered heterocyclyl, _C6-10 aryl, 5-10 membered heteroaryl, =O, =S, -Co- ₈ alkyl-SF5, -Co _-8 alkyl-S(O)(= _NR12 ) _R13 , -Co _{-8 alkyl} -N=S(O) _{R13R14 ,} -Co _-8 alkyl-N= _SR13R14 , -Co- ₈ alkyl-OS ₍ O) _{2R 18} ) _R 19 _, -C _0-8 alkyl-C( _{═NR 18} ) _{R 19} , -C _0-8 alkyl-N(R ₁₈ )-C _{( ═NR 19 ) R 19 , -C 0-8 alkyl - C ( O ) NR 18 R 19 and -C 0-8 alkyl-} substituted by a substituent of _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ .

"Alkynyl" refers to an alkyl group as defined above consisting of at least two carbon atoms and at least one carbon-carbon triple bond, preferably a straight-chain or branched alkynyl group containing 2-10 or 2-4 carbon atoms. For example, " _C2-10 alkynyl" refers to a straight-chain or branched alkynyl group containing 2-10 carbon atoms, and " _C2-4 alkynyl" refers to a straight-chain or branched alkynyl group containing 2-4 carbon atoms. Examples include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 1-, 2-, or 3-butynyl.

"Alkynyl" may be substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, _C1-10 alkyl, halogen-substituted _C1-10 alkyl, deuterium-substituted _C1-10 alkyl, _C2-10 alkenyl, C2-10 alkynyl, _C3-12 cycloalkyl, _3-12 membered heterocyclyl, _C6-10 aryl, 5-10 membered heteroaryl, =O, =S, -Co- ₈ alkyl-SF5, -Co _-8 alkyl-S(O)(= _NR12 ) _R13 , -Co _{-8 alkyl} -N=S(O) _{R13R14 ,} -Co _-8 alkyl-N= _SR13R14 , -Co- ₈ alkyl-OS ₍ O) _{2R 18} ) _R 19 _, -C _0-8 alkyl-C( _{═NR 18} ) _{R 19} , -C _0-8 alkyl-N(R ₁₈ )-C _{( ═NR 19 ) R 19 , -C 0-8 alkyl - C ( O ) NR 18 R 19 and -C 0-8 alkyl-} substituted by a substituent of _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ .

"Alkoxy" refers to an -O-alkyl group, wherein the definition of alkyl is as described above, for example, " _C1-10 alkoxy" refers to an alkyloxy group containing 1 _to 10 carbon atoms, " _C1-4 alkoxy" refers to an alkyloxy group containing 1 to 4 carbon atoms, and "C1-2 alkoxy" refers to an alkyloxy group containing 1 to 2 carbon atoms, including but not limited to methoxy, ethoxy, propoxy, butoxy, etc.

“Alkoxy” may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, ＝O, ＝S, -Co- ₈ alkyl-SF ₅ -Co- ₈ alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -Co- ₈ alkyl-N＝S(O)R ₁₃ R ₁₄ , -Co _-8 alkyl-N＝SR ₁₃ R ₁₄ , -Co _-8 alkyl-OS(O) ₂ R ₁₅ , -C _0-8 alkyl-S(O) _r R ₁₅ , -C _0-8 alkyl-OR ₁₆ , -C _0-8 alkyl-C(O)OR ₁₆ , -C _0-8 alkyl-C(O)SR ₁₆ , -C _0-8 alkyl-SC(O)R ₁₇ , -C _0-8 alkyl-C(O)R ₁₇ , -C _0-8 alkyl-OC(O)R ₁₇ , _{-C 0-8 alkyl} -P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ and -C substituted by a substituent of _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ .

"Cycloalkoxy" or "cycloalkyloxy" refers to -O-cycloalkyl, wherein cycloalkyl is as defined above, for example, "C _3-12 cycloalkoxy" refers to a cycloalkyloxy containing 3 to 12 carbon atoms, and "C _3-6 cycloalkoxy" refers to a cycloalkyloxy containing 3 to 6 carbon atoms, including but not limited to cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, and the like.

"Cycloalkoxy" or "cycloalkyloxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, _C1-10 alkyl, halogen-substituted _C1-10 alkyl, deuterium-substituted _C1-10 alkyl, _C2-10 alkenyl, _C2-10 alkynyl, _C3-12 cycloalkyl, _3-12 membered heterocyclyl, _C6-10 aryl, 5-10 membered heteroaryl, ＝O, ＝S, -Co _{- 8} alkyl- _SF5 , -Co _-8 alkyl-S(O)(＝ _NR12 ) _R13 , -Co- ₈ alkyl-N＝S(O) _R13R14 , -Co _{-8 alkyl} -N＝ _SR13R14 , -Co- ₈ alkyl- _{-C 0-8} alkyl-OS(O) ₂ R ₁₅ , -C _0-8 alkyl-S(O) _r R ₁₅ , -C _0-8 alkyl-OR ₁₆ , -C _0-8 alkyl-C(O)OR ₁₆ , -C _0-8 alkyl-C(O)SR ₁₆ , -C _0-8 alkyl-SC(O)R ₁₇ , -C _0-8 alkyl-C(O)R ₁₇ , _{-C 0-8 alkyl} -OC(O)R ₁₇ , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C The group is substituted by a substituent selected from the group consisting of _{-C 0-8} alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ .

"Heterocyclyloxy" or "heterocyclyloxy" refers to an -O-heterocyclyl group wherein heterocyclyl is as defined above and includes, but is not limited to, azetidinyloxy, oxetanyloxy, azopentyloxy, nitrogen, oxhexyloxy, and the like.

"Heterocyclyloxy" or "heterocyclyloxy" may be optionally substituted or unsubstituted. When substituted, the substituents are preferably one or more (preferably 1, 2, 3 or 4) of the following groups independently selected from deuterium, halogen, cyano, nitro, azido, _C1-10 alkyl, halogen-substituted _C1-10 alkyl, deuterium-substituted _C1-10 alkyl, _C2-10 alkenyl, _C2-10 alkynyl, _C3-12 cycloalkyl, _3-12 membered heterocyclyl, _C6-10 aryl, 5-10 membered heteroaryl, ＝O, ＝S, -Co _{-8 alkyl} - _SF5 , -Co _-8 alkyl-S(O)(＝ _NR12 ) _R13 , -Co- ₈ alkyl-N＝S(O) _{R13R14 ,} -Co _-8 alkyl- _N ＝ _SR13R14 , -C _{-C 0-8} alkyl-OS(O) ₂ R ₁₅ , -C _0-8 alkyl-S(O) _r R ₁₅ , -C _0-8 alkyl-OR ₁₆ , -C _0-8 alkyl-C(O)OR ₁₆ , -C _0-8 alkyl-C(O)SR ₁₆ , -C _0-8 alkyl-SC(O)R ₁₇ , -C _0-8 alkyl-C(O)R ₁₇ , _{-C 0-8 alkyl} -OC(O)R ₁₇ , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C The group is substituted by a substituent selected from the group consisting of _{-C 0-8} alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ .

"C _1-10 alkanoyl" refers to the monovalent atomic group remaining after removing the hydroxyl group from a C _1-10 alkyl acid, and is also commonly expressed as "C _{0- 9} alkyl-C(O)-", for example, "C ₁ alkyl-C(O)-" refers to acetyl; "C ₂ alkyl-C(O)-" refers to propionyl; "C ₃ alkyl-C(O)-" refers to butyryl or isobutyryl.

“—C _0-8 alkyl-S(O)(═NR ₁₂ )R ₁₃ ” means that the sulfur atom in —S(O)(═NR ₁₂ )R ₁₃ is bonded to a C _0-8 alkyl group, wherein the C _0-8 alkyl group is as defined above.

" _-C0-8alkyl -N=S(O) _R13R14 " means that _the nitrogen atom in -N= _S (O) _R13R14 is bonded to a _C0-8alkyl group, wherein the _C0-8alkyl group is as defined above.

" _-C0-8alkyl -N= _SR13R14 " _means that the nitrogen atom in -N= _SR13R14 is bonded to a _C0-8alkyl group, wherein the _C0-8alkyl group is _as defined above.

“—C _0-8 alkyl _- OS(O) ₂ R ₁₅ ” means that the oxygen atom in —OS(O) ₂ R ₁₅ is bonded to a C _0-8 alkyl group, wherein the C _0-8 alkyl group is as defined above.

“—C _0-8 alkyl-S(O) _r R ₁₅ ” means that the sulfur atom in —S(O) _r R ₁₅ is bonded to a C _0-8 alkyl group, wherein the C _0-8 alkyl group is as defined above.

"-C _0-8 alkyl-OR ₁₆ " means that the oxygen atom in -OR ₁₆ is bonded to a C _0-8 alkyl group, wherein the C _0-8 alkyl group is as defined above.

"-C _0-8 alkyl-C(O)OR ₁₆ " means that the carbonyl group in -C(O)OR ₁₆ is bonded to a C _0-8 alkyl group, wherein the C _0-8 alkyl group is as defined above.

“—C _0-8 alkyl-C(O)SR ₁₆ ” means that the carbonyl group in —C(O)SR ₁₆ is bonded to a C _0-8 alkyl group, wherein the C _0-8 alkyl group is as defined above.

"-C _0-8 alkyl-SC(O)R ₁₇ " means that the sulfur atom in -SC(O)R ₁₇ is bonded to a C _0-8 alkyl group, wherein the C _0-8 alkyl group is as defined above.

" _-C0-8alkyl -C(O) _R17 " means that the carbonyl group in -C(O) _R17 is connected to a _C0-8alkyl group, wherein the _C0-8alkyl group is as defined above.

"-C _0-8 alkyl-OC(O)R ₁₇ " means that the oxygen atom in -OC(O)R ₁₇ is bonded to a C _0-8 alkyl group, wherein the C _0-8 alkyl group is as defined above.

“—C _0-8 alkyl-P(O)(R ₁₇ ) ₂ ” means that the phosphorus atom in —P(O)(R ₁₇ ) ₂ is bonded to a C _0-8 alkyl group, wherein the C _0-8 alkyl group is as defined above.

"-C _0-8 alkyl-NR ₁₈ R ₁₉ " means that the nitrogen atom in -NR ₁₈ R ₁₉ is bonded to a C _0-8 alkyl group, wherein the C _0-8 alkyl group is as defined above.

“—C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ ” means that the carbon atom in —C(═NR ₁₈ )R ₁₇ is bonded to a C _0-8 alkyl group, wherein the C _0-8 alkyl group is as defined above.

“—C _0-8 alkyl-N(R ₁₈ )—C(═NR ₁₉ )R ₁₇ ” means that the nitrogen atom in —N(R ₁₈ )—C(═NR ₁₉ )R ₁₇ is bonded to a C _0-8 alkyl group, wherein the C _0-8 alkyl group is as defined above.

" _-C0-8alkyl -C(O) _NR18R19 " _means that the carbonyl group in -C(O) _NR18R19 is bonded to _{a C0-8alkyl} group, wherein _{the C0-8alkyl} group is as defined above.

“—C _0-8 alkyl-N(R ₁₈ )—C(O)R ₁₇ ” means that the nitrogen atom in —N(R ₁₈ )—C(O)R ₁₇ is bonded to a C _0-8 alkyl group, wherein the C _0-8 alkyl group is as defined above.

"Halogen-substituted C _1-10 alkyl" refers to an alkyl group of 1 to 10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by fluorine, chlorine, bromine or iodine atoms, including but not limited to difluoromethyl, dichloromethyl, dibromomethyl, trifluoromethyl, trichloromethyl, tribromomethyl and the like.

"Halogen-substituted C _1-10 alkoxy" refers to an alkoxy group having 1 to 10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by fluorine, chlorine, bromine or iodine atoms, including but not limited to difluoromethoxy, dichloromethoxy, dibromomethoxy, trifluoromethoxy, trichloromethoxy and tribromomethoxy.

"Deuterium-substituted C _1-10 alkyl" refers to an alkyl group of 1 to 10 carbon atoms in which the hydrogen atoms on the alkyl group are optionally replaced by deuterium atoms, including but not limited to monodeuteriomethyl, dideuteriomethyl, trideuteriomethyl, etc.

"Halogen" refers to fluorine, chlorine, bromine or iodine.

"Optional" or "optionally" means that the subsequently described event or circumstance may but need not occur, and the description includes instances where the event or circumstance occurs or does not occur, i.e., includes both substituted and unsubstituted instances. For example, "a heterocyclic group optionally substituted with an alkyl group" means that an alkyl group may but need not be present, and the description includes both instances where the heterocyclic group is substituted with an alkyl group and where the heterocyclic group is not substituted with an alkyl group.

"Substituted" means that one or more "hydrogen atoms" in a group are independently replaced by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, consistent with chemical valence theory, and those skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, amino or hydroxy groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated bonds (such as olefins).

"Stereoisomers," whose English name is stereoisomer, refer to isomers produced by the different spatial arrangements of atoms in a molecule. They can be divided into two types: cis-trans isomers and enantiomers, or into two major categories: enantiomers and diastereomers. Stereoisomers caused by the rotation of single bonds are called conformational stereoisomers, sometimes also called rotamers. Stereoisomers caused by bond length, bond angle, double bonds in the molecule, rings, etc. are called configurational stereoisomers, and configurational isomers are further divided into two categories. Among them, isomers caused by the inability of double bonds or single bonds of ring carbon atoms to rotate freely are called geometric isomers, also called cis-trans isomers, and are divided into two configurations: Z and E. For example, cis-2-butene and trans-2-butene are a pair of geometric isomers. Stereoisomers with different optical rotations due to the lack of anti-axial symmetry in the molecule are called optical isomers and are classified into R and S configurations. In this invention, "stereoisomers," unless otherwise specified, are understood to include one or more of the aforementioned enantiomers, configurational isomers, and conformational isomers.

"Pharmaceutically acceptable salt" in the present invention refers to pharmaceutically acceptable acid addition salts, including inorganic acid salts and organic acid salts, which can be prepared by methods known in the art.

A "pharmaceutical composition" refers to a mixture containing one or more compounds described herein, or their physiologically/pharmaceutically acceptable salts or prodrugs, together with other chemical components, as well as other components such as physiologically/pharmaceutically acceptable carriers and excipients. The purpose of a pharmaceutical composition is to facilitate administration to an organism, facilitating absorption of the active ingredient and thereby exerting its biological activity.

The present invention will be further described in detail and completely below with reference to the embodiments, but the present invention is by no means limited thereto, and the present invention is not limited to the contents of the embodiments.

The structures of the compounds of the present invention are determined by nuclear magnetic resonance (NMR) and/or liquid chromatography-mass spectrometry (LC-MS). NMR chemical shifts (δ) are given in parts per million (ppm). NMR measurements are performed using a Bruker AVANCE-400/500 NMR spectrometer, using deuterated dimethyl sulfoxide (DMSO-d ₆ ), deuterated methanol (CD ₃ OD), and deuterated chloroform (CDCl ₃ ) as the solvents, with tetramethylsilane (TMS) as the internal standard.

Liquid chromatography-mass spectrometry (LC-MS) was performed using an Agilent 6120 mass spectrometer. HPLC was performed using an Agilent 1200DAD high-pressure liquid chromatograph (Sunfire C18 150 × 4.6 mm column) and a Waters 2695-2996 high-pressure liquid chromatograph (Gimini C18 150 × 4.6 mm column).

Thin layer chromatography silica gel plates use Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plates. The specifications used for TLC are 0.15mm-0.20mm, and the specifications used for thin layer chromatography separation and purification products are 0.4mm-0.5mm. Column chromatography generally uses Yantai Huanghai silica gel 200-300 mesh silica gel as the carrier.

The starting materials in the embodiments of the present invention are known and commercially available, or can be synthesized using or according to methods known in the art. In the embodiments of the present invention, the reagent "Pd-118" refers to "[1,1'-bis(di-tert-butylphosphino)ferrocene]dichloropalladium" and "XPhos Pd G4" refers to "(SP-4-3)-[dicyclohexyl[2,4,6-tri(isopropyl)[1,1-biphenyl]-2-yl]phosphine](methanesulfonic acid)[2-(methylamino)[1,1-biphenyl]-2-yl]palladium".

Unless otherwise specified, all reactions of the present invention are carried out under continuous magnetic stirring in a dry nitrogen or argon atmosphere, with dry solvents and reaction temperatures expressed in degrees Celsius (°C).

1. Preparation of intermediates

Intermediate A1: Preparation of (2-methylene-5-(3,4,5-trifluorophenyl)tetrahydro-1H-pyrrolazin-7a(5H)-yl)methanol

Step 1: Synthesis of (3,4,5-trifluorophenyl)magnesium bromide

Dissolve 5-bromo-1,2,3-trifluorobenzene (25 g, 118.5 mmol) in tetrahydrofuran (100 mL), add magnesium (3 g, 123.4 mmol) and iodine (2.8 g, 11.0 mmol), and react at 70°C for 2 hours. Upon completion of the reaction, (3,4,5-trifluorophenyl)magnesium bromide (100 g, crude product) was obtained.

Step 2: Synthesis of methyl 2-((tert-butoxycarbonyl)amino)-5-oxo-5-(2,3,4-trifluorophenyl)pentanoate

1-(tert-Butyl)-2-methyl-5-oxopyrrolidine-1,2-dicarboxylate (25 g, 102.8 mmol) was dissolved in tetrahydrofuran (100 mL), and (3,4,5-trifluorophenyl)magnesium bromide (100 g, crude) was added. The reaction mixture was allowed to react at 20°C for 10 hours. After completion of the reaction, as determined by LCMS, the reaction solution was concentrated, and the residue was separated using a flash silica gel column [0-30% ethyl acetate:petroleum ether] to afford methyl 2-((tert-butoxycarbonyl)amino)-5-oxo-5-(2,3,4-trifluorophenyl)pentanoate (10 g, yield: 25.9%). MS m/z (ESI): 320.6 [M+1-56] ⁺ .

Step 3: Synthesis of 1-(tert-butyl) 2-methyl 5-(3,4,5-trifluorophenyl)pyrrolidine-1,2-dicarboxylate

Methyl 2-((tert-Butoxycarbonyl)amino)-5-oxo-5-(2,3,4-trifluorophenyl)pentanoate (10 g, 26.6 mmol) was dissolved in dichloromethane (10 mL) and trifluoroacetic acid (5 mL) was added. The reaction mixture was allowed to react at 20°C for 10 hours. Sodium borohydride (1 g, 26.4 mmol) was then added to the reaction mixture, and the reaction mixture was allowed to react at 20°C for 1 hour. Sodium carbonate (6 g, 56.6 mmol) and di-tert-butyl dicarbonate (5.9 g, 27.0 mmol) were then added to the reaction mixture, and the reaction mixture was allowed to react at 20°C for 2 hours. After completion of the reaction, the reaction mixture was concentrated, and the residue was separated using a flash silica gel column [0-30%:ethyl acetate:petroleum ether] to obtain 1-(tert-butyl)-2-methyl 5-(3,4,5-trifluorophenyl)pyrrolidine-1,2-dicarboxylate (5 g, yield: 52.2%). MS m/z(ESI):304.6[M+1-56] ⁺ .

Step 4: Synthesis of 1-(tert-butyl)2-methyl-2-(2-(chloromethyl)allyl)-5-(3,4,5-trifluorophenyl)pyrrolidine-1,2-dicarboxylate

1-(tert-Butyl)-2-methyl 5-(3,4,5-trifluorophenyl)pyrrolidine-1,2-dicarboxylate (5 g, 13.9 mmol) was dissolved in tetrahydrofuran (20 mL) and condensed to -78°C. Lithium bis(trimethylsilyl)amide (14 mL, 14.0 mmol) was added and the mixture reacted at -78°C for 1 hour. 3-Chloro-2-chloromethylpropene (1.8 g, 14.4 mmol) was then added and the mixture was heated to 25°C and stirred for 18 hours. The reaction solution was concentrated under reduced pressure to remove the solvent, and the residue was separated using a flash silica gel column [0-15%: ethyl acetate: petroleum ether] to afford 1-(tert-butyl)-2-methyl-2-(2-(chloromethyl)allyl)-5-(3,4,5-trifluorophenyl)pyrrolidine-1,2-dicarboxylate (3 g, yield: 48.1%). MS m/z (ESI): 392.6 [M+1-56] ⁺ .

Step 5: Synthesis of methyl 2-methylene-5-(3,4,5-trifluorophenyl)tetrahydro-1H-pyrrolazine-7a(5H)-carboxylate

1-(tert-Butyl)-2-methyl-2-(2-(chloromethyl)allyl)-5-(3,4,5-trifluorophenyl)pyrrolidine-1,2-dicarboxylate (3 g, 6.70 mmol) was dissolved in dichloromethane (5 mL) and trifluoroacetic acid (5 mL), heated to 25°C, and stirred for 18 hours. The reaction solution was concentrated under reduced pressure to remove the solvent, and the residue was separated using a flash silica gel column [0-15% ethyl acetate:petroleum ether] to afford methyl 2-methylene-5-(3,4,5-trifluorophenyl)tetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (1.5 g, yield: 71.9%). MS m/z (ESI): 312.6 [M+1] ⁺ .

Step 6: Synthesis of (2-methylene-5-(3,4,5-trifluorophenyl)tetrahydro-1H-pyrrolazin-7a(5H)-yl)methanol

Methyl 2-methylene-5-(3,4,5-trifluorophenyl)tetrahydro-1H-pyrrolazine-7a(5H)-carboxylate (0.5 g, 1.5 mmol) was dissolved in tetrahydrofuran (5 mL), and lithium aluminum tetrahydride (1.5 mL, 1.5 mmol) was added. The mixture was heated to 25°C and stirred for 18 hours. The reaction solution was concentrated under reduced pressure to remove the solvent, and the residue was separated using a flash silica gel column [0-15% dichloromethane:methanol] to afford (2-methylene-5-(3,4,5-trifluorophenyl)tetrahydro-1H-pyrrolazine-7a(5H)-yl)methanol (0.2 g, yield: 44.0%). MS m/z (ESI): 284.3 [M+1] ⁺ .

Preparation of Intermediate A2 Isomer 1 and Isomer 2: 3-(2,2-difluorobenzo[d][1,3]dioxazol-5-yl)tetrahydro-1H-pyrrolinazin-7a(5H)-yl)methanol (Isomer 1 and Isomer 2)

(1) Synthesis of Intermediate A2 Isomer 1: 3-(2,2-difluorobenzo[d][1,3]dioxazol-5-yl)tetrahydro-1H-pyrrolinazine-7a(5H)-yl)methanol (Isomer 1)

Ethyl 3-(2,2-difluorobenzo[d][1,3]dioxazol-5-yl)tetrahydro-1H-pyrrolidinosine-7a(5H)-carboxylate (isomer 1) (2.80 g, 8.25 mmol, prepared by the method disclosed in steps 1 to 4 of Example 140 on page 78 of patent document WO2023197984) was dissolved in tetrahydrofuran (50 mL), and then a tetrahydrofuran solution of lithium aluminum tetrahydride (6.60 mL, 16.50 mmol) was added dropwise at 0°C, and the reaction solution was reacted at 0°C for 1 hour. The reaction mixture was quenched with saturated aqueous ammonium chloride (200 mL) and extracted with ethyl acetate (200 mL). The mixture was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was separated using a flash silica gel column [0-30% EA in PE] to afford 3-(2,2-difluorobenzo[d][1,3]dioxazol-5-yl)tetrahydro-1H-pyrrolinazin-7a(5H)-yl)methanol (Isomer 1) (2 g, yield: 81.53%). ESI-MS: 298.4 [M+1] ⁺ .

(2) Synthesis of Intermediate A2 Isomer 2: 3-(2,2-difluorobenzo[d][1,3]dioxazol-5-yl)tetrahydro-1H-pyrrolinazine-7a(5H)-yl)methanol (Isomer 2)

Prepared by referring to the synthetic method of intermediate A2 isomer 1.

Intermediate A3: Preparation of (2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methanol (Isomer 1, Isomer 2, Isomer 3 and Isomer 4)

Step 1: Synthesis of ethyl 2,2-difluoro-5'-oxodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolidinazine)-7a'(5'H)-carboxylate (isomer B1 and isomer B2)

Dissolve ethyl 2-methylene-5-oxotetrahydro-1H-pyrrolidine-7a(5H)-carboxylate (9.5 g, 45.4 mmol) and (bromodifluoromethyl)trisilane (17.6 mL, 113 mmol) in toluene (100 mL). Add tetrabutylammonium bromide (0.704 g, 2.27 mmol) under nitrogen and react at 110°C for 16 hours. The reaction solution was directly concentrated under reduced pressure to remove the solvent, and the residue was separated by rapid silica gel column [0-30% EA in PE] to obtain ethyl 2,2-difluoro-5'-oxodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-carboxylate (isomer B1) (5.3 g, yield: 45.0%) and ethyl 2,2-difluoro-5'-oxodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-carboxylate (isomer B2) (4.5 g, yield: 38.23%).

Isomer B1:

¹ H NMR (400MHz, CDCl ₃ ) δ4.28 (q, J=7.1Hz, 2H), 4.06 (d, J=12.0Hz, 1H), 3.09 (br d,J＝12.0Hz,1H),2.87-2.76(m,1H),2.62(ddd,J＝1.9,9.1,13.2Hz,1H),2.49(ddd,J＝2.0,9.5 ,16.7Hz,1H),2.37-2.29(m,1H),2.23-2.10(m,2H),1.48-1.36(m,2H),1.33(t,J＝7.1Hz,3H).

Isomer B2:

¹ H NMR (400MHz, CDCl ₃ ) δ4.27 (q, J = 7.2Hz, 2H), 3.70 (br d,J＝11.7Hz,1H),3.43(d,J＝11.7Hz,1H),2.88-2.69(m,2H),2.55-2.43(m,2H),2.15(td,J ＝9.9,12.4Hz,1H),2.00(td,J＝3.3,13.0Hz,1H),1.49-1.39(m,2H),1.33(t,J＝7.2Hz,3H).

Step 2: Synthesis of (2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methanol (isomer 1 and isomer 2)

(1) Synthesis of Intermediate A3 Isomer 1: (2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolizine)-7a'(5'H)-yl)methanol (Isomer 1)

Ethyl 2,2-difluoro-5'-oxodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-carboxylate (isomer 1) (5.1 g, 19.672 mmol) was dissolved in tetrahydrofuran (50 mL). Lithium aluminum hydride (1.49 g, 39.3 mmol) was added at 0°C under nitrogen. The reaction was allowed to proceed at 60°C for 2 hours. LC-MS indicated the reaction was complete. The reaction was quenched by the dropwise addition of water (1 mL), 15% sodium hydroxide solution (2 mL), and water (1 mL) at 0°C. The insoluble solid was removed by filtration, and the solvent was removed by concentration under reduced pressure to afford (2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methanol (Intermediate A3 isomer 1) (3.6 g, yield: 90.0%). ESI-MS: 204.1[M+1] ⁺ .

¹ H NMR (400MHz, CDCl ₃ )δ3.47-3.30(m,2H),3.20-3.07(m,2H),2.83(d,J＝12.1Hz,1H),2.73-2.61(m,1H),2.08- 1.96(m,1H),1.95-1.84(m,3H),1.82-1.60(m,2H),1.41-1.32(m,1H),1.31-1.18(m,1H).

(2) Synthesis of Intermediate A3 Isomer 2: (2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolizine)-7a'(5'H)-yl)methanol (Isomer 2)

Ethyl 2,2-difluoro-5'-oxodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-carboxylate (isomer 2) (4.3 g, 16.6 mmol) was dissolved in tetrahydrofuran (50 mL). Lithium aluminum hydride (1.57 g, 41.4 mmol) was added at 0°C under nitrogen. The reaction was allowed to proceed at 60°C for 2 hours. LC-MS indicated the reaction was complete. The reaction was quenched by the dropwise addition of water (1 mL), 15% sodium hydroxide solution (2 mL), and water (1 mL) at 0°C. The insoluble solid was removed by filtration, and the solvent was removed by concentration under reduced pressure to afford (2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methanol (Intermediate A3 isomer 2) (2.8 g, yield: 83.1%). ESI-MS: 204.1[M+1] ⁺ .

¹ H NMR (400MHz, CDCl ₃ )δ3.42-3.30(m,2H),3.26(d,J＝11.0Hz,1H),3.15-3.03(m,1H),2.83-2.75(m,2H) ,2.05(d,J＝13.2Hz,1H),2.00-1.90(m,2H),1.89-1.68(m,3H),1.38-1.29(m,2H).

Step 3: Synthesis of 7a'-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-difluorotetrahydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolineoxazine)

Intermediate A3 isomer 1 (8.8 g, 43.301 mmol) and tert-butyldiphenylsilyl chloride (16.8 mL, 64.9 mmol) were dissolved in dichloromethane (200 mL). Imidazole (5.9 g, 86.6 mmol) was added under nitrogen at 0°C and allowed to react at 25°C for 18 hours. The reaction mixture was extracted with water (100 mL) and dichloromethane (100 mL x 3). The organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was separated by flash silica gel column chromatography (0-30% EA in PE) to yield 7a'-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-difluorotetrahydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine) (14.2 g, yield: 74.3%). ESI-MS:442.0[M+1] ⁺ .

¹ H NMR (400MHz, CDCl ₃ )δ7.69(ddd,J＝1.5,4.7,7.8Hz,4H),7.47-7.37(m,6H),3.51(s,2H),3.11-3.03(m,2H),2.79(d,J＝11.9Hz,1H), 2.64-2.55(m,1H),2.11-2.01(m,2H),1.90(d,J＝13.4Hz,1H),1.85-1.77(m,1H),1.72-1.55(m,4H),1.10(s,9H).

Step 4: Synthesis of 7a'-(((tert-butyldiphenylsilyl)oxy)methyl)-2,2-difluorotetrahydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolidine)isomer C1 and C2

7a'-(((tert-Butyldiphenylsilyl)oxy)methyl)-2,2-difluorotetrahydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine) (14.2 g) was subjected to chiral separation (Column: DAICEL CHIRALPAK IC (250 mm*50 mm, 10 um), Condition _: CO2 _- EtOH (0.1% NH3H2O), Begin B: 20%, End B: 20%, Flow Rate 200 mL/ _min )) to give isomer C1 (6.2 g, purity: 99.770%, ee value: 99.98%) and isomer C2 (5.8 g, purity: 99.687%, ee value: 99.76%), respectively. ESI-MS: 442.0 [M+1] ⁺ .

Isomer C1:

¹ H NMR (400MHz, CDCl ₃ ) δ7.72-7.66(m,4H),7.47-7.37(m,6H),3.51(br s,2H),3.13-3.02(m,2H),2.79(br d,J＝12.1Hz,1H),2.65-2.54(m,1H),2.06(dt,J＝6.1,12.7Hz,2H),1.90(d,J＝13.2Hz,1H) ,1.86-1.77(m,1H),1.72-1.64(m,1H),1.29-1.24(m,1H),1.24-1.16(m,2H),1.10(s,9H).

Isomer C2:

¹ H NMR (400MHz, CDCl ₃ )δ7.69(ddd,J＝1.4,5.5,7.0Hz,4H),7.47-7.36(m,6H),3.50(s,2H),3.11-3.01(m,2H),2.79(d,J＝11.9Hz,1H),2.63-2.5 5(m,1H),2.11-2.01(m,2H),1.90(d,J＝13.2Hz,1H),1.85-1.76(m,1H),1.65-1.55(m,2H),1.23-1.15(m,2H),1.10(s,9H).

Step 5: Synthesis of (2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methanol Intermediate A3 Isomer 3 and Intermediate A Isomer 4

Isomer C1 (3 g, 6.79 mmol) was dissolved in methanol (30 mL) and potassium bifluoride (2.65 g, 33.9 mmol) was added. The mixture was allowed to react at 25°C for 5 hours. After completion, the reaction was filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was separated using a flash silica gel column (0-30% EA in PE) to afford Intermediate A3 Isomer 3 (1.1 g, 79.7% yield). ESI-MS: 204.1 [M+1] ⁺ .

¹ H NMR (400MHz, CDCl ₃ ) δ3.49-3.33(m,2H),3.24-3.10(m,2H),2.85(d,J=12.1Hz,1H),2.74-2.63(m,1H),2.06(br dd,J＝6.3,13.3Hz,1H),1.97-1.85(m,3H),1.85-1.65(m,2H),1.42-1.25(m,2H).

Dissolve isomer C2 (0.9 g, 2.04 mmol) in methanol (15 mL) and add potassium bifluoride (3.18 g, 40.7 mmol) to react at 25°C for 5 hours. After the reaction is complete, filter and concentrate the filtrate under reduced pressure to remove the solvent. The residue is separated by a rapid silica gel column ( 20 g 0-50% tetrahydrofuran-petroleum ether, 80 mL/min) to give A3 isomer 4 (350 mg, yield 78.1%). ESI-MS: 204.1 [M+1] ⁺ .

¹ H NMR (400MHz, CDCl ₃ )δ3.43-3.31(m,2H),3.18-3.06(m,2H),2.83(d,J＝12.3Hz,1H),2.72-2.62(m,1 H),2.05-1.97(m,1H),1.93-1.84(m,3H),1.81-1.63(m,2H),1.39-1.23(m,2H).

Preparation of Intermediate A4 Isomers 1 and 2: ((2S)-2-(methylthio)tetrahydro-1H-pyrrolinazin-7a(5H)-yl)methanol (Isomers 1 and 2)

Step 1: Synthesis of 1-(tert-butyl) 2-methyl (2R, 4R)-4-((methylsulfonyl)oxy) pyrrolidine-1,2-dicarboxylate

1-(tert-Butyl)-2-methyl (2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate (25 g, 101.92 mmol) was dissolved in dichloromethane (200 mL). Methanesulfonic anhydride (14.36 mL, 112.12 mmol) and triethylamine (28.33 mL, 203.85 mmol) were added at 0°C. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was extracted with water (300 mL) and ethyl acetate (300 mL). The organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent, yielding 1-(tert-butyl)-2-methyl (2R,4R)-4-((methylsulfonyl)oxy)pyrrolidine-1,2-dicarboxylate (20 g, yield: 60.7%). ESI-MS: 346.4 [M+Na] ⁺ .

Step 2: Synthesis of 1-(tert-butyl) 2-methyl (2R,4S)-4-(methylthio) pyrrolidine-1,2-dicarboxylate

1-(tert-Butyl)-2-methyl (2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxylate (20 g, 61.85 mmol) was dissolved in tetrahydrofuran (200 mL), and sodium thiomethoxide (8.67 g, 123.70 mmol) and 15-crown-5 (12.39 mL, 61.85 mmol) were added. The reaction mixture was stirred at 70°C for 16 hours. The reaction mixture was extracted with saturated brine (300 mL) and ethyl acetate (300 mL). The organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was separated on a flash silica gel column (0-30% EA in PE) to provide 1-(tert-butyl)-2-methyl (2R,4S)-4-(methylthio)pyrrolidine-1,2-dicarboxylate (5 g, yield: 29.4%). ESI-MS: 276.4[M+1] ⁺ .

Step 3: Synthesis of 1-(tert-butyl)2-methyl(4S)-2-(3-chloropropyl)-4-(methylthio)pyrrolidine-1,2-dicarboxylate

1-(tert-Butyl)-2-methyl(2R,4S)-4-(methylthio)pyrrolidine-1,2-dicarboxylate (5 g, 18.16 mmol) was dissolved in tetrahydrofuran (30 mL). Lithium bistrimethylsilylamide (27.24 mL, 27.24 mmol) was then added dropwise under a nitrogen atmosphere at -78°C. The reaction solution was stirred at -78°C for 0.5 hours. A solution of 1-bromo-3-chloropropane (3.60 mL, 36.32 mmol) in tetrahydrofuran (10 mL) was then added dropwise to the reaction solution. The reaction solution was allowed to warm to room temperature and stirred at room temperature for 2 hours. The reaction mixture was extracted with saturated ammonium chloride solution (100 mL) and ethyl acetate (100 mL). The aqueous phase was washed with ethyl acetate (20 mL). The combined organic phases were dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent, yielding 1-(tert-butyl)-2-methyl (4S)-2-(3-chloropropyl)-4-(methylthio)pyrrolidine-1,2-dicarboxylate (4 g, yield: 62.6%). ESI-MS: 252.4 [M-99] ⁺ .

Step 4: Synthesis of methyl 2-(methylthio)tetrahydro-1H-pyrrolizine-7a(5H)-carboxylate (isomer 1 and isomer 2)

1-(tert-Butyl)-2-methyl (4S)-2-(3-chloropropyl)-4-(methylthio)pyrrolidine-1,2-dicarboxylate (4 g, 11.37 mmol) was dissolved in dichloromethane (20 mL), followed by the addition of trifluoroacetic acid (10 mL, 134.63 mmol). The reaction mixture was stirred at room temperature for 0.5 hours. The solvent was removed by concentration under reduced pressure, and the mixture was then separated by normal phase chromatography (0-30% EA in PE) to afford methyl 2-(methylthio)tetrahydro-1H-pyrrolinazine-7a(5H)-carboxylate (Isomer 1) (250 mg, 10.2% yield) and methyl 2-(methylthio)tetrahydro-1H-pyrrolinazine-7a(5H)-carboxylate (Isomer 1) (240 mg, 9.8% yield). ESI-MS: 216.4 [M+1] ⁺ .

Step 5: Synthesis of ((2S)-2-(methylthio)tetrahydro-1H-pyrrolinazin-7a(5H)-yl)methanol (isomer 1 and isomer 2)

(1) Synthesis of ((2S)-2-(methylthio)tetrahydro-1H-pyrrolinazin-7a(5H)-yl)methanol (isomer 1)

Methyl 2-(methylthio)tetrahydro-1H-pyrrolinazine-7a(5H)-carboxylate (Isomer 1) (240 mg, 1.12 mmol) was dissolved in tetrahydrofuran (10 mL). Lithium aluminum hydride (85 mg, 2.23 mmol) was added at 0°C, and the reaction mixture was stirred at 0°C for 1 hour. The reaction mixture was extracted with saturated aqueous ammonium chloride (40 mL) and ethyl acetate (40 mL). The organic phase was washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was separated using a flash silica gel column (0-30% EA in PE) to provide ((2S)-2-(methylthio)tetrahydro-1H-pyrrolinazine-7a(5H)-yl)methanol (Isomer 1) (140 mg, yield: 67.1%). ESI-MS: 188.4 [M+1] ⁺ .

(2) Synthesis of ((2S)-2-(methylthio)tetrahydro-1H-pyrrolinazin-7a(5H)-yl)methanol (isomer 2)

The synthesis of ((2S)-2-(methylthio)tetrahydro-1H-pyrrolinazine-7a(5H)-yl)methanol (isomer 2) was carried out by referring to the synthesis of intermediate A3 isomer 1, except that methyl 2-(methylthio)tetrahydro-1H-pyrrolinazine-7a(5H)-carboxylate (isomer 1) was replaced by methyl 2-(methylthio)tetrahydro-1H-pyrrolinazine-7a(5H)-carboxylate (isomer 2).

Intermediate B1: Preparation of (9H-fluoren-9-yl)methyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate-1,5-d ₂

Step 1: Synthesis of tert-butyl (1R,5S)-3-trityl-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

Tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (3 g, 14.1 mmol) and trityl-Cl (4.33 g, 15.5 mmol) were dissolved in dichloromethane (20 mL), and triethylamine (2.35 mL, 16.9 mmol) was added. The reaction solution was stirred at 25°C for 18 hours. The reaction solution was poured into 100 mL of water and extracted with dichloromethane (200 mL). The organic phase was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to remove the solvent. The residue was separated by flash silica gel column [0-30% EA in PE] to obtain tert-butyl (1R,5S)-3-trityl-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (6 g, yield: 93.4%).

¹ H NMR (400MHz, CDCl ₃ ) δ7.37-7.24(m,12H),7.20-7.14(m,3H),4.24-4.12(m,1H),4.05(br s,1H),2.99(br d,J＝10.9Hz,2H),2.46-2.32(m,2H),2.04-1.95(m,2H),1.89-1.69(m,2H),1.27(s,9H).

Step 2: Synthesis of tert-butyl (1R,5S)-3-trityl-3,8-diazabicyclo[3.2.1]octane-8-carboxylate-1,5-d ₂

Dissolve tert-butyl (1R,5S)-3-trityl-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (1 g, 2.20 mmol) and TMEDA (1.66 mL, 10.9 mmol) in tetrahydrofuran (20 mL). Add tert-butyl lithium (8.46 mL, 10.9 mmol) dropwise to the solution under nitrogen. After the addition, stir at 0°C for 0.5 hours. Then, add deuterated water (0.8 mL, 44.0 mmol) to the reaction mixture. After the addition, stir at 0°C for 0.5 hours. The reaction solution was quenched with saturated aqueous ammonium chloride solution (20 mL) and extracted with ethyl acetate (60 mL). The organic phase was dried over anhydrous magnesium sulfate and concentrated under reduced pressure to remove the solvent to obtain tert-butyl (1R,5S)-3-trityl-3,8-diazabicyclo[3.2.1]octane-8-carboxylate-1,5-d ₂ (650 mg, yield: 65.0%).

¹ H NMR (400MHz, CDCl ₃ ) δppm 7.35-7.24(m,12H),7.20-7.12(m,3H),2.99(br d,J＝11.1Hz,2H),2.37(br d,J＝6.8Hz,2H),2.00(br d,J＝7.5Hz,2H),1.87-1.72(m,2H),1.30-1.25(m,9H).

ESI-MS: 215[M+1] ⁺ .

Step 3: Synthesis of tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate-1,5- _d2

Tert-butyl (1R,5S)-3-trityl-3,8-diazabicyclo[3.2.1]octane-8-carboxylate-1,5- _d2 (4 g, 8.760 mmol) was dissolved in anhydrous acetic acid (40 mL). The mixture was stirred at 25°C for 18 hours. LC-MS indicated the reaction was complete. The reaction solution was then concentrated under reduced pressure to remove the solvent to yield tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate-1,5- _d2 (1.88 g crude product). ESI-MS: 159.1 [M-55] ⁺ .

Step 4: Synthesis of 3-((9H-fluoren-9-yl)methyl)8-(tert-butyl)(1R,5S)-3,8-diazabicyclo[3.2.1]octane-3,8-dicarboxylate-1,5-d ₂

Tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate-1,5-d ₂ (1.88 g, 8.772 mmol) was dissolved in anhydrous dichloromethane (40 mL). Fmoc-Cl (2.72 g, 10.5 mmol) and triethylamine (7.32 mL, 52.6 mmol) were added at 0°C. The mixture was stirred at 25°C for 2 hours. LC-MS indicated the reaction was complete. Saturated aqueous ammonium chloride (45 mL) was added to the reaction mixture, and the mixture was extracted with dichloromethane (3 x 40 mL). The combined organic phases were washed with saturated brine (25 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated using a flash silica gel column [0-30% EA in PE] to afford 3-((9H-fluoren-9-yl)methyl)8-(tert-butyl)(1R,5S)-3,8-diazabicyclo[3.2.1]octane-3,8-dicarboxylate-1,5- _d2 (2 g, yield: 26.1%). ESI-MS: 459.3 [M+23] ⁺ .

Step 5: Synthesis of (9H-fluoren-9-yl)methyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate-1,5-d ₂

3-((9H-fluoren-9-yl)methyl)8-(tert-butyl)(1R,5S)-3,8-diazabicyclo[3.2.1]octane-3,8-dicarboxylate-1,5- _d2 (1 g, 1.14 mmol) was dissolved in a hydrochloric acid/dioxane solution (30 mL, 2 N) and allowed to react at 25°C for 16 hours. LC-MS indicated the reaction was complete. The reaction solution was then concentrated under reduced pressure to remove the solvent, yielding (9H-fluoren-9-yl)methyl(1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate-1,5- _d2 (0.8 g, 92.3% yield).

Intermediate B2: Preparation of 2-oxa-6-azabicyclo[5.1.0]octane

Step 1: Synthesis of benzyl 1,4-oxazepane-4-carboxylate

1,4-Oxazoline hydrochloride (12.7 g, 92.3 mmol) was dissolved in dichloromethane (130 mL). Triethylamine (38.5 mL, 277 mmol) and benzyl chloroformate (13.4 mL, 94.1 mmol) were added dropwise at 0°C under a nitrogen atmosphere. The reaction mixture was stirred at 25°C for 2 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure, and the residue was separated using a flash silica gel column [0-30% EA in PE] to obtain benzyl 1,4-oxazepane-4-carboxylate (19.0 g, yield: 83.1%).

¹ H NMR (400MHz, DMSO-d ₆ ) δ7.13-7.51 (m, 5H), 5.09 (d, J = 1.54Hz, 2H), 3.59-3.66 (m, 4H), 3.46-3.54 (m, 4H), 1.77 (quin, J = 5.61Hz, 2H).

Step 2: Synthesis of benzyl 3-methoxy-1,4-oxazepane-4-carboxylate

Dissolve benzyl 1,4-oxazepane-4-carboxylate (14.0 g, 59.5 mmol) in anhydrous methanol (150 mL) and add tetraethylammonium p-toluenesulfonate (0.900 g, 2.98 mmol) at 25°C. Electrolysis was performed at a constant current of 100 mA (terminal voltage 20-30 V) (graphite electrode). A current of 2.5 Fmol⁻¹ was passed through the solution. Stir at 25°C for 18 hours. After completion of the reaction, the reaction solution was concentrated under reduced pressure, and the residue was separated using a flash silica gel column [0-30% EA in PE] to obtain benzyl 3-methoxy-1,4-oxazepane-4-carboxylate (13.0 g, yield: 74.1%).

¹ H NMR (400MHz, DMSO-d ₆ ) δ7.18-7.51(m,5H),5.29-5.44(m,1H),5.07-5.23(m,2H),3.88-4.11(m,1H),3.64-3.77(m,2H),3.37(br s,1H),3.07-3.25(m,5H),2.16-2.38(m,1H),1.69-1.85(m,1H).

Step 3: Synthesis of benzyl 6,7-dihydro-1,4-oxazepine-4(5H)-carboxylate

Benzyl 3-methoxy-1,4-oxazepane-4-carboxylate (16.0 g, 60.3 mmol) and N,N-diisopropylethylamine (26.3 mL, 159 mmol) were dissolved in dichloromethane (300 mL), and trimethylsilyl trifluoromethanesulfonate (28.9 mL, 159 mmol) was added dropwise at 0°C. The mixture was stirred at 0°C under a nitrogen atmosphere for 3 hours. After the reaction was completed, the reaction solution was quenched and diluted with water, extracted with dichloromethane (400 mL), and the organic phase was washed with saturated aqueous sodium chloride (200 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated using a flash silica gel column [0-30% EA in PE] to obtain benzyl 6,7-dihydro-1,4-oxazepine-4(5H)-carboxylate (2.50 g, yield: 17.8%).

¹ H NMR (400MHz, CDCl ₃ ) δ7.17-7.48(m,5H),5.60-5.88(m,2H),5.08(s,2H),4.00(br d,J＝4.63Hz,2H),3.76(br t,J＝5.19Hz,2H),1.78-2.00(m,2H).

Step 4: Synthesis of benzyl 2-oxa-6-azabicyclo[5.1.0]octane-6-carboxylate

Benzyl 6,7-dihydro-1,4-oxazepine-4(5H)-carboxylate (2.50 g, 10.7 mmol) and diiodomethane (7.78 mL, 96.5 mmol) were dissolved in toluene (25 mL), and the mixture was stirred at 0°C for 30 minutes under a nitrogen atmosphere. Diethylzinc (107 mL, 107 mmol) was then added dropwise to the solution. The reaction mixture was stirred at 25°C for 17.5 hours under a nitrogen atmosphere. After completion of the reaction, the reaction mixture was quenched and diluted with water, extracted with ethyl acetate (300 mL), and the organic phase was washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated using a flash silica gel column [0-30% EA in PE] to obtain benzyl 2-oxa-6-azabicyclo[5.1.0]octane-6-carboxylate (2.43 g, yield: 87.1%).

¹ H NMR (400MHz, CDCl ₃ )δ7.18-7.48(m,5H),4.94-5.23(m,2H),3.80-4.18(m,2H),3.50-3.66(m,1H),3.25-3.41(m,1H),2.95-3.16(m,1H),2.37(br s,1H),1.61-1.94(m,2H),0.98-1.23(m,2H).

Step 5: Synthesis of 2-oxa-6-azabicyclo[5.1.0]octane

Benzyl 2-oxa-6-azabicyclo[5.1.0]octane-6-carboxylate (500 mg, 2.02 mmol) was dissolved in a solution of hydrobromic acid in acetic acid (10 mL). The reaction mixture was stirred at 25°C under a nitrogen atmosphere for 18 hours. After completion of the reaction, the reaction mixture was concentrated under reduced pressure to yield 2-oxa-6-azabicyclo[5.1.0]octane (500 mg, yield: 95.6%).

¹ H NMR (400MHz, CDCl ₃ ) δ10.04-10.54(m,1H),8.56-9.11(m,1H),4.14(br d,J＝12.10Hz,1H),3.52-3.86(m,3H),3.05-3.24(m,1H),2.73-2.89(m,1H),2.46-2.65(m,1H),1.99(br d,J＝9.24Hz,2H),1.15-1.30(m,1H).

Intermediate B3: Preparation of N,N-di(4-methoxybenzyl)-3-(1-(methylamino)ethyl)pyridin-2-amine

Step 1: Synthesis of 1-(2-(di(4-methoxybenzyl)amino)pyridin-3-yl)ethan-1-one

3-Acetyl-2-chloropyridine (10 g, 64.3 mmol) was dissolved in anhydrous N,N-dimethylformamide (100 mL), followed by the addition of triethylamine (13 g, 128 mmol) and bis(4-methoxybenzyl)amine (32.9 g, 128 mmol). The mixture was then stirred at 110°C for 18 hours. LCMS analysis indicated the reaction was complete. The reaction mixture was poured into water (300 mL) and extracted with ethyl acetate (100 mL x 2). The combined organic phases were washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated by flash silica gel column chromatography (0-30% EA in PE) to afford 1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethan-1-one (14 g, yield: 57.9%). ESI-MS: 362.9 [M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ ) δ8.27 (dd, J＝4.57, 1.56Hz, 1H) 7.84 (dd, J＝7.50, 1.63Hz, 1H) 7.26 (s, 1H) 7.04 (d, J＝8.50Hz, 4H) 6.84 (br d,J＝8.63Hz,4H)4.42(s,4H)3.71(s,6H)2.42(s,3H).

Step 2: Synthesis of (Z)-N,N-di(4-methoxybenzyl)-3-(1-(methylimino)ethyl)pyridin-2-amine

Dissolve 1-(2-(bis(4-methoxybenzyl)amino)pyridin-3-yl)ethan-1-one (14 g, 37.2 mmol) in anhydrous ethanol (150 mL). Add tetraethyl titanate (17 g, 74.4 mmol) and a solution of methylamine in tetrahydrofuran (37.2 mL, 3N, 112 mmol). Stir at 80°C for 18 hours. TLC indicates complete consumption of the starting material. Use the reaction mixture directly in the next step.

Step 3: Synthesis of N,N-di(4-methoxybenzyl)-3-(1-(methylamino)ethyl)pyridin-2-amine

(Z)-N,N-Di(4-methoxybenzyl)-3-(1-(methylimino)ethyl)pyridin-2-amine (reaction solution from the previous step, 37.2 mmol) was cooled to 0°C under nitrogen. Sodium borohydride (5.6 g, 149 mmol) was slowly added portionwise, followed by stirring at 0°C for 2 hours. LCMS analysis indicated the reaction was complete. Water (30 mL) was added dropwise to the reaction solution, which was then filtered through celite. The filtrate was concentrated, and the residue was separated by flash silica gel column chromatography (0-30% EA in PE) to afford N,N-di(4-methoxybenzyl)-3-(1-(methylamino)ethyl)pyridin-2-amine (6 g, yield: 41.2%). ESI-MS: 392.0 [M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ ) δppm 8.17(dd,J＝4.63,1.88Hz,1H)7.79(dd,J＝7.63,1.75Hz,1H)7.17(d,J＝8.63Hz,4H)7.05(dd,J＝7. 57,4.69Hz,1H)6.84(d,J＝8.50Hz,4H)4.12(m,5H)3.70(s,6H)1.97(s,3H)1.14(d,J＝6.38Hz,3H).

Intermediate B4: Preparation of 3-chloro-N,N-dimethyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine-2-carboxamide

Step 1: Synthesis of 5-(tert-butyl)2-methyl7,8-dihydro-4H-pyrazolo[1,5-a][1,4]diazepine-2,5(6H)-dicarboxylate

5-(tert-Butoxycarbonyl)-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine-2-carboxylic acid (500 mg, 1.77 mmol) was dissolved in N-dimethylformamide (10 mL), and cesium carbonate (1737 mg, 5.33 mmol) and iodomethane (0.166 mL, 2.66 mmol) were added. The mixture was then stirred at 25°C for 2 hours. LCMS indicated the reaction was complete. Water (50 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (2 x 30 mL). The combined organic phases were washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford 5-(tert-butyl) 2-methyl 7,8-dihydro-4H-pyrazolo[1,5-a][1,4]diazepine-2,5(6H)-dicarboxylate (400 mg, yield: 76.2%). ESI-MS: 296.1[M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ ) δ6.71-6.55(m,1H),4.57-4.36(m,4H),3.78(s,3H),3.65(br s,2H),1.87-1.69(m,2H),1.33(br s,9H).

Step 2: Synthesis of 5-(tert-butyl)-2-methyl-3-chloro-7,8-dihydro-4H-pyrazolo[1,5-a][1,4]diazepine-2,5(6H)-dicarboxylate

5-(tert-Butyl)-2-methyl-7,8-dihydro-4H-pyrazolo[1,5-a][1,4]diazepine-2,5(6H)-dicarboxylate (400 mg, 1.35 mmol) was dissolved in N,N-dimethylformamide (5 mL), and N-chlorosuccinimide (180 mg, 1.35 mmol) was added. The mixture was then stirred at 80°C for 2 hours. LCMS indicated the reaction was complete. Water (30 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford 5-(tert-butyl)-2-methyl-3-chloro-7,8-dihydro-4H-pyrazolo[1,5-a][1,4]diazepine-2,5(6H)-dicarboxylate (350 mg, yield: 78.3%). ESI-MS: 330.0[M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ ) δ4.63-4.43(m,4H),3.85-3.76(m,3H),3.67(br s,2H),1.82(br s,2H),1.36(s,9H).

Step 3: Synthesis of 5-(tert-butyloxycarbonyl)-3-chloro-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine-2-carboxylic acid

5-(tert-Butyl)-2-methyl-3-chloro-7,8-dihydro-4H-pyrazolo[1,5-a][1,4]diazepine-2,5(6H)-dicarboxylate (300 mg, 0.91 mmol) was dissolved in anhydrous methanol (5 mL) and water (2 mL). Potassium hydroxide (255 mg, 4.54 mmol) was then added and stirred at 25°C for 1 hour. LCMS confirmed the reaction was complete. The methanol was removed by concentration under reduced pressure. Dilute hydrochloric acid (1 M) was added to the residue to adjust the pH to ~6-7. The residue was extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with saturated brine (20 mL) and concentrated under reduced pressure to afford 5-(tert-butyloxycarbonyl)-3-chloro-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine-2-carboxylic acid (250 mg, yield: 87%). ESI-MS: 319.5[M+1] ⁺ .

Step 4: Synthesis of tert-butyl 3-chloro-2-(dimethylcarbamoyl)-7,8-dihydro-4H-pyrazolo[1,5-a][1,4]diazepine-5(6H)-carboxylate

5-(tert-Butoxycarbonyl)-3-chloro-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine-2-carboxylic acid (200 mg, 0.633 mmol) was dissolved in N,N-dimethylformamide (5 mL). N,N-diisopropylethylamine (0.314 mL, 1.9 mmol) and HATU (240 mg, 0.633 mmol) were added to the solution, and the mixture was stirred at 25°C for 0.5 hour. Dimethylamine hydrochloride (57.1 mg, 1.26 mmol) was then added to the solution, and stirring was continued for 2 hours. LCMS indicated the reaction was complete. Water (30 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (2 x 20 mL). The combined organic phases were washed with saturated brine (20 mL) and concentrated under reduced pressure to remove the solvent. The residue was separated using a flash silica gel column [0-30% EA in PE] to afford tert-butyl 3-chloro-2-(dimethylcarbamoyl)-7,8-dihydro-4H-pyrazolo[1,5-a][1,4]diazepine-5(6H)-carboxylate (200 mg, yield: 92.1%). ESI-MS: 343.1 [M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ ) δ4.59-4.33 (m, 4H), 3.67 (br s, 2H), 2.97 (s, 6H), 1.82 (br d, J = 2.6Hz, 2H), 1.37 (s, 9H).

Step 5: Synthesis of 3-chloro-N,N-dimethyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine-2-carboxamide

Tert-butyl 3-chloro-2-(dimethylcarbamoyl)-7,8-dihydro-4H-pyrazolo[1,5-a][1,4]diazepine-5(6H)-carboxylate (200 mg, 0.583 mmol) was dissolved in acetonitrile (5 mL) and then added to dioxane hydrochloride (10 mL, 2 M). The mixture was stirred at 25°C for 1 hour. LCMS confirmed the reaction was complete. The reaction solution was then concentrated under reduced pressure to afford 3-chloro-N,N-dimethyl-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepine-2-carboxamide (140 mg, yield: 98.8%). ESI-MS: 243.1 [M+1] ⁺ .

Intermediate C1: Preparation of 6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-ol

Step 1: Synthesis of 4-bromo-5-fluoro-6-nitroisobenzofuran-1(3H)-one

5-Fluoroisobenzofuran-1(3H)-one (20 g, 131 mmol) was dissolved in concentrated sulfuric acid (200 mL). The mixture was heated to 65°C and concentrated _HNO₃ (26.80 g, 289 mmol) was slowly added dropwise. The mixture was stirred at 65°C for 1 hour. TLC confirmed the complete consumption of the starting material and the mixture was cooled to room temperature. Dibromohydantoin (150 g, 526 mmol) was then added portionwise to the reaction mixture, which was stirred overnight at room temperature. The reaction mixture was poured into 500 mL of stirred ice water. A large amount of solid precipitated and was filtered. The filter cake was extracted with water (300 mL) and ethyl acetate (200 mL x 2). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent, yielding 4-bromo-5-fluoro-6-nitroisobenzofuran-1(3H)-one (19.3 g, 53% yield).

¹ H NMR (400MHz, DMSO-d ₆ ) δ8.57 (d, J = 6.1 Hz, 1H), 5.51 (s, 2H).

Step 2: Synthesis of 4-bromo-5-fluoro-6-nitro-1,3-dihydroisobenzofuran-1-ol

4-Bromo-5-fluoro-6-nitroisobenzofuran-1(3H)-one (45 g, 163 mmol) was dissolved in anhydrous dichloromethane (500 mL) and cooled to -78°C. Diisobutylaluminum hydride (245 mL, 245 mmol) was added dropwise under nitrogen. The mixture was allowed to react at -78°C for 3 hours. 10 mL of water was slowly added to the reaction mixture and stirred for 10 minutes. Then, 10 mL of 5N aqueous NaOH was added and stirred for 10 minutes. Finally, 25 mL of water was added and stirred for 10 minutes. 100 g of anhydrous magnesium sulfate was added and stirred for 20 minutes. The reaction mixture was filtered, and the filtrate was concentrated. The mixture was then extracted with brine (100 mL) and ethyl acetate (200 mL x 3). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent to yield 4-bromo-5-fluoro-6-nitro-1,3-dihydroisobenzofuran-1-ol (37 g, yield: 81.6%).

¹ H NMR (400MHz, DMSO-d ₆ ) δ8.15 (d, J = 6.1 Hz, 1H), 7.26 (br d, J = 7.3 Hz, 1H), 6.50 (br d, J = 5.3 Hz, 1H), 5.15-5.09 (m, 1H), 5.02-4.96 (m, 1H).

Step 3: Synthesis of 4-bromo-5-fluoro-6-nitro-1,3-dihydroisobenzofuran

Dissolve 4-bromo-5-fluoro-6-nitro-1,3-dihydroisobenzofuran-1-ol (37 g, 133 mmol) in anhydrous dichloromethane (400 mL), cool to 0°C, and dropwise add triethylsilyl hydrochloride (129 mL, 798 mmol) followed by trifluoroacetic acid (29 mL, 399 mmol). The mixture is allowed to react overnight at 25°C. TLC indicates completion of the reaction. The reaction mixture is then concentrated under reduced pressure, and the residue is extracted with 300 mL of saturated aqueous sodium carbonate and ethyl acetate (200 mL x 2). The organic phase is washed with saturated aqueous sodium chloride (300 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent to yield 4-bromo-5-fluoro-6-nitro-1,3-dihydroisobenzofuran (45 g, yield: 96.8%).

¹ H NMR (400MHz, DMSO-d ₆ ) δ8.16 (d, J = 6.4 Hz, 1H), 5.17 (s, 2H), 5.09 (s, 2H).

Step 4: Synthesis of 7-bromo-6-fluoro-1,3-dihydroisobenzofuran-5-amine

4-Bromo-5-fluoro-6-nitro-1,3-dihydroisobenzofuran (45 g, 128 mmol) and ammonium chloride (34.5 g, 644 mmol) were dissolved in anhydrous ethanol (400 mL) and water (80 mL). The mixture was heated to approximately 80°C. Iron powder (36 g, 644 mmol) was added portionwise, and the mixture was allowed to react at 80°C for 3 hours. LCMS indicated the reaction was complete. The reaction mixture was cooled to room temperature, filtered through celite, and the filtrate was concentrated. The residue was then extracted with 300 mL of water and ethyl acetate (200 mL x 3). The organic phase was washed with saturated sodium chloride (200 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent to yield 7-bromo-6-fluoro-1,3-dihydroisobenzofuran-5-amine (27.2 g, yield: 91.0%). ESI-MS: 231.9/233.9 [M+1/M+3] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ ) δ6.65 (d, J = 7.4 Hz, 1H), 5.42 (s, 2H), 4.97 (s, 2H), 4.85 (s, 2H).

Step 5: Synthesis of ethyl N-[(7-bromo-6-chloro-1,3-dihydroisobenzofuran-5-yl)aminomethylthioyl]carbamate

7-Bromo-6-fluoro-1,3-dihydroisobenzofuran-5-amine (27.2 g, 117 mmol) was dissolved in anhydrous dichloromethane (300 mL), and ethyl isothiocyanatoformate (14 mL, 117 mmol) was added. The mixture was reacted at 25°C for 4 hours. The reaction solution was concentrated directly, and the residue was slurried with 300 mL of petroleum ether for 10 minutes, filtered, and the filter cake was dried to obtain ethyl N-[(7-bromo-6-chloro-1,3-dihydroisobenzofuran-5-yl)carbamoylthioyl]carbamate (41 g, yield: 96.3%). ESI-MS: 362.9/364.9 [M+1/M+3] ⁺ .

¹ H NMR(400MHz,DMSO-d ₆ )δ11.52(br s,1H),11.37(br s,1H),7.67(d,J＝6.1Hz,1H),5.12(s,2H),5.02(s,2H),4.23(q,J＝7.1Hz,2H),1.27(t,J＝7.1Hz,3H).

Step 6: Synthesis of ethyl (Z)-(((7-bromo-6-fluoro-1,3-dihydroisobenzofuran-5-yl)amino)(ethylthio)methylene)carbamate

Dissolve ethyl N-[(7-bromo-6-chloro-1,3-dihydroisobenzofuran-5-yl)carbamate (41 g, 113 mmol) in acetone (500 mL). Add potassium carbonate (46.8 g, 339 mmol) under nitrogen. Add iodoethane (9 mL, 113 mmol) dropwise. The mixture is reacted at 25°C for 18 hours. LC-MS indicates the reaction is complete. The reaction mixture was concentrated directly, and the residue was extracted with ethyl acetate (600 mL) and water (600 mL). The organic phase was washed with saturated aqueous sodium chloride (200 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was separated using a flash silica gel column [0-30% EA in PE] to provide ethyl (Z)-(((7-bromo-6-fluoro-1,3-dihydroisobenzofuran-5-yl)amino)(ethylthio)methylene)carbamate (32.2 g, yield: 72.8%). ESI-MS: 390.8 [M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ ) δ9.99 (br s, 1H), 6.80 (br d, J = 4.9Hz, 1H), 5.06 (br s, 2H), 4.97 (br s, 2H), 4.01 (d, J = 7.1Hz, 2H), 2.94 (br d,J＝7.1Hz,2H),1.25(s,3H),1.14(br d,J＝6.2Hz,3H).

Step 7: Synthesis of 6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-ol

Heat 150 mL of anhydrous N-methylpyrrolidone dried over molecular sieves to 175°C under _nitrogen protection. Remove water in vacuo. Dissolve ethyl (Z)-(((7-bromo-6-fluoro-1,3-dihydroisobenzofuran-5-yl)amino)(ethylthio)methylene)carbamate (24 g, 61.3 mmol) in anhydrous N-methylpyrrolidone dried over molecular sieves (150 mL) and add the resulting mixture to the heated N-methylpyrrolidone solution under _nitrogen protection. React at 175°C for 1 hour. LC-MS indicates the reaction is complete. After cooling to room temperature, the reaction mixture was poured into 800 mL of water and stirred for 30 minutes. The mixture was then filtered and the filter cake was separated using a flash silica gel column [0-30% EA in PE] to afford 6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-ol (11.53 g, 54.5% yield). ESI-MS: 344.9 [M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ ) δ12.86 (br s, 1H), 5.41 (br s, 2H), 5.04 (br s, 2H), 3.22 (q, J = 7.3Hz, 2H), 1.36 (s, 3H).

Intermediate C2: Preparation of 6-bromo-3-(ethylthio)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-1-ol

Step 1: Synthesis of 2-bromo-1-(2,2-diethoxyethoxy)-3-fluorobenzene

2-Bromo-3-fluorophenol (45.0 g, 236 mmol) and bromoacetaldehyde diethyl acetal (47.2 mL, 306 mmol) were dissolved in N,N-dimethylformamide (900 mL), and potassium iodide (39.1 g, 236 mmol) and potassium carbonate (48.8 g, 353 mmol) were added. The reaction mixture was stirred at 145°C under a nitrogen atmosphere for 2 hours. After completion of the reaction, the reaction mixture was diluted with water and extracted with ethyl acetate (1000 mL). The organic phase was washed with saturated brine (2000 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated using a flash silica gel column [0-30% EA in PE] to obtain 2-bromo-1-(2,2-diethoxyethoxy)-3-fluorobenzene (72.0 g, yield: 94.5%).

¹ H NMR (400MHz, DMSO-d ₆ )δ7.37(td,J＝8.34,6.79Hz,1H), 6.93-7.05(m,2H), 4.85(t,J＝5.26Hz,1H), 4.04-4.09(m,2H), 3.67-3.76(m,2H), 3.57-3.66(m,2H), 1.13-1.17(m,6H).

Step 2: Synthesis of 7-bromo-6-fluorobenzofuran

2-Bromo-1-(2,2-diethoxyethoxy)-3-fluorobenzene (72.0 g, 234 mmol) was dissolved in anhydrous toluene (1200 mL), and para-polyphosphoric acid (76.9 g, 938 mmol) was added at 25°C. The mixture was stirred at 90°C for 2 hours. After the reaction was completed, the reaction solution was poured into a saturated aqueous sodium bicarbonate solution and extracted with ethyl acetate (3000 mL). The organic phase was washed with a saturated aqueous sodium chloride solution (2000 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated using a flash silica gel column [0-30% EA in PE] to obtain 7-bromo-6-fluorobenzofuran (40.0 g, yield: 71.4%).

¹ H NMR (400MHz, DMSO-d ₆ ) δ 8.15 (d, J = 2.13 Hz, 1H), 7.70 (dd, J = 8.57, 5.07 Hz, 1H), 7.25-7.37 (m, 1H), 7.12 (d, J = 2.13 Hz, 1H).

Step 3: Synthesis of 7-bromo-6-fluoro-2,3-dihydrobenzofuran

7-Bromo-6-fluorobenzofuran (40.0 g) was subjected to flow chemical hydrogenation using Ru/ _SiO2 as a catalyst and ethanol as a solvent. After completion of the reaction, the mixture was concentrated under reduced pressure to afford 7-bromo-6-fluoro-2,3-dihydrobenzofuran (40.0 g, yield: 89.2%).

¹ H NMR (400MHz, DMSO-d ₆ ) δ7.15-7.35 (m, 1H), 6.79 (dd, J = 9.24, 8.14Hz, 1H), 4.69 (t, J = 8.80Hz, 2H), 3.27 (t, J = 8.69Hz, 2H).

Step 4: Synthesis of 7-bromo-6-fluoro-5-nitro-2,3-dihydrobenzofuran

7-Bromo-6-fluoro-2,3-dihydrobenzofuran (40.0 g, 184 mmol) was dissolved in trifluoroacetic acid (400 mL). Nitric acid (17.4 g, 276 mmol) was added dropwise to the solution at 0°C under a nitrogen atmosphere. The reaction mixture was stirred at 25°C under a nitrogen atmosphere for 1 hour. After completion of the reaction, the reaction mixture was poured into ice water. A solid precipitated and was filtered. The filter cake was rinsed with water (900 mL) and dried to yield 7-bromo-6-fluoro-5-nitro-2,3-dihydrobenzofuran (45.0 g, yield: 83.9%).

¹ H NMR (400MHz, CDCl ₃ ) δ7.77-8.08(m,1H), 4.86-4.89(m,2H), 3.38-3.46(m,2H).

Step 5: Synthesis of 7-bromo-6-fluoro-2,3-dihydrobenzofuran-5-amine

7-Bromo-6-fluoro-5-nitro-2,3-dihydrobenzofuran (25.0 g, 85.9 mmol) and ammonium chloride (45.9 g, 859 mmol) were dissolved in ethanol (400 mL) and water (100 mL). Iron powder (48.0 g, 859 mmol) was added while heating and stirring. The reaction mixture was stirred at 80°C for 2 hours. After completion of the reaction, the reaction mixture was filtered, the filtrate was concentrated, and then extracted with ethyl acetate (900 mL) and water (300 mL). The organic phase was washed with saturated brine (200 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated using a flash silica gel column (0-30% EA in PE) to yield 7-bromo-6-fluoro-2,3-dihydrobenzofuran-5-amine (10.5 g, yield: 51.5%). ESI-MS: 231.9 [M+1] ⁺ .

Step 6: Synthesis of ethyl N-[(7-bromo-6-chloro-2,3-dihydrobenzofuran-5-yl)aminomethylthioyl]carbamate

Dissolve 7-bromo-6-fluoro-2,3-dihydrobenzofuran-5-amine (8.50 g, 36.6 mmol) in dichloromethane (85 mL), then add ethoxycarbonyl isothiocyanate (5.18 mL, 44.0 mmol). The reaction mixture was stirred at 25°C for 4 hours. After completion of the reaction, the product was filtered to yield ethyl N-[(7-bromo-6-chloro-2,3-dihydrobenzofuran-5-yl)carbamoylthioyl]carbamate (14.0 g, yield: 94.7%). ESI-MS: 362.9 [M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ ) δ11.42 (br s, 1H), 11.10 (br s,1H), 7.41(d,J＝7.38Hz,1H), 4.72(t,J＝8.76Hz,2H), 4.22(q,J＝7.09Hz,2H), 3.25-3.33(m,2H), 1.27(t,J＝7.07Hz,3H).

Step 7: Synthesis of ethyl (Z)-(((7-bromo-6-fluoro-2,3-dihydrobenzofuran-5-yl)amino)(ethylthio)methylene)carbamate

Ethyl N-[(7-bromo-6-chloro-2,3-dihydrobenzofuran-5-yl)carbamoylthioyl]carbamate (5.7 g, 15.7 mmol) was dissolved in acetone (100 mL). Potassium carbonate (6.51 g, 47.1 mmol) and iodoethane (2.69 g, 17.3 mmol) were added at 25°C. The reaction mixture was stirred at 40°C for 2 hours. After completion, the reaction mixture was quenched and diluted with water, extracted with ethyl acetate (300 mL), and the organic phase was washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated using a flash silica gel column (0-30% EA in PE) to provide ethyl (Z)-(((7-bromo-6-fluoro-2,3-dihydrobenzofuran-5-yl)amino)(ethylthio)methylene)carbamate (5.00 g, yield: 76.6%). ESI-MS:390.9[M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ )δ9.68-10.25(m,1H), 6.58-7.34(m,1H), 4.59-4.76(m,2H), 3.90-4.06(m,2H), 3.18-3.33(m,2H), 2.86-3.04(m,2H), 1.08-1.27(m,6H).

Step 8: Synthesis of 6-bromo-3-(ethylthio)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-1-ol

Ethyl (Z)-(((7-bromo-6-fluoro-2,3-dihydrobenzofuran-5-yl)amino)(ethylthio)methylene)carbamate (9.00 g, 23.0 mmol) was dissolved in diphenyl ether (90 mL). The mixture was stirred at 200°C for 2 hours under a nitrogen atmosphere. After the reaction was complete, the reaction mixture was cooled to room temperature to allow solids to precipitate. The solids were filtered and collected to yield 6-bromo-3-(ethylthio)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-1-ol (2.40 g, yield: 27.2%).

¹ H NMR (400MHz, DMSO-d ₆ ) δ 12.25-12.70 (m, 1H), 4.74 (q, J = 9.38Hz, 2H), 3.59-3.72 (m, 2H), 3.17 (q, J = 7.38Hz, 2H), 1.34 (t, J = 7.32Hz, 3H).

Intermediate C3: Preparation of 4-bromo-7,9-dichloro-5-fluoro-2,3-dihydrofuro[2,3-f]quinazoline

Step 1: Synthesis of 4-bromo-2,3,6-trifluorobenzaldehyde

Dissolve 1-bromo-2,3,5-trifluorobenzene (10.0 g, 47.4 mmol) in anhydrous tetrahydrofuran (300 mL). Cool the mixture to -78°C and slowly add lithium diisopropylamide (26.1 mL, 52.1 mmol, 2 M) dropwise under nitrogen. After incubating the reaction at -78°C under nitrogen for 0.5 hour, slowly add N,N-dimethylformamide (3.81 g, 52.1 mmol) dropwise to the reaction mixture. Continue the reaction at -78°C under nitrogen for 0.5 hour. TLC indicates the reaction is complete. Saturated aqueous ammonium chloride solution (100 mL) was slowly added dropwise to the reaction solution for quenching. Water (300 mL) and ethyl acetate (300 mL) were added to the reaction solution for extraction. The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent. The residue was separated by a fast silica gel column [0-30% EA in PE] to obtain 4-bromo-2,3,6-trifluorobenzaldehyde (10.5 g, yield: 92.7%).

¹ H NMR (400MHz, CDCl ₃ ) δ10.29 (s, 1H), 7.52-7.11 (m, 1H).

Step 2: Synthesis of 4-bromo-2,3,6-trifluorobenzene(formaldehyde)oxime

4-Bromo-2,3,6-trifluorobenzaldehyde (10.5 g, 43.9 mmol) was dissolved in water (500 mL). Hydroxylamine sulfate (5.47 g, 48.4 mmol) was added to the mixture at room temperature, and the mixture was reacted at 105 ° C for 3 hours. TLC showed that the reaction was complete. The reaction solution was poured into water (500 mL) and extracted with ethyl acetate (500 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent to obtain a crude product, which was then separated by a flash silica gel column [0-30% EA in PE] to obtain 4-bromo-2,3,6-trifluorobenzaldehyde oxime (isomer 1) (4.50 g, yield: 40.3%).

¹ H NMR (400MHz, CDCl ₃ ) δ9.47-9.23 (m, 1H), 8.27 (s, 1H), 7.23 (ddd, J=2.2, 5.0, 9.4Hz, 1H).

Step 3: Synthesis of 4-bromo-2,3,6-trifluorobenzaldehyde O-acetyl oxime

4-Bromo-2,3,6-trifluorobenzaldehyde oxime (4.50 g, 17.7 mmol) was dissolved in anhydrous toluene (100 mL). Acetic anhydride (4.99 mL, 53.1 mmol) was added to the mixture at room temperature, and the mixture was reacted at 80°C for 18 hours. TLC indicated the reaction was complete. The reaction solution was poured into water (100 mL) and extracted with ethyl acetate (100 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent to obtain the crude product. The crude product was then separated by flash silica gel column chromatography (0-30% EA in PE) to afford 4-Bromo-2,3,6-trifluorobenzaldehyde O-acetyl oxime (5.20 g, yield: 79.3%, purity: 80%).

¹ H NMR (400MHz, CDCl ₃ ) δ8.50 (s, 1H), 7.26 (dt, J = 2.3, 4.6Hz, 1H), 2.28 (s, 3H).

Step 4: Synthesis of 4-bromo-2,3,6-trifluorobenzonitrile

4-Bromo-2,3,6-trifluorobenzaldehyde O-acetyl oxime (5.20 g, purity: 80%, 14.1 mmol) was dissolved in anhydrous toluene (100 mL). Ferric chloride (1.14 g, 7.03 mmol) was added to the mixture at room temperature, and the mixture was reacted at 25°C for 18 hours. TLC showed that the reaction was complete. The reaction solution was poured into water (100 mL) and extracted with ethyl acetate (100 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent to obtain the crude product. The residue was separated by a flash silica gel column [0-30% EA in PE] to obtain 4-bromo-2,3,6-trifluorobenzonitrile (3.81 g, yield: 91.9%).

¹ H NMR (400MHz, CDCl ₃ ) δ7.35 (ddd, J=2.2, 4.8, 7.5Hz, 1H).

Step 5: Synthesis of 2-amino-4-bromo-3,6-difluorobenzonitrile

4-Bromo-2,3,6-trifluorobenzonitrile (7.80 g, 33.1 mol) was dissolved in isopropanol (400 mL). Aqueous ammonia (100 mL) was added to the mixture at room temperature, and the mixture was reacted at 90°C for 18 hours. TLC indicated the reaction was complete. The reaction solution was poured into water (100 mL), resulting in the precipitation of a large amount of solid. The filter cake was filtered and dried to yield 2-amino-4-bromo-3,6-difluorobenzonitrile (7.16 g, yield: 92.9%).

¹ H NMR (400MHz, CDCl ₃ ) δ6.70 (dd, J=5.0, 8.0Hz, 1H), 4.79 (br s, 2H).

Step 6: Synthesis of 2-amino-4-bromo-6-(2,2-diethoxyethoxy)-3-fluorobenzonitrile

Dissolve 2,2-diethoxyethane-1-ol (8.57 mL, 57.5 mmol) in anhydrous tetrahydrofuran (500 mL). Slowly add sodium hydride (2.30 g, 57.5 mmol) to the mixture at 0°C under nitrogen protection. The mixture is allowed to react at 0°C for 0.5 hours. The temperature is then raised to 25°C and allowed to react for 0.5 hours. The reaction mixture is then cooled to 0°C and slowly added with 2-amino-4-bromo-3,6-difluorobenzonitrile (6.70 g, 28.8 mmol). The temperature is then raised to 70°C and allowed to react for 17 hours. TLC indicates the reaction is complete. Saturated aqueous ammonium chloride solution (100 mL) was slowly added dropwise to the reaction solution to quench the reaction. The reaction solution was poured into water (100 mL) and extracted with ethyl acetate (200 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent. The residue was separated by a fast silica gel column [0-30% EA in PE] to obtain 2-amino-4-bromo-6-(2,2-diethoxyethoxy)-3-fluorobenzonitrile (9 g, yield: 90.2%).

¹ H NMR (400MHz, CDCl ₃ ) δ6.40 (d, J = 4.8Hz, 1H), 4.84 (t, J = 5.2Hz, 1H), 4.63 (br s,2H),4.01(d,J＝5.1Hz,2H),3.82(qd,J＝7.1,9.3Hz,2H),3.74-3.63(m,2H),1.27(t,J＝7.0Hz,6H).

Step 7: Synthesis of 6-amino-4-bromo-5-fluorobenzofuran-7-carbonitrile

2-Amino-4-bromo-6-(2,2-diethoxyethoxy)-3-fluorobenzonitrile (8.50 g, 24.5 mmol) was dissolved in anhydrous toluene (100 mL). Polyphosphoric acid (20.1 g, 245 mmol) was added to the mixture at room temperature, and the mixture was reacted at 90°C for 2 hours. TLC showed that the reaction was complete. The reaction solution was poured into saturated aqueous sodium bicarbonate solution (200 mL) and extracted with ethyl acetate (200 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent. The residue was separated by rapid [0-30% EA in PE] to obtain 6-amino-4-bromo-5-fluorobenzofuran-7-carbonitrile (1.50 g, yield: 24.0%).

¹ H NMR (400MHz, CDCl ₃ ) δ7.62 (d, J = 2.2 Hz, 1H), 6.77 (d, J = 2.2 Hz, 1H), 4.68 (br s, 2H).

Step 8: Synthesis of 6-amino-4-bromo-5-fluorobenzofuran-7-carboxamide

6-Amino-4-bromo-5-fluorobenzofuran-7-carbonitrile (1.30 g, 5.10 mol) was dissolved in ethanol (45 mL). Potassium hydroxide (1.14 g, 20.4 mmol) and water (15 mL, 832 mmol) were added to the mixture at room temperature, and the mixture was reacted at 90°C for 4 hours. TLC indicated the reaction was complete. The reaction solution was cooled to room temperature and concentrated under reduced pressure to a small amount. Dilute hydrochloric acid was added to adjust the pH to 4, resulting in the precipitation of a solid. The filter cake was then filtered and dried to yield 6-amino-4-bromo-5-fluorobenzofuran-7-carboxamide (820 mg, 58.9% yield).

¹ H NMR (400MHz, CDCl ₃ ) δ7.63-7.47 (m, 2H), 6.80 (d, J = 2.1Hz, 1H), 6.67-6.30 (m, 2H), 5.81 (br s, 1H).

Step 9: Synthesis of 6-amino-4-bromo-5-fluoro-2,3-dihydrobenzofuran-7-carboxamide

6-Amino-4-bromo-5-fluorobenzofuran-7-carboxamide (500 mg, 1.83 mmol) was dissolved in trifluoroacetic acid (10 mL). Triethylsilane (5 mL, 31.0 mol) was added to the mixture at room temperature, and the mixture was reacted at 80°C for 2 hours. TLC indicated the reaction was complete. The reaction solution was cooled to room temperature and concentrated under reduced pressure to a small amount. Sodium bicarbonate was added to adjust the pH to 8, and the mixture was extracted with ethyl acetate (10 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent. The residue was separated by flash silica gel column chromatography (0-30% EA in PE) to yield 6-amino-4-bromo-5-fluoro-2,3-dihydrobenzofuran-7-carboxamide (250 mg, yield: 49.6%). ESI-MS: 276.8 [M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ ) δ7.60-7.35 (m, 2H), 6.88 (s, 2H), 4.68 (t, J = 8.7Hz, 2H), 3.14-3.06 (m, 2H).

Step 10: Synthesis of 4-bromo-5-fluoro-3,6-dihydrofuro[2,3-f]quinazoline-7,9(2H,8H)-dione

6-Amino-4-bromo-5-fluoro-2,3-dihydrobenzofuran-7-carboxamide (200 mg, 0.727 mol) was dissolved in N,N-dimethylformamide (10 mL). N,N'-Carbonyldiimidazole (472 mg, 2.91 mmol) and potassium carbonate (402 mg, 2.91 mmol) were added to the mixture at room temperature, and the mixture was reacted at 80°C for 18 h. TLC indicated the reaction was complete. The reaction solution was cooled to room temperature and poured into water (20 mL), resulting in a large amount of solid precipitation. The mixture was filtered and the filter cake was dried to yield 4-bromo-5-fluoro-3,6-dihydrofuro[2,3-f]quinazoline-7,9(2H,8H)-dione (118 mg, yield: 53.9%).

¹ H NMR (400MHz, DMSO-d ₆ ) δ4.58 (t, J = 8.8 Hz, 2H), 3.06 (br t, J = 8.9 Hz, 2H).

Step 11: Synthesis of 4-bromo-7,9-dichloro-5-fluoro-2,3-dihydrofuro[2,3-f]quinazoline

4-Bromo-5-fluoro-3,6-dihydrofuro[2,3-f]quinazoline-7,9(2H,8H)-dione (100 mg, 0.332 mmol) was dissolved in phosphorus oxychloride (5 mL). N,N-Diisopropylethylamine (172 mg, 1.33 mmol) was added to the mixture at room temperature, and the mixture was reacted at 120°C for 3 hours. LCMS indicated the reaction was complete. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The residue was poured into aqueous sodium bicarbonate solution and extracted with ethyl acetate (10 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent, yielding 4-bromo-7,9-dichloro-5-fluoro-2,3-dihydrofuro[2,3-f]quinazoline (80.0 mg, yield: 71.2%). ESI-MS: 338.8 [M+1] ⁺ .

¹ H NMR (400MHz, CDCl ₃ ) δ4.94-4.94(m,1H),5.00-4.89(m,2H),3.55-3.39(m,2H).

2. Preparation of Specific Examples

Example 1 (Isomer 1): Preparation of 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile (Isomer 1)

Step 1: Synthesis of 6-bromo-1-chloro-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline

6-Bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-ol (2 g, 4.63 mmol) and N,N-diisopropylethylamine (7.66 mL, 46.3 mmol) were dissolved in anhydrous acetonitrile (20 mL), and then phosphorus oxychloride (4.32 mL, 46.3 mmol) was added. The reaction solution was stirred at 80°C for 18 hours. LCMS showed that the reaction was complete. The reaction solution was concentrated under reduced pressure to remove the solvent, and the residue was poured into 100 mL of ice water and extracted with ethyl acetate (50 mL*2). The combined organic phases were washed with saturated sodium chloride aqueous solution (50 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was purified by flash silica gel column [0-30% EA and PE] were used to separate 6-bromo-1-chloro-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline (1.46 g, yield: 86.4%). ESI-MS: 362.9 [M+1] ⁺ .

Step 2: Synthesis of tert-butyl (1R,5S)-8-(6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

6-Bromo-1-chloro-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline (970 mg, 2.67 mmol) was dissolved in anhydrous tetrahydrofuran (30 mL), and then N,N-diisopropylethylamine (2.2 mL, 13.3 mmol) and tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (680 mg, 3.2 mmol) were added. The reaction solution was reacted at 40°C for 1 hour. LCMS showed the reaction was complete. 30 mL of water was poured into the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL x 2). The combined organic phases were washed with saturated sodium chloride (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was separated using a flash silica gel column (0-30% EA in PE) to afford tert-butyl (1R,5S)-8-(6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (1.37 g, yield: 95.2%). ESI-MS: 539.1 [M+1] ⁺ .

Step 3: Synthesis of tert-butyl (1R,5S)-8-(6-bromo-3-(ethylsulfonyl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

Dissolve tert-butyl (1R,5S)-8-(6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (2 g, 3.707 mmol) in anhydrous dichloromethane (30 mL). The mixture was cooled to 0°C and then added with m-chloroperbenzoic acid (2.26 g, 11.1 mmol, 85% purity). The mixture was reacted at 25°C for 1 hour. LCMS indicated the reaction was complete. The reaction mixture was then poured into 50 mL of saturated aqueous sodium bicarbonate solution, extracted with dichloromethane (50 mL x 2), and washed with saturated aqueous sodium chloride solution (50 mL). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent, yielding tert-butyl (1R,5S)-8-(6-bromo-3-(ethylsulfonyl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (2.05 g, crude product), which was used directly in the next reaction. ESI-MS: 571.1 [M+1] ⁺ .

Step 4: Synthesis of tert-butyl (1R,5S)-8-(6-bromo-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

Tert-butyl (1R,5S)-8-(6-bromo-3-(ethylsulfonyl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (500 mg, 0.875 mmol) was dissolved in anhydrous tetrahydrofuran (20 mL). (2,2-Difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methanol (Intermediate A3 Isomer 1) (178 mg, 0.875 mmol) was added. The reaction mixture was cooled to 0°C and sodium tert-butoxide (252 mg, 2.62 mmol) was added. The mixture was reacted at 25°C for 1 hour. LCMS indicated the reaction was complete. 30 mL of water was poured into the reaction mixture, and the mixture was extracted with ethyl acetate (20 mL x 2). The combined organic phases were washed with saturated aqueous sodium chloride (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was separated using a flash silica gel column [0-30% EA in PE] to afford tert-butyl (1R,5S)-8-(6-bromo-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (638 mg, yield: 97%). ESI-MS: 680.2 [M+1] ⁺ .

Step 5: Synthesis of tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

Dissolve tert-butyl (1R,5S)-8-(6-bromo-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (400 mg, 0.588 mmol) in anhydrous dioxane (20 mL) To a solution of tert-butyl (3-cyano-7-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborol-2-yl)benzo[b]thiophen-2-yl)carbamate (399 mg, 0.764 mmol), potassium phosphate (374 mg, 1.76 mmol), and Pd-118 (38.3 mg, 0.059 mmol) was added to water (5 mL). The mixture was reacted at 100°C under nitrogen for 1 hour. LCMS indicated the reaction was complete. 30 mL of water was poured into the reaction solution, and the mixture was extracted with ethyl acetate (20 mL*2). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was separated by flash silica gel column [0-30% EA in PE] to give tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (288 mg, yield: 54.9%). ESI-MS:892.3[M+1] ⁺ .

Step 6: Synthesis of 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

Tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (288 mg, 0.323 mmol) was dissolved in acetonitrile (3 mL). A solution of hydrogen chloride in dioxane (3 mL, 2 N) was added, and the mixture was reacted at 25°C for 1 hour. LCMS indicated the reaction was complete. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the residue was separated using a reverse phase column [5%-60% MeCN in H ₂ O] to afford 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile formate (100.3 mg, yield: 40.7%). ESI-MS: 692.2 [M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ ) δ8.21 (s, 1H), 8.09 (s, 2H), 7.32 (dd, J = 5.2, 8.1Hz, 1H), 7.14 (t, J = 8.9Hz, 1H), 5.46 (br s, 2H), 4.87 (br d,J＝12.2Hz,1H),4.68(br d,J＝12.5Hz,1H),4.27-4.17(m,4H),3.17-2.98(m,5H),2.83-2.71(m,3H),2.12-2.05(m,1H),2.02-1.96(m,1H),1.91(br d,J＝13.9Hz,3H),1.86-1.74(m,4H),1.66-1.54(m,2H),1.47(dt,J＝3.8,8.5Hz,1H).

Example 1 (Isomer 2): Preparation of 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile (Isomer 2)

Example 1 (Isomer 2) was prepared according to the synthetic method of Compound Reference Example 1 (Isomer 1) using Intermediate A3 Isomer 2 instead of Intermediate A3 Isomer 1. ESI-MS: 692.2 [M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ ) δ8.18(s,1H),8.10(s,2H),7.29(s,1H),7.22-7.01(m,1H),5.46(br s,2H),4.86(br d,J＝2.4Hz,1H),4.68(br d,J＝12.5Hz,1H),4.24(br d,J＝5.3Hz,2H),4.09(br d,J＝7.8Hz,1H),3.98(d,J＝10.4Hz,1H),3.22-3.09(m,2H),3.08(s,1H),3. 03-2.93(m,1H),2.88-2.75(m,3H),2.73-2.64(m,1H),2.55(s,1H),2.13(br d,J＝13.2Hz,1H),2.00-1.78(m,9H),1.58-1.51(m,2H).

Example 2 (Isomer 1): Preparation of 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-5-fluoro-3-(((2S)-2-(methylthio)tetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

The compound of Example 2 (Isomer 1) was prepared by referring to the synthetic method of Example 1 (Isomer 1).

ESI-MS: 676.8[M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ )δ8.10(s,2H),7.33-7.29(m,1H),7.13(t,J＝8.8Hz,1H),5.44(s,2H),4.86(d,J＝10.6 Hz,1H),4.67(d,J＝12.2Hz,1H),4.19(s,2H),4.10(dd,J＝10.4,4.8Hz,1H),4.02(d,J＝1 0.4Hz,1H),3.04(t,J＝14.2Hz,2H),2.88(dd,J＝10.8,5.6Hz,2H),2.69(d,J＝14.2Hz,3H ),2.43-2.32(m,3H),2.06(d,J＝1.8Hz,3H),1.86-1.70(m,9H),1.48(t,J＝10.2Hz,1H).

Example 2 (Isomer 2): Preparation of 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-5-fluoro-3-(((2S)-2-(methylthio)tetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile (Isomer 2)

The compound of Example 2 (Isomer 2) was prepared by referring to the synthetic method of Example 1 (Isomer 1).

ESI-MS: 676.8[M+1] ⁺ .

¹ H NMR (400 MHz, DMSO-d ₆ )δ8.10(s,2H),7.32(ddd,J＝8.4,5.2,1.4Hz,1H),7.13(dd,J＝9.4,8.4Hz,1H),5 .44(s,2H),4.86(d,J＝12.4Hz,1H),4.67(d,J＝12.2Hz,1H),4.23-4.05(m,4H),3 .26(d,J＝6.8Hz,1H),3.08-2.97(m,4H),2.73-2.65(m,3H),2.59-2.54(m,1H),2 .11(dd,J＝12.4,6.6Hz,1H),2.06(s,3H),2.00-1.97(m,1H),1.88-1.52(m,9H).

The compounds of Examples 3 to 25 can be prepared by selecting corresponding raw materials according to the synthesis method of Example 1 (Isomer 1):

The NMR data of the compound prepared in the above example are as follows:

Example 26 (Isomer 1) and (Isomer 2): Preparation of 4-(1-(2-oxa-6-azabicyclo[5.1.0]octan-6-yl)-5-fluoro-3-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile (Isomer 1) and (Isomer 2)

The compounds of Example 6 (Isomer 1) and (Isomer 2) were prepared by selecting appropriate raw materials according to the synthetic route of Example 1 (Isomer 1), and Isomer 1 and Isomer 2 were separated in the final step. ESI-MS: 649.1 [M+1] ⁺ .

Isomer 1:

¹ H NMR (400MHz, DMSO-d ₆ ) δ8.11 (s, 2H), 7.30-7.37 (m, 1H), 7.14 (t, J = 8.91Hz, 1H), 5.47 (br d, J = 13.20Hz, 1H), 5.25 (br d,J＝12.76Hz,2H),4.60-4.75(m,2H),4.35(br d,J＝13.42Hz,1H),3.95-4.15(m,2H),3.81-3.90(m,1H),3.62-3.74(m,1H),3.42-3.57(m,2H),2.98-3.19(m,4H),2. 76-2.89(m,1H),2.55-2.66(m,1H),1.94-2.18(m,3H),1.64-1.89(m,4H),1.00(q,J＝7.34Hz,1H),0.30-0.45(m,1H).

Isomer 2:

¹ H NMR (400MHz, DMSO-d ₆ ) δ8.10 (s, 2H), 7.30 (dd, J = 8.36, 5.28Hz, 1H), 7.12 (t, J = 8.91Hz, 1H), 5.47 (br d,J＝13.20Hz,1H),5.18-5.37(m,2H),4.83-4.93(m,1H),4.48-4.58(m,1H), 4.24-4.34(m,1H),3.95-4.12(m,2H),3.83-3.93(m,1H),3.65-3.76(m,1H), 3.47-3.59(m,2H),2.99-3.14(m,4H),2.77-2.88(m,1H),2.59-2.73(m,1H), 1.96-2.21(m,3H),1.65-1.89(m,4H),1.07-1.18(m,1H),0.20-0.34(m,1H).

Example 27: Preparation of 4-(1-(3,8-diazabicyclo[3.2.1]octan-8-yl-1,5-d ₂ )-5-fluoro-3-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

Step 1: Synthesis of (9H-fluoren-9-yl)methyl 8-(6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate-1,5-d ₂

The corresponding raw materials were selected and synthesized by referring to the first step of the synthesis method in Example 1 (isomer 1).

Step 2: Synthesis of 1-(3,8-diazabicyclo[3.2.1]octan-8-yl-1,5-d ₂ )-6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline

(9H-Fluoren-9-yl)methyl 8-(6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate-1,5- _d2 (1.2 g, 1.085 mmol) was dissolved in anhydrous tetrahydrofuran (20 mL). Dimethylamine tetrahydrofuran solution (10.8 mL, 21.7 mmol) was added at 0°C, and the mixture was stirred at 25°C for 3 hours. LC-MS indicated the reaction was complete. Saturated ammonium chloride solution (30 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (3*30 mL). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford 1-(3,8-diazabicyclo[3.2.1]octan-8-yl-1,5-d ₂ )-6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline (1 g, yield: 93.7%). ESI-MS: 441.0 [M+1] ⁺ .

Step 3: Synthesis of tert-butyl 8-(6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate-1,5-d ₂

1-(3,8-diazabicyclo[3.2.1]octan-8-yl-1,5-d ₂ )-6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline (1 g, 1.02 mmol, purity: 45%) was dissolved in anhydrous dichloromethane (30 mL). Boc anhydride (0.327 mL, 1.53 mmol) and triethylamine (0.425 mL, 3.05 mmol) were added at 25°C, and the mixture was stirred at 25°C for 16 hours. LC-MS showed the reaction was complete. Water (20 mL) was added to the reaction solution, and the mixture was extracted with ethyl acetate (2*20 mL). The combined organic phases were washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated using a flash silica gel column [0-30% EA in PE] to afford tert-butyl 8-(6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate-1,5- _d2 (450 mg, yield: 81.5%). ESI-MS: 543.1 [M+3] ⁺ .

Step 4-Step 7: Synthesis of 4-(1-(3,8-diazabicyclo[3.2.1]octan-8-yl-1,5-d ₂ )-5-fluoro-3-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

The corresponding raw materials were selected and synthesized by referring to the synthesis method of steps 3 to 6 of Example 1 (isomer 1). ESI-MS: 650.1 [M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ ) δ8.19(s,1H),8.11(s,2H),7.32(dd,J＝5.4,7.9Hz,1H),7.14(t,J＝8.9Hz,1H),5.46(br s,2H),5.37-5.20(m,1H),4.87(br d,J＝12.3Hz,1H),4.68(br d,J＝12.5Hz,1H),4.15-4.11(m,1H),4.05(br dd,J＝2.9,10.4Hz,1H),3.16-3.00(m,6H),2.87-2.75(m,3H),2.18-1.99(m,3H),1.90-1.75(m,7H).

Example 28 (Isomer 1): Preparation of 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-2-amino-7-fluorothieno[3,2-c]pyridine-3-carbonitrile

Step 1: Synthesis of tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorothieno[3,2-c]pyridin-4-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

Tert-butyl (1R, 5S)-8-(6-bromo-3-((2,2-difluorodihydro-1'H, 3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (isomer 1) (250 mg, 0 0.367 mmol) was dissolved in anhydrous dioxane (10 mL), and 5,5,5',5'-tetramethyl-2,2'-bi(1,3,2-dioxaborinyl) (124 mg, 0.551 mmol), potassium acetate (108 mg, 1.102 mmol), and Pd-117 (26.3 mg, 0.037 mmol) were added. The mixture was reacted at 95°C under nitrogen for 2 hours. LCMS indicated the reaction was complete. The reaction solution was cooled to room temperature, and then tert-butyl (4-chloro-3-cyano-7-fluorothieno[3,2-c]pyridin-2-yl)carbamate (144 mg, 0.441 mmol), potassium phosphate (234 mg, 1.10 mmol), and XPhos Pd G4 (31.6 mg, 0.037 mmol) were added. The mixture was reacted at 95°C under nitrogen for 2 hours. LCMS indicated the reaction was complete. 30 mL of water was poured into the reaction solution, and the mixture was extracted with ethyl acetate (20 mL*2). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was separated by flash silica gel column [0-30% EA in PE] to give tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorothieno[3,2-c]pyridin-4-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (107 mg, yield: 32.6%). ESI-MS:893.3[M+1] ⁺ .

Step 2: Synthesis of 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-2-amino-7-fluorothieno[3,2-c]pyridine-3-carbonitrile

Tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorothieno[3,2-c]pyridin-4-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (107 mg, 0.074 mmol) was dissolved in acetonitrile (3 mL). A solution of hydrogen chloride in dioxane (3 mL, 2 N) was added, and the mixture was reacted at 25°C for 1 hour. LCMS indicated the reaction was complete. The reaction mixture was concentrated under reduced pressure to remove the solvent, and the residue was separated using a reverse phase column [5%-60% MeCN in H ₂ O] to afford 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-2-amino-7-fluorothieno[3,2-c]pyridine-3-carbonitrile formate (Isomer 1) (29.5 mg, yield: 56.6%). ESI-MS: 693.2 [M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ ) δ 8.43 (s, 2H), 8.21 (s, 1H), 5.46 (br s, 2H), 5.04 (br d, J = 12.5Hz, 1H), 4.69 (br d, J = 12.7Hz, 1H), 4.30 (br s,1H),4.24-4.19(m,3H),3.17-2.99(m,5H),2.80-2.70(m,3H),2.09(td,J＝5.6,13.1Hz,1H),2.02-1.97(m,1H),1.92(s,1H),1.89(br s,3H),1.84-1.70(m,4H),1.65-1.55(m,2H),1.50-1.44(m,1H).

Example 29 (Isomer 1): Preparation of 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-6-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile (Isomer 1)

Step 1: Synthesis of 6-bromo-1-chloro-3-(ethylthio)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazoline

6-Bromo-3-(ethylthio)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-1-ol (1 g, 1.74 mmol) was dissolved in anhydrous acetonitrile (50 mL). Phosphorus oxychloride (1.62 mL, 17.4 mmol) and N,N-diisopropylethylamine (2.87 mL, 17.4 mmol) were added. The mixture was then stirred at 100°C for 4 hours. LCMS analysis indicated the reaction was complete. The reaction mixture was concentrated, and the residue was poured into water (30 mL). The mixture was extracted with ethyl acetate (30 mL x 2). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to yield 6-bromo-1-chloro-3-(ethylthio)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazoline (690 mg, yield: 76.4%). ESI-MS:362.9[M+1] ⁺ .

¹ H NMR (400MHz, CDCl ₃ ) δ4.87 (t, J = 9.2 Hz, 2H), 3.96 (dt, J = 2.1, 9.2 Hz, 2H), 3.26 (q, J = 7.4 Hz, 2H), 1.46 (t, J = 7.3 Hz, 3H).

Step 2: Synthesis of tert-butyl (1R,5S)-8-(6-bromo-3-(ethylthio)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

Dissolve 6-bromo-1-chloro-3-(ethylthio)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazoline (600 mg, 1.15 mmol) in anhydrous tetrahydrofuran (10 mL). Add tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (319 mg, 1.50 mmol) and N,N-diisopropylethylamine (0.955 mL, 5.77 mmol). Stir at 50°C for 4 hours. LCMS analysis indicates the reaction is complete. Water (40 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (20 mL x 2). The combined organic phases were washed with saturated brine (20 mL) and dried over anhydrous magnesium sulfate. The residue was separated using a flash silica gel column [0-30% EA in PE] to afford tert-butyl (1R,5S)-8-(6-bromo-3-(ethylthio)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (500 mg, yield: 80.2%). ESI-MS: 541.1 [M+3] ⁺ .

¹ H NMR (400MHz, CDCl ₃ ) δ4.75 (br t, J = 8.4Hz, 2H), 4.29 (br s,2H),4.03-3.79(m,2H),3.70(dt,J＝1.7,8.7Hz,2H),3.40-3.26(m,2H),3.21(q,J＝7.4Hz,2H),2.01-1.85(m,2H),1.78(br d,J＝9.5Hz,2H),1.63-1.54(m,1H),1.49(s,8H),1.46-1.40(m,3H).

Step 3: Synthesis of tert-butyl (1R,5S)-8-(6-bromo-3-(ethylsulfonyl)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

Tert-butyl (1R,5S)-8-(6-bromo-3-(ethylthio)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (400 mg, 0.741 mmol) was dissolved in anhydrous dichloromethane (20 mL). Meta-chloroperbenzoic acid (451 mg, 2.22 mmol, 85% purity) was added to the mixture at 0°C, followed by stirring at 25°C for 2 hours. LCMS analysis indicated the reaction was complete. Saturated sodium bicarbonate (30 mL) was added to the reaction solution, and the mixture was extracted with dichloromethane (20 mL x 2). The organic phase was washed with saturated brine (20 mL) and dried over anhydrous magnesium sulfate. The residue was separated using a flash silica gel column [0-30% EA in PE] to afford tert-butyl (1R,5S)-8-(6-bromo-3-(ethylsulfonyl)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (400 mg, yield: 94.4%). ESI-MS: 573.1 [M+3] ⁺ .

Step 4: Synthesis of tert-butyl (1R,5S)-8-(6-bromo-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (isomer 1)

Tert-butyl (1R,5S)-8-(6-bromo-3-(ethylsulfonyl)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (110 mg, 0.192 mmol) and (2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methanol (isomer 1) (46.9 mg, 0.231 mmol) were dissolved in anhydrous tetrahydrofuran (6 mL). Sodium tert-butoxide (55.5 mg, 0.577 mmol) was added at 0°C under nitrogen. The mixture was allowed to react at 25°C for 0.5 h. LC-MS indicated the reaction was complete. Water (15 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (2 x 15 mL). The combined organic phases were washed with saturated brine (25 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to provide tert-butyl (1R,5S)-8-(6-bromo-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (Isomer 1) (151 mg). ESI-MS: 680.2 [M+1] ⁺ .

Step 5: Synthesis of tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (Isomer 1)

Tert-butyl (1R,5S)-8-(6-bromo-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (120 mg, 0.176 mmol) and tert-butyl (3-cyano-7-fluoro-4- (4,4,5,5-Tetramethyl-1,3,2-dioxaborol-2-yl)benzo[b]thiophen-2-yl)carbamate (119.8 mg, 0.229 mmol) was dissolved in dioxane (6 mL) and water (2 mL). Pd-118 (11.5 mg, 0.018 mmol) and potassium phosphate (112.3 mg, 0.529 mmol) were added at 25 °C. The reaction solution was stirred at 100 °C under nitrogen for 1 hour. The reaction mixture was extracted with water (20 mL) and ethyl acetate (20 mL), and the organic phase was washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure. The residue was separated by flash silica gel column [0-30% EA in PE] to give tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorobenzo[b]thiophene-4-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolizine)-7a'(5'H)-yl)methoxy)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (isomer 1) (180 mg, yield: 91.5%).

ESI-MS:892.4[M+1] ⁺ .

Step 6: Synthesis of 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-6-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile (isomer 1)

Tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (Isomer 1) (130 mg, 0.117 mmol) was dissolved in dioxane (3 mL). Hydrochloric acid/dioxane (3 mL) was added at 0°C and the reaction was stirred at 25°C for 1 hour. The reaction mixture was concentrated under reduced pressure, and the residue was separated using a reverse phase column [5%-60% MeCN in H ₂ O] to give 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-6-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile trifluoroacetate (Isomer 1) (21.4 mg, yield: 25.9%). ESI-MS: 692.3 [M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ )δ10.98-10.82(m,1H),9.53-9.40(m,1H),8.89-8.74(m,1H),8.08(s,2H),7 .28(dd,J＝5.3,8.3Hz,1H),7.14(t,J＝8.9Hz,1H),4.75-4.68(m,1H),4.63(br s,2H),4.57(br d,J＝9.4Hz,1H),4.43(br s,1H),3.80-3.73(m,1H),3.73-3.60(m,4H),3.57-3.52(m,2H),3.37-3.29(m,4H),3.16(br dd,J＝3.1,7.8Hz,1H),2.47-2.43(m,1H),2.29-2.23(m,2H),2.22-2.13(m,2H),2.09-1.98(m,4H),1.89(br dd,J＝6.8,11.0Hz,2H).

Example 29 (Isomer 2): Preparation of 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-8,9-dihydrofuro[3,2-f]quinazolin-6-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile (Isomer 2)

The compound of Example 29 (Isomer 2) was prepared by referring to the synthetic method of Example 1 (Isomer 1).

ESI-MS:692.3[M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ )δ8.24(s,1H),8.05(s,2H),7.29(td,J＝5.2,8.5Hz,1H),7.11(t,J＝8.9H z,1H),4.64-4.50(m,2H),4.33-4.25(m,1H),4.21-4.13(m,1H),4.02(br dd,J＝5.8,10.7Hz,1H),3.92(br dd,J＝1.8,10.8Hz,1H),3.60(br dd,J＝2.0,5.9Hz,2H),3.19-3.11(m,2H),3.04(br d,J＝10.1Hz,2H),2.97(td,J＝4.8,10.1Hz,2H),2.77(br dd,J＝6.2,10.3Hz,1H),2.69(br d,J＝11.0Hz,2H),2.12(dd,J＝3.2,13.1Hz,1H),1.92-1.82(m,6H),1.78-1.70(m,2H),1.57-1.49(m,2H).

Example 30 (Isomer 1) and (Isomer 2): Preparation of 2-amino-4-(1-((1-(2-aminopyridin-3-yl)ethyl)(methyl)amino)-5-fluoro-3-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-8,9-dihydrofuro[3,2-f]quinazolin-6-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile (Isomer 1) and (Isomer 2)

The compounds of Example 30 (Isomer 1) and (Isomer 2) were prepared by referring to the synthesis method of Example 29 (Isomer 1), and Isomer 1 and Isomer 2 were separated in the last step.

Isomer 1:

¹ H NMR (400MHz, DMSO-d ₆ )δ8.20(s,1H),8.03(s,2H),7.90(dd,J＝1.7,5.0Hz,1H),7.60-7.55(m,1H),7.27(dd,J＝5.3 ,8.4Hz,1H),7.11(dd,J＝8.6,9.4Hz,1H),6.60(dd,J＝4.9,7.5Hz,1H),5.83(s,2H),5.38-5. 19(m,2H),4.65-4.46(m,2H),4.09-3.99(m,2H),3.59-3.50(m,2H),3.13-3.00(m,3H),2.86 -2.80(m,1H),2.76(s,3H),2.15-2.09(m,1H),2.06-1.97(m,2H),1.88-1.75(m,3H),1.63(br d,J＝6.6Hz,3H).

Isomer 2:

¹ H NMR (400MHz, DMSO-d ₆ ) δ8.25 (s, 1H), 8.04 (s, 2H), 7.90 (br d, J = 4.2Hz, 1H), 7.57 (br d,J＝6.4Hz,1H),7.27(dd,J＝5.0,8.5Hz,1H),7.11(t,J＝8.9Hz,1H),6.59(dd,J＝5.0,7.2Hz, 1H),5.91(s,2H),5.38-5.19(m,2H),4.57(dt,J＝4.4,8.6Hz,2H),4.10-3.96(m,2H),3.55(br t,J＝8.5Hz,2H),3.14-3.02(m,3H),2.87-2.79(m,1H),2.74(s,3H),2.13(br dd,J＝2.1,6.5Hz,1H),2.08-1.98(m,2H),1.86-1.75(m,3H),1.67-1.58(m,3H).

Examples 31-37 can be prepared by selecting corresponding raw materials according to the synthesis method of Example 29 (Isomer 1):

The NMR data of the compound prepared in the above example are as follows:

Example 38: Preparation of 4-(9-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-2,3-dihydrofuro[2,3-f]quinazolin-4-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

Step 1: Synthesis of tert-butyl (1R,5S)-8-(4-bromo-7-chloro-5-fluoro-2,3-dihydrofuro[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

4-Bromo-7,9-dichloro-5-fluoro-2,3-dihydrofuro[2,3-f]quinazoline (35.0 mg, 0.104 mmol) and 3-tert-butoxycarbonyl-3,8-diazabicyclo[3.2.1]octane (22.1 mg, 0.104 mmol) were dissolved in anhydrous dichloromethane (2 mL). N,N-diisopropylethylamine (53.5 mg, 0.414 mmol) was added at 25°C under nitrogen. The mixture was reacted at 50°C for 0.5 hours. LC-MS indicated the reaction was complete. The reaction mixture was poured into water (15 mL) and extracted with dichloromethane (20 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent. The residue was separated using a flash silica gel column [0-30% EA in PE] to afford tert-butyl (1R,5S)-8-(4-bromo-7-chloro-5-fluoro-2,3-dihydrofuro[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (40.0 mg, yield: 75.2%). ESI-MS: 515.1 [M+3] ⁺ .

Step 2: Synthesis of tert-butyl (1R,5S)-8-(4-bromo-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-2,3-dihydrofuro[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

Dissolve tert-butyl (1R,5S)-8-(4-bromo-7-chloro-5-fluoro-2,3-dihydrofuro[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (40.0 mg, 0.078 mmol) and [(2R,8S)-2-fluoro-1,2,3,5,6,7-hexahydropyrrolizin-8-yl]methanol (24.8 mg, 0.156 mmol) in anhydrous tetrahydrofuran (5 mL). Add sodium tert-butoxide (29.9 mg, 0.311 mmol) at 0°C under nitrogen. The mixture was allowed to react at 0°C for 0.5 h. LC-MS indicated the reaction was complete. The reaction mixture was poured into water (15 mL) and extracted with ethyl acetate (15 mL). The organic phase was dried over anhydrous sodium sulfate and then concentrated under reduced pressure to remove the solvent. The residue was separated using a flash silica gel column (0-30% EA in PE) to afford tert-butyl (1R,5S)-8-(4-bromo-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-2,3-dihydrofuro[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (20.0 mg, yield: 40.3%). ESI-MS: 636.3 [M+1] ⁺ .

Step 3: Synthesis of tert-butyl (1R,5S)-8-(4-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-2,3-dihydrofuro[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

Tert-butyl (1R,5S)-8-(4-bromo-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-2,3-dihydrofuro[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (20.0 mg, 0.0310 mmol) and tert-butyl (3-cyano-7-fluoro-4 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborol-2-yl)benzo[b]thiophen-2-yl)carbamate (21.4 mg, 0.0410 mmol) was dissolved in anhydrous dioxane (3 mL) and water (1 mL). Potassium phosphate (20.0 mg, 0.094 mmol) and Pd-118 (2.05 mg, 0.003 mmol) were added under nitrogen at 25°C. The mixture was allowed to react at 100°C for 1 hour. LC-MS indicated the reaction was complete. The reaction mixture was poured into water (20 mL) and extracted with ethyl acetate (20 mL). The organic phase was dried over anhydrous sodium sulfate and then concentrated under reduced pressure to remove the solvent. The residue was separated using a flash silica gel column (0-30% EA in PE) to afford tert-butyl (1R,5S)-8-(4-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-2,3-dihydrofuro[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (12.0 mg, yield: 45.0%). ESI-MS: 848.4 [M+1] ⁺ .

Step 4: Synthesis of 4-(9-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-2,3-dihydrofuro[2,3-f]quinazolin-4-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

Dissolve tert-butyl (1R,5S)-8-(4-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-2,3-dihydrofuro[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (12 mg, 0.014 mmol) in dioxane hydrochloride (1 mL). The mixture was reacted at 25°C for 2 hours. LC-MS indicated the reaction was complete. The reaction mixture was directly concentrated under reduced pressure to remove the solvent, and the residue was separated using a reverse phase column [5%-60% MeCN in _H2O ] to afford 4-(9-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-2,3-dihydrofuro[2,3-f]quinazolin-4-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile (2.70 mg, yield: 26.1%). ESI-MS: 648.1 [M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ ) δ8.23 (s, 1H), 8.06 (s, 2H), 7.29 (dd, J = 5.2, 8.4Hz, 1H), 7.12 (t, J = 8.9Hz, 1H), 5.35-5.18 (m, 1H), 4.68 (br t,J＝9.0Hz,2H),4.57-4.47(m,2H),4.07-4.03(m,1H),3.96(br dd,J＝3.9,10.5Hz,1H),3.10-3.05(m,3H),3.00(br s,2H),2.90-2.77(m,3H),2.73-2.65(m,3H),2.13-1.98(m,3H),1.91-1.73(m,7H).

Example 39: Preparation of 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-3-((1-((4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-2-amino-7-fluorothieno[3,2-c]pyridine-3-carbonitrile

Step 1: Synthesis of tert-butyl (1R,5S)-8-(6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

6-Bromo-1-chloro-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline (1.71 g, 4.71 mmol) was dissolved in THF (50 mL), and ethyldiisopropylamine (532 mg, 4.13 mmol) and 2-methylprop-2-yl 3,8-diazabicyclo[3.2.1]octane-3-carboxylate (1.11 mL, 5.64 mmol) were added. The reaction solution was heated to 50°C for 2 hours. After the reaction was completed, the product was extracted with ethyl acetate, the organic phase was dried by rotary evaporation, and the residue was separated by flash silica gel column [0-20%: ethyl acetate: petroleum ether] to give (1R,5S)-8-(6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid tert-butyl ester (2.26 g, yield: 87.3%).

ESI-MS:539.5[M+1] ⁺ .

Step 2: Synthesis of (1-((1R,5S)-3-(tert-butyloxycarbonyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-ylboronic acid

Dissolve tert-butyl (1R,5S)-8-(6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (1300 mg, 2.41 mmol) and 2-(5,5-dimethyl-1,3,2-dioxaborolan-2-yl)-5,5-dimethyl-1,3,2-dioxaborolan-2-yl)-5,5-dimethyl-1,3,2-dioxaborolan-3-yl (1633.1 mg, 7.23 mmol) in dioxane (50 mL). Add potassium acetate (709.5 mg, 7.23 mmol) and (DPEPhos) _PdCl₂ (517.5 mg, 0.72 mmol). Heat at 95°C for 2 hours. After completion of the reaction, the crude product was used directly in the next step.

ESI-MS:505.5[M+1] ⁺ .

Step 3: Synthesis of tert-butyl (1R,5S)-8-(6-(2-((tert-butyloxycarbonyl)amino)-3-cyano-7-fluorothieno[3,2-c]pyridin-4-yl)-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

To the reaction mixture from step 2, add water (10 mL), methyl 2-methylpropan-2-yl((4-chloro-3-cyano-7-fluorothieno[3,2-c]pyridin-2-yl)amino)carboxylate (701.8 mg, 2.14 mmol), Xphos-Pd-G4 (552.76 mg, 0.642 mmol), and potassium phosphate (1363.50 mg, 6.424 mmol). Heat to 95°C and react for 2 hours. Upon completion of the reaction, remove the solvent. The residue was purified by flash silica gel column chromatography [0-30% ethyl acetate:petroleum ether] to give tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorothieno[3,2-c]pyridin-4-yl)-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (718 mg, yield: 54%). ESI-MS: 752.8 [M+1] ⁺ .

Step 4: Synthesis of tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorothieno[3,2-c]pyridin-4-yl)-3-(ethylsulfinyl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

Tert-butyl (1R,5S)-8-(6-(2-((tert-Butyloxycarbonyl)amino)-3-cyano-7-fluorothieno[3,2-c]pyridin-4-yl)-3-ethylthio-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (909 mg, 1.21 mmol) was dissolved in dichloromethane (20 mL), and m-chloroperbenzoic acid (269.98 mg, 1.330 mmol) was added at 0°C. The reaction mixture was reacted at room temperature for 0.5 hours. After completion of the reaction, the reaction mixture was poured into a sodium bicarbonate solution and extracted with dichloromethane. The organic phase was dried, filtered, and the solvent removed to yield tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorothieno[3,2-c]pyridin-4-yl)-3-(ethylsulfinyl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (910 mg, yield: 88%). ESI-MS: 768.8 [M+1] ⁺ .

Step 5: Synthesis of tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorothieno[3,2-c]pyridin-4-yl)-5-fluoro-3-(2,2,2-trifluoroethoxy)-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

2,2,2-Trifluoroethanol (0.341 mL, 4.740 mmol) was dissolved in tetrahydrofuran (20 mL), and LiHDMS (2.370 mL, 2.370 mmol) was added at 0°C. The reaction mixture was stirred at 0°C for 15 minutes. Tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorothieno[3,2-c]pyridin-4-yl)-3-(ethylsulfinyl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (910 mg, 1.19 mmol) was then dissolved in tetrahydrofuran (20 mL) and added dropwise to the above solution at 0°C. The reaction mixture was allowed to react at room temperature for 1 hour. After the reaction was completed, the reaction mixture was poured into water and extracted with ethyl acetate. The organic phase was dried, filtered, and the solvent removed. The residue was separated using a flash silica gel column [0-30% ethyl acetate:petroleum ether] to afford tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorothieno[3,2-c]pyridin-4-yl)-5-fluoro-3-(2,2,2-trifluoroethoxy)-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (630 mg, yield: 61%). ESI-MS: 790.7 [M+1] ⁺ .

Step 6: Synthesis of tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorothieno[3,2-c]pyridin-4-yl)-3-((1-((4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

Tert-butyl (1R,5S)-8-(6-(2-((tert-Butyloxycarbonyl)amino)-3-cyano-7-fluorothieno[3,2-c]pyridin-4-yl)-5-fluoro-3-(2,2,2-trifluoroethoxy)-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (510 mg, 0.65 mmol) and (((4-(difluoromethylene)hexahydropyridin-1-yl)methyl)cyclopropyl)methanol (210.44 mg, 0.969 mmol) were dissolved in tetrahydrofuran (30 mL), and sodium tert-butoxide (1241.2 mg, 12.92 mmol) was added at 0°C. The reaction mixture was allowed to react at room temperature for 1 hour. After completion of the reaction, the reaction mixture was poured into water and extracted with ethyl acetate. The organic phase was dried, filtered, and the solvent removed. The residue was separated using a flash silica gel column [0-38%: ethyl acetate: petroleum ether] to provide tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorothieno[3,2-c]pyridin-4-yl)-3-((1-((4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (480 mg, yield: 74%). ESI-MS: 907.8 [M+1] ⁺ .

Step 7: Synthesis of 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-3-((1-((4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-2-amino-7-fluorothieno[3,2-c]pyridine-3-carbonitrile

Dissolve tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorothieno[3,2-c]pyridin-4-yl)-3-((1-((4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (460 mg, 0.51 mmol) in dichloromethane (5 mL), and then add trifluoroacetic acid (5 mL). The reaction mixture is reacted at room temperature for 1 hour. After the reaction is complete, the solvent is removed. The residue was prepared by reverse phase reaction [5%-60% MeCN in H ₂ O] to give 4-(1-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-3-((1-((4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)-2-amino-7-fluorothieno[3,2-c]pyridine-3-carbonitrile (150 mg, yield: 41%). ESI-MS: 707.8 [M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ )δ8.42(s,3H),5.44(s,2H),5.02(d,J＝12.6Hz,1H),4.68(d,J＝12.4Hz,1H),4.41-4.08(m,4H),3.04(dd,J＝30. 7,12.2Hz,2H),2.69(d,J＝13.3Hz,2H),2.41-2.30(m,6H),2.10(s,4H),1.85(s,4H),0.65(s,2H),0.40(s,3H).

Examples 40-41 can be prepared by referring to the synthesis method of Example 39 (Isomer 1) by selecting the corresponding raw materials:

The NMR data of the compound prepared in the above example are as follows:

Example 42: Preparation of 4-(9-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2,2,5-trifluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-[1,3]dioxazolo[4,5-f]quinazolin-4-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

Step 1: Synthesis of 3-bromo-5-fluoro-dihydroxybenzoic acid

5-Fluoro-dihydroxybenzoic acid (25 g, 160.143 mmol) and N-bromosuccinimide (28.50 g, 160.143 mmol) were added to acetic acid (200 mL). The mixture was stirred at 80°C for 24 hours. After the reaction was complete, the reaction solution was cooled to room temperature. The precipitated solid was filtered, and the filter cake was washed with petroleum ether and dried to obtain 3-bromo-5-fluoro-dihydroxybenzoic acid (19.6 g, yield: 52.08%). ESI-MS: 234/235 [M-1] ^- .

¹ H NMR (400MHz, DMSO-d ₆ ) δ7.96-7.78 (m, 1H), 7.58 (dd, J = 8.6, 3.2Hz, 1H).

Step 2: Synthesis of 5-fluoro-2,3-dihydroxybenzoic acid

3-Bromo-5-fluoro-dihydroxybenzoic acid (19 g, 80.848 mmol), copper acetate hydrate (3.22 g, 16.170 mmol), and D-anhydrous glucose (2.91 g, 16.170 mmol) were added to a sealed tube. Dimethyl sulfoxide (100 mL), water (100 mL), and potassium hydroxide (36.29 g, 646.781 mmol) were then added. The tube was sealed and stirred at 120°C for 24 hours. After the reaction was complete, the mixture was cooled to room temperature. The reaction solution was neutralized with hydrochloric acid, diluted with water, extracted with ethyl acetate, and the organic phase was dried over anhydrous sodium sulfate. Concentration under reduced pressure afforded 5-fluoro-2,3-dihydroxybenzoic acid (13.9 g, yield: 99.89%), which was used directly in the next reaction. ESI-MS: 171.2 [M-1] ^- .

¹ H NMR (400MHz, MeOH-d ₄ ) δ6.99 (dd, J = 8.9, 3.1 Hz, 1H), 6.77 (dd, J = 9.7, 3.1 Hz, 1H).

Step 3: Synthesis of methyl 5-fluoro-2,3-dihydroxybenzoate

Thionyl chloride (20 mL, 275.723 mmol) was added dropwise to methanol (50 mL) cooled to 0°C. 5-Fluoro-2,3-dihydroxybenzoic acid (2.6 g, 15.107 mmol) was then added. The mixture was stirred at 70°C for 18 hours. After completion of the reaction, the solvent was removed, and the residue was diluted with ethyl acetate, washed with water, and extracted with ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated using a flash column [eluent: ethyl acetate/petroleum ether: 0-30%] to afford methyl 5-fluoro-2,3-dihydroxybenzoate (2.8 g, yield: 99.58%). ESI-MS: 185.2 [M-1] ^- .

¹ H NMR (400MHz, CDCl ₃ ) δ 10.68 (s, 1H), 7.11-6.98 (m, 1H), 6.88 (ddd, J = 9.2, 3.0, 0.7Hz, 1H), 5.89-5.59 (m, 1H), 3.96 (s, 3H).

Step 4: Synthesis of methyl 4-bromo-5-fluoro-2,3-dihydroxybenzoate

Methyl 5-fluoro-2,3-dihydroxybenzoate (1 g, 5.810 mmol) was dissolved in dichloromethane (50 mL) and cooled to 0°C. Dibromohydantoin (0.92 g, 3.223 mmol) was added. The reaction mixture was stirred at 0°C for 10 minutes, then warmed to room temperature and allowed to react overnight. After completion of the reaction, water was added to the reaction mixture and the mixture was extracted with dichloromethane. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was separated using a flash column [eluent: ethyl acetate/petroleum ether: 0-30%] to afford methyl 4-bromo-5-fluoro-2,3-dihydroxybenzoate (1.2 g, yield: 82.28%). ESI-MS: 263.0/265.0 [M-1] ^- .

¹ H NMR (400MHz, CDCl ₃ ) δ10.85 (s, 1H), 7.16 (d, J = 8.6 Hz, 1H), 6.16 (d, J = 1.5 Hz, 1H), 3.98 (s, 3H).

Step 5: Synthesis of methyl 7-bromo-6-fluoro-2-thiobenzo[d][1,3]dioxole-4-carboxylate

Methyl 4-bromo-5-fluoro-2,3-dihydroxybenzoate (0.132 g, 0.498 mmol) was dissolved in dichloromethane (5 mL). The solution was cooled to 0°C. 4-Dimethylaminopyridine (DMAP) (0.12 g, 0.996 mmol) and thiophosgene (0.057 mL, 0.747 mmol) were added sequentially to the reaction solution. The mixture was stirred at room temperature for 3 hours. After completion of the reaction, the solvent was removed, and the residue was separated using a flash column [eluent: ethyl acetate/petroleum ether: 0-16%] to afford methyl 7-bromo-6-fluoro-2-thiobenzo[d][1,3]dioxole-4-carboxylate (105 mg, yield: 68.65%).

¹ H NMR (400MHz, CDCl ₃ ) δ7.69 (d, J=9.2Hz, 1H), 4.02 (s, 3H).

Step 6: Synthesis of methyl 7-bromo-2,2,6-trifluorobenzo[d][1,3]dioxole-4-carboxylate

Methyl 7-bromo-6-fluoro-2-thiobenzo[d][1,3]dioxole-4-carboxylate (153 mg, 0.498 mmol) was dissolved in dichloromethane and cooled to -40°C. A 70% hydrogen fluoride solution in pyridine (0.5 mL) was then added. The mixture was stirred at -40°C for 10 minutes, followed by the slow addition of N-iodosuccinimide (336.29 mg, 1.495 mmol). The mixture was stirred at -40°C for 30 minutes. After completion, the reaction was quenched with saturated aqueous sodium sulfite, washed with saturated brine, extracted with dichloromethane, and concentrated. The residue was separated using a flash column [eluent: ethyl acetate/petroleum ether: 0-15%] to afford methyl 7-bromo-2,2,6-trifluorobenzo[d][1,3]dioxole-4-carboxylate (110 mg, yield: 70.53%).

¹ H NMR (400MHz, CDCl ₃ ) δ7.47 (d, J=9.3Hz, 1H), 3.97 (s, 3H).

Step 7: Synthesis of methyl 7-bromo-2,2,6-trifluoro-5-nitrobenzo[d][1,3]dioxole-4-carboxylate

Add 98% concentrated sulfuric acid (5 mL) to the reaction flask and cool to 0°C. Add methyl 7-bromo-2,2,6-trifluorobenzo[d][1,3]dioxole-4-carboxylate (400 mg, 1.278 mmol) to the reaction flask, followed by 68% nitric acid (5 mL). Stir the mixture at 0°C for 1 hour. After the reaction is complete, slowly pour the reaction solution into ice water, extract with dichloromethane, dry over anhydrous sodium sulfate, and concentrate to obtain methyl 7-bromo-2,2,6-trifluoro-5-nitrobenzo[d][1,3]dioxole-4-carboxylate, which is used directly in the next reaction.

¹ H NMR (400MHz, CDCl ₃ ) δ3.98 (s, 3H).

Step 8: Synthesis of methyl 5-amino-7-bromo-2,2,6-trifluorobenzo[d][1,3]dioxole-4-carboxylate

Dissolve methyl 7-bromo-2,2,6-trifluoro-5-nitrobenzo[d][1,3]dioxole-4-carboxylate (400 mg, 1.117 mmol) in N,N-dimethylformamide (30 mL). The mixture is cooled to 0°C. 2,2-Bipyridine (0.030 mL, 0.223 mmol) and tetrahydroxydiboron (600.97 mg, 6.704 mmol) are added, and the reaction mixture is stirred at 0°C for 20 minutes. After completion of the reaction, the mixture is diluted with water and extracted with ethyl acetate. The organic phase is dried over anhydrous sodium sulfate and concentrated. The residue is separated using a flash column [eluent: ethyl acetate/petroleum ether: 0-10%] to afford methyl 5-amino-7-bromo-2,2,6-trifluorobenzo[d][1,3]dioxole-4-carboxylate (295 mg, yield: 80.49%). ESI-MS:328.2/330.2[M+1] ⁺ .

¹ H NMR (400MHz, CDCl ₃ ) δ5.72 (s, 2H), 3.95 (s, 3H).

Step 9: Synthesis of methyl 7-bromo-2,2,6-trifluoro-5-(3-(2,2,2-trichloroacetyl)ureido)benzo[d][1,3]dioxole-4-carboxylate

Methyl 5-amino-7-bromo-2,2,6-trifluorobenzo[d][1,3]dioxole-4-carboxylate (200 mg, 0.610 mmol) was dissolved in tetrahydrofuran (3 mL), and trichloroacetyl isocyanate (0.072 mL, 0.610 mmol) was added. The reaction mixture was stirred at room temperature for 1 hour. The solvent was removed, and the residue was added to a 1/10 ethyl acetate/petroleum ether solution, stirred for 10 minutes, and filtered to yield methyl 7-bromo-2,2,6-trifluoro-5-(3-(2,2,2-trichloroacetyl)ureido)benzo[d][1,3]dioxole-4-carboxylate (290 mg, yield: 92.11%). ESI-MS: 515.2/517.2/519.2 [M+1] ⁺ .

Step 10: Synthesis of 4-bromo-2,2,5-trifluoro-[1,3]dioxolo[4,5-f]quinazoline-7,9(6H,8H)-dione

Methyl 7-bromo-2,2,6-trifluoro-5-(3-(2,2,2-trichloroacetyl)ureido)benzo[d][1,3]dioxole-4-carboxylate (100 mg, 0.194 mmol) was dissolved in methanol (2 mL), and a 7M solution of ammonia in methanol (0.5 mL) was added. The mixture was stirred at room temperature for 1 hour. After completion of the reaction, the solvent was removed. The residue was added with ethyl acetate and stirred for 5 minutes. Filtering afforded 4-bromo-2,2,5-trifluoro-[1,3]dioxolo[4,5-f]quinazoline-7,9(6H,8H)-dione (60 mg, 92.31%). ESI-MS: 339.2/341.2 [M+1] ⁺ .

Step 11: Synthesis of 4-bromo-7,9-dichloro-2,2,5-trifluoro-[1,3]dioxolo[4,5-f]quinazoline

4-Bromo-2,2,5-trifluoro-[1,3]dioxolo[4,5-f]quinazoline-7,9(6H,8H)-dione (935 mg, 2.758 mmol) was dissolved in phosphorus oxychloride (6 mL). N,N-diisopropylethylamine (172 mg, 1.33 mmol) was added to the mixture at room temperature, and the mixture was reacted at 90°C for 18 hours. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The residue was poured into aqueous sodium bicarbonate solution and extracted with ethyl acetate (10 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent. The residue was separated using a flash column [eluent: ethyl acetate/petroleum ether: 0-15%] to afford 4-bromo-7,9-dichloro-2,2,5-trifluoro-[1,3]dioxolo[4,5-f]quinazoline (890 mg, yield: 97.52%). ESI-MS:375.2/377.2[M+1] ⁺ .

Step 12: Synthesis of tert-butyl (1R,5S)-3-(4-bromo-7-chloro-2,2,5-trifluoro-[1,3]dioxazolo[4,5-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

4-Bromo-7,9-dichloro-2,2,5-trifluoro-[1,3]dioxolo[4,5-f]quinazoline (890 mg, 2.368 mmol) was dissolved in anhydrous dichloromethane (30 mL), and then N,N-diisopropylethylamine (918.03 mg, 7.103 mmol) was added, followed by the addition of tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (502.62 mg, 2.368 mmol). The reaction solution was reacted at room temperature for 0.5 hour. After the reaction was complete, 30 mL of water was poured into the reaction mixture, and the mixture was extracted with ethyl acetate (30 mL x 2). The combined organic phases were washed with saturated sodium chloride (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was separated using a flash silica gel column (0-30% EA in PE) to afford tert-butyl (1R,5S)-3-(4-bromo-7-chloro-2,2,5-trifluoro-[1,3]dioxazolo[4,5-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (1.02 g, yield: 72.66%). ESI-MS: 551.4/553.4 [M+1] ⁺ .

Step 13: Synthesis of tert-butyl (1R,5S)-3-(4-bromo-2,2,5-trifluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-[1,3]dioxazolo[4,5-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

Dissolve ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methanol (167.95 mg, 1.055 mmol) in anhydrous tetrahydrofuran (2 mL). The reaction solution was cooled to 0°C and 60% sodium hydride (42.20 mg, 1.055 mmol) was added. The mixture was reacted at 0°C for 10 minutes. Tert-butyl (1R,5S)-3-(4-bromo-7-chloro-2,2,5-trifluoro-[1,3]dioxazolo[4,5-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (290 mg, 0.527 mmol) was then added, and the mixture was allowed to react at room temperature for 2 hours. After the reaction was complete, 30 mL of water was poured into the reaction mixture, and the mixture was extracted with ethyl acetate (20 mL x 2). The combined organic phases were washed with saturated sodium chloride (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was separated using a flash silica gel column (0-30% EA in PE) to afford tert-butyl (1R,5S)-3-(4-bromo-2,2,5-trifluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-[1,3]dioxazolo[4,5-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (183 mg, 51.59% yield). ESI-MS: 674.6/67636 [M+1] ⁺ .

Step 14: Synthesis of tert-butyl (1R,5S)-3-(4-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-2,2,5-trifluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-[1,3]dioxazolo[4,5-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate

Tert-butyl (1R,5S)-3-(4-bromo-2,2,5-trifluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-[1,3]dioxazolo[4,5-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (183 mg, 0.271 mmol) was dissolved in tetrahydrofuran (10 mL), and tert-butyl (3 A mixture of 7-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborol-2-yl)benzo[b]thiophen-2-yl)-7-cyano-carbamate (131.62 mg, 0.326 mmol), cesium carbonate (265.20 mg, 0.814 mmol), and bis(2-diphenylphosphinophenyl) ether palladium dichloride (38.85 mg, 0.054 mmol) was reacted at 80°C under nitrogen for 2 hours. The reaction was complete. 30 mL of water was poured into the reaction solution, and the mixture was extracted with ethyl acetate (20 mL*2). The combined organic phases were washed with saturated aqueous sodium chloride solution (20 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was separated by flash silica gel column [0-30% EA in PE] to give tert-butyl (1R,5S)-3-(4-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-2,2,5-trifluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-[1,3]dioxazolo[4,5-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (50 mg, yield 20.8%). ESI-MS:886.8[M+1] ⁺ .

Step 15: Synthesis of 4-(9-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2,2,5-trifluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-[1,3]dioxazolo[4,5-f]quinazolin-4-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

Tert-butyl (1R,5S)-3-(4-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-2,2,5-trifluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-[1,3]dioxazolo[4,5-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-8-carboxylate (40 mg, 0.045 mmol) was dissolved in dichloromethane (1 mL). Trifluoroacetic acid (1 mL) was added, and the mixture was reacted at 25°C for 2 hours. The reaction was complete. The reaction mixture was concentrated to remove the solvent, and the residue was separated using a reverse-phase column [eluent: acetonitrile/water (5% ammonium bicarbonate): 0-95%] to afford 4-(9-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-3-yl)-2,2,5-trifluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)-[1,3]dioxazolo[4,5-f]quinazolin-4-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile (20.95 mg, yield: 64.28%). ESI-MS: 686.5 [M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ )δ8.25(s,2H),7.45(dd,J＝8.4,5.1Hz,1H),7.20(t,J＝8.9Hz,1H),5.27(d,J＝54.3 Hz,1H),4.50(d,J＝19.7Hz,2H),4.06(ddd,J＝36.6,10.4,3.4Hz,2H),3.08(d,J＝9.9 Hz,3H),3.00(d,J＝6.9Hz,3H),2.82(d,J＝6.9Hz,1H),2.73(d,J＝12.2Hz,2H),2.13 (d,J＝8.2Hz,1H),2.03(d,J＝18.6Hz,2H),1.94(d,J＝7.0Hz,2H),1.86-1.73(m,5H).

Example 43: Preparation of 4-(9-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)furo[2,3-f]quinazolin-4-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

Step 1: Synthesis of 4-bromo-5-fluorofuro[2,3-f]quinazoline-7,9(6H,8H)-dione

6-Amino-4-bromo-5-fluorobenzofuran-7-carboxamide (250 mg, 0.916 mol) was dissolved in N,N-dimethylformamide (20 mL). Carbonyldiimidazole (594 mg, 3.66 mmol) and potassium carbonate (506 mg, 3.66 mmol) were added to the mixture at room temperature, and the mixture was reacted at 80°C for 18 hours. TLC indicated the reaction was complete. The reaction solution was cooled to room temperature and poured into water (50 mL), resulting in a large amount of solid precipitation. The mixture was filtered and the filter cake was dried to yield 4-bromo-5-fluorofuro[2,3-f]quinazoline-7,9(6H,8H)-dione (200 mg, yield: 73.1%).

¹ H NMR (400MHz, DMSO-d ₆ ) δ7.89 (d, J = 2.2 Hz, 1H), 6.78 (d, J = 2.0 Hz, 1H).

Step 2: Synthesis of 4-bromo-7,9-dichloro-5-fluorofuro[2,3-f]quinazoline

4-Bromo-5-fluorofuro[2,3-f]quinazoline-7,9(6H,8H)-dione (180 mg, 0.598 mmol) was dissolved in phosphorus oxychloride (10 mL). N,N-Diisopropylethylamine (346 mg, 2.68 mmol) was added to the mixture at room temperature, and the mixture was reacted at 120°C for 3 h. LCMS indicated the reaction was complete. The reaction solution was cooled to room temperature and concentrated under reduced pressure. The residue was poured into water (20 mL), and the pH was adjusted to a weakly alkaline state with sodium bicarbonate. The mixture was extracted with ethyl acetate (30 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent to yield 4-bromo-7,9-dichloro-5-fluorofuro[2,3-f]quinazoline (200 mg, yield: 89.0%). ESI-MS: 336.8 [M+1] ⁺ .

¹ H NMR (400MHz, CDCl ₃ ) δ 8.08 (d, J = 2.1 Hz, 1H), 7.18 (d, J = 2.1 Hz, 1H).

Step 3: Synthesis of tert-butyl (1R,5S)-8-(4-bromo-7-chloro-5-fluorofuro[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

4-Bromo-7,9-dichloro-5-fluorofuro[2,3-f]quinazoline (100 mg, 0.296 mmol) and tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (62.8 mg, 0.296 mmol) were dissolved in anhydrous tetrahydrofuran (20 mL). N,N-diisopropylethylamine (153 mg, 1.18 mmol) was added at 0°C under nitrogen. The mixture was reacted at 50°C for 1 hour. LC-MS indicated the reaction was complete. The reaction mixture was poured into water (20 mL) and extracted with ethyl acetate (20 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent. The residue was separated using a flash silica gel column [0-30% EA in PE] to afford tert-butyl (1R,5S)-8-(4-bromo-7-chloro-5-fluorofuro[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (110 mg, yield: 72.3%). ESI-MS: 513.0 [M+1] ⁺ .

Step 4: Synthesis of tert-butyl (1R,5S)-8-(4-bromo-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)furo[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

Dissolve tert-butyl (1R,5S)-8-(4-bromo-7-chloro-5-fluorofuro[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (110 mg, 0.215 mmol) and ((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methanol (68.4 mg, 0.430 mmol) in anhydrous tetrahydrofuran (20 mL). Add sodium tert-butoxide (82.6 mg, 0.860 mmol) at 0°C under nitrogen. Reaction was continued at 0°C for 0.5 h. LC-MS indicated the reaction was complete. The reaction mixture was poured into water (15 mL) and extracted with ethyl acetate (15 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent. The residue was separated using a flash silica gel column [0-30% EA in PE] to provide tert-butyl (1R,5S)-8-(4-bromo-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)furo[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (120 mg, yield: 87.9%). ESI-MS: 636.1 [M+1] ⁺ .

Step 5: Synthesis of tert-butyl (1R,5S)-8-(4-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)furo[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

Tert-butyl (1R,5S)-8-(4-bromo-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)furo[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (120 mg, 0.189 mmol) and tert-butyl (3-cyano-7-fluoro-4-(4 To a solution of 4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[b]thiophen-2-yl)carbamate (128 mg, 0.245 mmol) in anhydrous dioxane (15 mL) and water (5 mL), potassium phosphate (120 mg, 0.566 mmol) and Pd-118 (12.3 mg, 0.0190 mmol) were added under nitrogen at 25°C. The mixture was allowed to react at 100°C for 1 hour. LC-MS indicated the reaction was complete. The reaction mixture was poured into water (15 mL) and extracted with ethyl acetate (15 mL). The organic phase was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent. The residue was separated on a flash silica gel column (0-30% EA in PE) to afford tert-butyl (1R,5S)-8-(4-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)furo[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (138 mg, yield: 86.3%). ESI-MS: 846.3 [M+1] ⁺ .

Step 6: Synthesis of 4-(9-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)furo[2,3-f]quinazolin-4-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile

Dissolve tert-butyl (1R,5S)-8-(4-(2-((tert-butoxycarbonyl)amino)-3-cyano-7-fluorobenzo[b]thiophen-4-yl)-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)furo[2,3-f]quinazolin-9-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (120 mg, 0.142 mmol) in dioxane hydrochloride (10 mL). The mixture was reacted at 25°C for 2 hours. LC-MS indicated the reaction was complete. The reaction mixture was directly concentrated under reduced pressure to remove the solvent, and the residue was separated using a reverse phase column (0-30% EA in PE) to afford 4-(9-((1R,5S)-3,8-diazabicyclo[3.2.1]octan-8-yl)-5-fluoro-7-(((2R,7aS)-2-fluorotetrahydro-1H-pyrrolinazin-7a(5H)-yl)methoxy)furo[2,3-f]quinazolin-4-yl)-2-amino-7-fluorobenzo[b]thiophene-3-carbonitrile (35.8 mg, yield: 37.8%). ESI-MS: 646.1 [M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ ) δ8.19 (br s,1H),8.19(s,1H),8.06(s,2H),7.37(dd,J＝5.3,8.4Hz,1H),7.24-7.14(m,1H),6.6 6(d,J＝1.3Hz,1H),5.42-5.19(m,1H),4.72-4.61(m,2H),4.17-4.13(m,1H),4.06(br dd,J＝3.0,10.5Hz,1H),3.35(br s,1H),3.26(s,2H),3.12(br d,J＝11.2Hz,2H),3.04(br s,1H),2.96(br d,J＝11.7Hz,2H),2.85(br d,J＝6.6Hz,1H),2.20-2.13(m,1H),2.08-1.80(m,9H).

Example 44: Synthesis of 2-amino-4-(3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-1-((1R,5S)-3-(2-hydroxypropyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)benzo[b]thiophene-3-carbonitrile (Isomers B1 and B2)

Step 1: Synthesis of 6-bromo-1-chloro-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline

Intermediate C1 (12 g, 70% purity, 24.3 mmol) was dissolved in anhydrous acetonitrile (150 mL), and phosphorus oxychloride (22.7 mL, 243 mmol) and N,N-diisopropylethylamine (40.2 mL, 243 mmol) were added. The mixture was then stirred at 90°C for 18 hours. LCMS analysis indicated the reaction was complete. The reaction solution was concentrated, and the residue was poured into water (300 mL). The mixture was extracted with ethyl acetate (300 mL x 2). The combined organic phases were washed with saturated brine (300 mL), dried over anhydrous magnesium sulfate, and concentrated under reduced pressure. The residue was separated using a flash silica gel column (0-30% EA in PE) to afford 6-bromo-1-chloro-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline (5.86 g, yield: 66.2%). ESI-MS: 362.9 [M+1] ⁺ .

Step 2: Synthesis of tert-butyl (1R,5S)-8-(6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

Dissolve 6-bromo-1-chloro-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazoline (4.86 g, 13.3 mmol) in anhydrous tetrahydrofuran (70 mL). Add tert-butyl (1R,5S)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (3.12 g, 14.7 mmol) and N,N-diisopropylethylamine (11.0 mL, 66.8 mmol). Stir at 50°C for 1 hour. LCMS analysis indicates the reaction is complete. The reaction mixture was added with brine (200 mL), extracted with ethyl acetate (200 mL x 2), and the combined organic phases were dried over anhydrous magnesium sulfate and concentrated under reduced pressure to afford tert-butyl (1R,5S)-8-(6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (7.6 g, yield: 94.9%). ESI-MS: 541.1 [M+3] ⁺ .

Step 3: Synthesis of tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyanobenzo[b]thiophen-4-yl)-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

Tert-butyl (1R,5S)-8-(6-bromo-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (4.5 g, 7.51 mmol) and Interm.06 (3.31 g, 8.26 mmol) were dissolved in a mixed solvent of water (30 mL) and anhydrous dioxane (80 mL). Anhydrous potassium phosphate (4.78 g, 22.5 mmol) was then added. Pd-118 (490 mg, 0.751 mmol) was then added under nitrogen, and the reaction mixture was stirred at 100°C for 1 hour. LCMS analysis indicated the reaction was complete. The reaction mixture was extracted with ethyl acetate (100 mL x 2) and saturated brine (100 mL). The organic phase was dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was separated using a flash silica gel column [0-30% EA in PE] to afford tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyanobenzo[b]thiophen-4-yl)-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (4.3 g, yield: 78.1%). ESI-MS: 733.2 [M+1] ⁺ .

Step 4: Resolution of tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyanobenzo[b]thiophen-4-yl)-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

Chiral separation (column: DAICEL CHIRALPAK AD (250 mm*50 mm, 10 um), Condition: CO 2 -i-PrOH (0.1% NH 3 H 2 O), Begin B: 45%, End B: 45%, Flow Rate: 200 mL/min) of tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyanobenzo[b]thiophen-4 _- yl)-3-(ethylthio)-5-fluoro-7,9-dihydrofuro[ _3,4 - _f ]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (4 g) gave isomer A1 (1.82 g, yield: 36.4%) and isomer A2 (1.78 g, yield: 44.5%). ESI-MS:733.2[M+1] ⁺ .

Isomer A1:

¹ H NMR (400MHz, DMSO-d ₆ ) δppm 11.41 (br s, 1H), 8.09 (dd, J＝1.0, 7.8Hz, 1H), 7.52-7.46 (m, 1H), 7.45-7.41 (m, 1H), 5.51 (br s, 2H), 4.92 (br d,J＝12.6Hz,1H),4.66(br d,J＝12.7Hz,1H),4.44-4.34(m,2H),4.30(br d,J＝4.9Hz,1H),3.95(br s,1H),3.88(br d,J＝13.2Hz,1H),3.21-3.12(m,3H),1.92(br s,1H),1.76(t,J＝3.4Hz,1H),1.64(br d,J＝7.6Hz,2H),1.51(s,9H),1.44(s,9H),1.36(t,J＝7.3Hz,3H).

Isomer A2:

¹ H NMR (400MHz, DMSO-d ₆ ) δppm 11.41 (br s, 1H), 8.09 (d, J = 7.9Hz, 1H), 7.52-7.47 (m, 1H), 7.45-7.41 (m, 1H), 5.51 (br s, 2H), 4.92 (br d,J＝12.8Hz,1H),4.66(br d,J＝12.8Hz,1H),4.42(br d,J＝5.4Hz,1H),4.37(s,1H),4.30(br d,J＝5.3Hz,1H),3.92-3.77(m,2H),3.22-3.13(m,3H),1.97-1.86(m,1H),1.84-1.73(m,1H),1.64(br d,J＝7.8Hz,2H),1.51(s,9H),1.44(s,9H),1.36(t,J＝7.3Hz,3H).

Step 5: Synthesis of tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyanobenzo[b]thiophen-4-yl)-3-(ethylsulfinyl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

The above isomer A1 (750 mg, 0.768 mmol) was dissolved in anhydrous dichloromethane (20 mL). Meta-chloroperbenzoic acid (467 mg, 2.30 mmol, purity: 85%) was added under nitrogen at 0°C. The mixture was reacted at 25°C for 1 hour. LC-MS indicated the reaction was complete. Saturated aqueous sodium bicarbonate (20 mL) was added to the reaction mixture, followed by extraction with dichloromethane (2 x 15 mL). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to afford tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyanobenzo[b]thiophen-4-yl)-3-(ethylsulfinyl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (560 mg, yield: 97.4%). ESI-MS: 749.2 [M+1] ⁺ .

Step 6: Synthesis of tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyanobenzo[b]thiophen-4-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

Tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyanobenzo[b]thiophen-4-yl)-3-(ethylsulfinyl)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (167 mg, 0.823 mmol) was dissolved in anhydrous tetrahydrofuran (15 mL). Sodium hydride (89.7 mg, 2.24 mmol) was added at 0°C under nitrogen protection. The mixture was stirred for 10 minutes, followed by the addition of Intermediate A3 Isomer 3 (650 mg, 0.748 mmol). The mixture was reacted at 0°C for 20 minutes. LC-MS indicated the reaction was complete. Water (20 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (2*20 mL). The combined organic phases were washed with saturated brine (30 mL), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to provide tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyanobenzo[b]thiophen-4-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (650 mg, yield: 90.7%). ESI-MS: 874.3 [M+1] ⁺ .

Step 7: Synthesis of tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyanobenzo[b]thiophen-4-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate

Tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyanobenzo[b]thiophen-4-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (650 mg, 0.744 mmol) was dissolved in acetonitrile (10 mL). Hydrochloric acid/dioxane (15 mL) was added at 0°C and the reaction was stirred at 40°C for 1 hour. LCMS showed the reaction was complete, and the reaction mixture was concentrated under reduced pressure to provide tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyanobenzo[b]thiophen-4-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro[cyclopropane-1,2'-pyrrolinazine]-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (500 mg, yield: 79.8%). ESI-MS: 674.2 [M+1] ⁺ .

Step 8: Synthesis of 2-amino-4-(3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-1-((1R,5S)-3-(2-hydroxypropyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)benzo[b]thiophene-3-carbonitrile

Tert-butyl (1R,5S)-8-(6-(2-((tert-butoxycarbonyl)amino)-3-cyanobenzo[b]thiophen-4-yl)-3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-7,9-dihydrofuro[3,4-f]quinazolin-1-yl)-3,8-diazabicyclo[3.2.1]octane-3-carboxylate (500 mg, 0.594 mmol) was dissolved in acetonitrile (10 mL), and then (S)-2-methyloxirane (3 mL, 42.2 mmol) was added. The reaction was stirred at 70°C for 16 hours. LCMS showed the reaction was complete. The reaction mixture was concentrated under reduced pressure, and the residue was separated using a reverse phase column [5%-60% MeCN in H ₂ O] to afford 2-amino-4-(3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-1-((1R,5S)-3-(2-hydroxypropyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)benzo[b]thiophene-3-carbonitrile (racemate) (154.3 mg, yield: 35.5%). ESI-MS: 732.4 [M+1] ⁺ .

¹ H NMR (400MHz, DMSO-d ₆ )δ7.88-7.73(m,3H),7.28-7.19(m,2H),5.45(s,2H),4.86(d,J＝12.5Hz,1H),4.66(d,J＝12.3 Hz,1H),4.30(d,J＝4.2Hz,3H),4.24-4.15(m,2H),3.76(d,J＝6.5Hz,1H),3.12-3.08(m,1H),3. 05-3.01(m,1H),2.823-2.78(m,2H),2.74-2.67(m,1H),2.36-2.32(m,1H),2.25-2.20(m,1H) ,2.09-2.06(m,1H),1.99(s,1H),1.92-1.65(m,8H),1.65-1.41(m,4H),1.08(d,J＝6.1Hz,3H).

2-Amino-4-(3-((2,2-difluorodihydro-1'H,3'H-spiro(cyclopropane-1,2'-pyrrolinazine)-7a'(5'H)-yl)methoxy)-5-fluoro-1-((1R,5S)-3-(2-hydroxypropyl)-3,8-diazabicyclo[3.2.1]octan-8-yl)-7,9-dihydrofuro[3,4-f]quinazolin-6-yl)benzo[b]thiophene-3-carbonitrile (154 mg) was subjected to chiral separation (column: DAICEL CHIRALPAK AD (250mm*30mm, 10um), Condition: _CO2 -i-PrOH (0.1% _NH3H2O ) _, Begin B: 35%, End B: 35%; Flow Rate: 80 mL/min) to give Isomer B1 (54.8 mg) and Isomer B2 (54.2 mg).

Isomer B1:

¹ H NMR (400MHz, DMSO-d ₆ ) δppm 7.83 (s, 2H), 7.78 (dd, J = 2.3, 6.6Hz, 1H), 7.26-7.19 (m, 2H), 5.51-5.40 (m, 2H), 4.86 (br d, J = 12.1Hz, 1H), 4.66 (br d,J＝12.3Hz,1H),4.34-4.25(m,3H),4.24-4.15(m,2H),3.80-3.73(m,1H),3.10(br dd,J＝6.8,11.8Hz,1H),3.01(ddd,J＝3.6,6.1,9.5Hz,1H),2.85-2.79(m,2H),2.71(br d,J＝11.9Hz,1H),2.55(br s,1H),2.36-2.31(m,1H),2.22(br dd,J＝6.0,12.3Hz,1H),2.08(br dd,J＝5.7,13.4Hz,1H),2.02-1.95(m,1H),1.93-1.84(m,3H),1.83-1.66(m,5H ),1.62-1.52(m,2H),1.46(ddd,J＝3.9,8.2,12.5Hz,1H),1.08(d,J＝6.1Hz,3H).

Isomer B2:

¹ H NMR (400MHz, DMSO-d ₆ ) δppm 7.82 (br s, 2H), 7.78 (dd, J＝2.6, 6.2Hz, 1H), 7.26-7.20 (m, 2H), 5.48-5.42 (m, 2H), 4.86 (br d, J＝12.0Hz, 1H), 4.66 (br d,J＝12.3Hz,1H),4.33-4.26(m,3H),4.22-4.16(m,2H),3.81-3.74(m,1H),3.10(br dd,J＝6.8,11.6Hz,1H),3.04-2.99(m,1H),2.82(br d,J＝10.5Hz,2H),2.71(br d,J＝11.9Hz,1H),2.54(br s,1H),2.37-2.31(m,1H),2.22(br dd,J＝5.8,12.3Hz,1H),2.07(br dd,J＝5.7,13.1Hz,1H),2.02-1.96(m,1H),1.92-1.84(m,3H),1.82-1.66(m,5H),1.62-1.53(m,2H),1.50-1.44(m,1H),1.08(br d,J＝6.0Hz,3H).

Examples 45-50 can be prepared by referring to the synthesis method of Example 44 (Isomer 1) and selecting corresponding raw materials:

The NMR data of the compound prepared in the above example are as follows:

Biological test evaluation

1. GMPPNP-KRAS/c-RAF Binding Test

1. KRAS G12D/c-RAF biochemical activity detection

1.1 Preparation of experimental buffer solution

First prepare 5X buffer solution (250mM PH 7.4 HEPES, 500mM NaCl, 2.5% TritionX-100), and then prepare 1X buffer solution (50mM PH 7.4 HEPES, 100mM NaCl, 0.5% TritionX-100, 0.5% BSA).

1.2 Compound dilution and preparation

Serially dilute the 10 mM stock solution at a ratio of 1:5 for 9 points, dilute with 1X buffer solution to a 10X compound solution, transfer 2 μL to the corresponding wells of a 384-well plate, and centrifuge (1000 rpm, 1 minute).

1.3 Preparation of KRAS and GMPPNP working solutions

A 5X KRAS and GMPPNP mixture (50 nM KRAS G12D, 50 μM GMPPNP) was prepared in 1X buffer and pre-incubated on ice for 30 minutes. Then, 4 μL was transferred to the corresponding wells of a 384-well plate and centrifuged (1000 rpm, 1 minute). The mixture was then incubated at room temperature for 15 minutes.

1.4 Preparation of cRAF working solution

Prepare 5X cRAF working solution (250 nM cRAF) in 1X buffer, transfer 4 μL to the corresponding wells of a 384-well plate, and centrifuge (1000 rpm, 1 minute). Incubate at room temperature for 15 minutes.

1.5 Add detection reagent

Prepare 2X detection reagent (4X Alphascreen GSH donor beads, 4X Alphalisa NICKEL Acceptor beads) in 1X buffer, transfer 10 μL to the corresponding wells of a 384-well plate, and centrifuge (1000 rpm, 1 minute). Incubate at room temperature for 1 hour. Read the results on a SpectraMax Paradigm (MD) microplate reader.

2. KRAS G12V/c-RAF biochemical activity detection

2.1 Preparation of experimental buffer solution

First prepare 5X buffer solution (250mM PH 7.4 HEPES, 500mM NaCl, 2.5% TritionX-100), and then prepare 1X buffer solution (50mM PH7.4 HEPES, 100mM NaCl, 0.5% TritionX-100, 0.5% BSA).

2.2 Compound dilution and preparation

Serially dilute 9 points from the 10 mM stock solution at a ratio of 1:5, dilute with 1X buffer solution to a 10X compound solution, transfer 2 μL to the corresponding wells of a 384-well plate, and centrifuge (1000 rpm, 1 minute).

2.3 Preparation of KRAS and GMPPNP working solutions

A 5X KRAS and GMPPNP mixture (50 nM KRASG12D, 400 nM GMPPNP) was prepared in 1X buffer and pre-incubated on ice for 30 minutes. Then, 4 μL was transferred to the corresponding wells of a 384-well plate and centrifuged (1000 rpm, 1 minute). The mixture was then incubated at room temperature for 15 minutes.

1.4 Preparation of cRAF working solution

Prepare 5X cRAF working solution (250 nM cRAF) in 1X buffer, transfer 4 μL to the corresponding wells of a 384-well plate, and centrifuge (1000 rpm, 1 minute). Incubate at room temperature for 15 minutes.

1.5 Add detection reagent

Prepare 2X detection reagent (4X Alphascreen GSH donor beads, 4X Alphalisa NICKEL Acceptor beads) in 1X buffer, transfer 10 μL to the corresponding wells of a 384-well plate, and centrifuge (1000 rpm, 1 minute). Incubate at room temperature for 1 hour. Read the results on a SpectraMax Paradigm (MD) microplate reader.

Table 1: Biological test results

2. KRas mutant cell anti-proliferation 2D CTG test

1. Experimental steps:

1.1 Day 0 Cell Culture and Plating

Harvest cells in the logarithmic growth phase and count them using a platelet counter. Assess cell viability by trypan blue exclusion to ensure viability is above 90%. Adjust the cell concentration to achieve the desired final density, and add 90 μL of the cell suspension to a 96-well plate. Incubate overnight at 37°C, 5% CO2, and 95% humidity. The cell density and cell culture conditions are shown in the table below.

1.2 Day 1 Baseline Reading

Add 10 μL of PBS to each well of the T0 plate containing cells. Thaw CTG reagent and equilibrate the plate to room temperature for 30 minutes. Add 50 μL/well of CTG solution to each well. Shake on an orbital shaker for 5 minutes to lyse the cells. Allow the plate to stand at room temperature for 20 minutes to stabilize the luminescence signal. Read the T0 fluorescence signal.

1.3 Compound Treatment on Day 1

Make nine serial dilutions at a 1:5 ratio from a 10 mM stock solution. Transfer 10X compound-containing medium to the corresponding wells of a 96-well plate. The final highest compound concentration is 10 μM, and the final DMSO concentration is 0.1%. Place the 96-well plate in a 37°C incubator and incubate for 4 days.

1.4 Reading the signal on the 5th day

50 μL/well of detection reagent (CTG) was added to the cells, and the signal was read in the Envision machine.

Table 2: Biological test results

The “positive compound” used in the biological test evaluation of this application is Example 45 in WO2023183585A1 (the positive compound used in the mouse pharmacokinetic experiment is the same as this one), and its chemical structure is as follows:

The activity data of the compounds in the specific examples show that the compounds of the present invention have a strong inhibitory effect on KRAS cell activity. Under the same test conditions, the cell inhibitory activity of some of the compounds in the examples is comparable to that of the positive compounds, or is improved to a certain extent.

3. Pharmacokinetic Experiments in Mice

1. Experimental drugs

The compounds used in this test are from the specific examples of the present invention.

2. Experimental Animals

ICR mice male N=3 Original source: Shanghai Xipul-Bikai Laboratory Animal Co., Ltd.

3. Drug preparation and administration

Single oral (PO) administration in ICR mice: Weigh each compound into a solution of 10% PG + 10% solutol + 80% pH 3 citrate buffer, shake well, and sonicate. Administer orally to three mice after an overnight fast at a dose of 10 mg/kg.

ICR mice were dosed via a single intravenous (IV) injection: the compound was weighed and added to a vehicle consisting of 10% PG, 10% solutol, and 80% pH 3 citrate buffer, shaken, and sonicated. Three mice were fasted overnight and administered via the tail vein at a dose of 2 mg/kg.

4. Sample collection:

Approximately 90 μL of blood was collected via orbital sampling at each time point, anticoagulated with sodium heparin, placed on ice, and centrifuged within 1 hour to separate plasma (centrifugation conditions: 8000 rpm, 6 minutes, 2-8°C). Blood was collected at 0, 0.25, 0.5, 1, 2, 4, 6, 8, and 24 hours. Samples were stored at -20°C.

40 μL of plasma sample was added to 160 μL of ice-cold acetonitrile containing internal standard, vortexed for 1 minute, and centrifuged at 18,000 rpm for 10 minutes. The supernatant was transferred to a 96-well plate, and 5 μL was injected into the LC-MS/MS for analysis.

Table 3: Pharmacokinetic data

Based on the pharmacokinetic data of the compounds in the above specific examples, the compounds of this invention exhibit excellent PK data after IV or oral administration in mice. Compared to the positive compounds, the compounds of this invention exhibit significantly improved AUCs after both IV and oral administration. In particular, some of the compounds in the examples exhibited oral AUC increases of several-fold or even more than ten-fold, and their T _1/2 was significantly prolonged, demonstrating significantly improved bioavailability. These experiments demonstrate that the compounds of this invention have excellent development prospects and are expected to address the issue of positive compounds being unable to be administered orally and only IV.

All documents mentioned in this application are incorporated herein by reference, just as if each document were incorporated herein by reference individually. It should also be understood that after reading the above disclosure, those skilled in the art may make various changes or modifications to the present invention, and that such equivalents also fall within the scope of the claims appended hereto.

Claims (44)

A compound of formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof:
in, is a double bond or a single bond; Y ₁ is O, S, N, N (R _9a ), CH ₂ , CH, CH ₂ CH ₂ or CH=CH; Y ₂ is O, S, N, N(R _9b ), CH ₂ , CH, CH ₂ CH ₂ or CH=CH; Y ₃ is O, S, N, N(R _9c ), CH ₂ , CH, CH ₂ CH ₂ or CH=CH; _Z1 is N or C( _R10a ); _Z2 is N or C( _R10b ); Ring A is selected from the following structures:
_R1 is selected from _C3-12 cycloalkyl, _C1-10 alkyl substituted with 3-12 membered heterocyclyl and 5-10 membered heteroaryl, _R2 is selected from hydrogen, _C1-10 alkyl, _C2-10 alkenyl, _C2-10 alkynyl, C3-12 cycloalkyl and _3-12 membered heterocyclyl, or, _R1 and _R2 together with the nitrogen atom to which they are directly attached form a 4-12 membered heterocyclyl, said 4-12 membered heterocyclyl being optionally fused to a 5-10 membered heteroaryl, said group being optionally further substituted with one or more radicals selected from deuterium, halogen, cyano, _C1-10 alkyl, _C2-10 alkenyl, _C2-10 alkynyl, C3-12 cycloalkyl, _3-12 membered heterocyclyl, _C6-10 aryl, 5-10 membered heteroaryl, =O, =S, _-C0-8 alkyl- _SF5 , -C _-Co- 8alkyl-S(O)(═NR ₁₂ )R ₁₃ , -Co _- 8alkyl-N═S(O)R ₁₃ R ₁₄ , -Co _- 8alkyl-N═SR ₁₃ R ₁₄ , -Co _- 8alkyl-OS(O) ₂ R ₁₅ , -Co _- 8alkyl-S(O) _r R ₁₅ , -Co _- 8alkyl-OR ₁₆ , -Co _- 8alkyl-C(O)OR ₁₆ , -Co _- 8alkyl-C(O)SR ₁₆ , -Co _- 8alkyl-SC(O)R ₁₇ , -Co _- 8alkyl-C(O)R ₁₇ , -Co _- 8alkyl-OC(O)R ₁₇ , -Co _- 8alkyl-P(O)(R ₁₇ ) ₂ , -Co _- 8alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C(＝NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(＝NR ₁₉ )R ₁₇ , -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, ＝O, ＝S, -C _0-8 alkyl-SF ₅ , -C _-Co- 8alkyl-S(O)(═NR ₁₂ )R ₁₃ , -Co _- 8alkyl-N═S(O)R ₁₃ R ₁₄ , -Co _- 8alkyl-N═SR ₁₃ R ₁₄ , -Co _- 8alkyl-OS(O) ₂ R ₁₅ , -Co _- 8alkyl-S(O) _r R ₁₅ , -Co _- 8alkyl-OR ₁₆ , -Co _- 8alkyl-C(O)OR ₁₆ , -Co _- 8alkyl-C(O)SR ₁₆ , -Co _- 8alkyl-SC(O)R ₁₇ , -Co _- 8alkyl-C(O)R ₁₇ , -Co _- 8alkyl-OC(O)R ₁₇ , -Co _- 8alkyl-P(O)(R ₁₇ ) ₂ , -Co _- 8alkyl-NR ₁₈ R ₁₉ , _-C0-8alkyl -C(= _NR18 ) _R17 , _-C0-8alkyl -N( _R18 )-C(= _NR19 ) _R17 , _-C0-8alkyl -C(O) _{NR18R19 and -C0-8alkyl} -N( _R18 )-C(O) _R17 ; each R ₃ and each R ₄ are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -Co _0-8 alkyl-SF ₅ , -Co _0-8 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -Co _0-8 alkyl-N═S(O)R ₁₃ R ₁₄ , -Co _0-8 alkyl-N═SR ₁₃ R ₁₄ , -Co _0-8 alkyl-OS(O) ₂ R ₁₅ , -Co _0-8 alkyl-S(O) _r R ₁₅ , -Co _0-8 alkyl-OR ₁₆ , -Co _0-8 alkyl-C(O)OR ₁₈ )R 17 , -C _0-8 alkyl-C(O)SR ₁₆ , -C _0-8 alkyl-SC(O)R ₁₇ , -C _0-8 alkyl-C(O)R ₁₇ , -C _0-8 alkyl-OC(O)R ₁₇ , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ , or R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, ＝O, ＝S, -Co _0-8 alkyl-SF ₅ , -Co _0-8 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -Co _0-8 alkyl-N＝S(O)R ₁₃ R ₁₄ , -Co _0-8 alkyl-N＝SR ₁₃ R ₁₄ , -Co _0-8 alkyl-OS(O) ₂ R ₁₅ , -C ₁₈ ) _{R 17} , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , _{-C 0-8} alkyl-C(═NR 18 )R ₁₇ , -C _0-8 alkyl- _N ( _{R 18 ) -C(═NR 19 )R 17 , -C 0-8 alkyl -} C(O _{) NR 18 R 19 and -C 0-8 alkyl-} substituted by a substituent of _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ ; R ₅ is selected from -NR _11a R _11b , C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl and 5-10 membered heteroaryl, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, C _2-10 alkenyl, C _1-10 alkylene, C _2-10 alkynyl, C _3-12 cycloalkyl, _3-12 membered heterocyclyl, C _6-10 aryl, C _6-10 aryl and 3-12 membered heterocyclyl, 5-10 membered heteroaryl, ＝O, ＝S, -C _0-8 alkyl-SF ₅ , -C _0-8 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -C _0-8 alkyl-N＝S(O)R ₁₃ R ₁₄ , -C _{17 、-C 0-8 alkyl-C(O)R 17 、} -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ 、-C _0-8 alkyl-NR _{18 R 19} 、-C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ 、-C _0-8 alkyl-N═SR 13 R ₁₄ 、-C _0-8 alkyl-OS(O) 2 R ₁₅ 、-C _0-8 alkyl-S(O) r R ₁₅ 、-C _0-8 alkyl-OR 16 、-C _0-8 alkyl-C(O)OR ₁₆ 、-C _0-8 alkyl-C(O) _{SR 16} 、-C _0-8 alkyl-SC(O _{)R 17 、} -C _0-8 alkyl-C(O)R ₁₇ 、-C _0-8 alkyl-OC(O _{)R 17 、 wherein the alkyl radical is a C 0-8 alkyl radical , ... ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​} 18 )R ₁₇ , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR 18 R ₁₉ , -C _0-8 alkyl-C(═NR 18 ) _{R 17} , -C _0-8 alkyl-N═SR ₁₃ R ₁₄ , -C _0-8 alkyl-OS(O) 2 R 15 , -C _0-8 alkyl-S(O) r R ₁₅ , -C _0-8 alkyl-OR 16 , -C _0-8 alkyl-C(O)OR ₁₆ , -C 0-8 alkyl-C(O)SR ₁₆ , -C _0-8 alkyl-SC(O)R ₁₇ , -C _0-8 alkyl-C(O)R ₁₇ , -C _0-8 alkyl-OC(O)R ₁₇ , -C _0-8 alkyl-P(O)(R 17 ) 2 , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C 0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ ; each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -Co _0-8 alkyl-SF ₅ , -Co _0-8 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -Co _0-8 alkyl-N═S(O)R ₁₃ R ₁₄ , -Co _0-8 alkyl-N═SR ₁₃ R ₁₄ , -Co _0-8 alkyl-OS(O) ₂ R ₁₅ , -Co _0-8 alkyl-S(O) _r R ₁₅ , -Co _0-8 alkyl-OR ₁₆ , -C _0-8 alkyl-C(O)OR ₁₆ , -C _0-8 alkyl-C(O)SR ₁₆ , -C _0-8 alkyl-SC(O)R ₁₇ , -C _0-8 alkyl-C(O)R ₁₇ , -C _0-8 alkyl-OC(O)R ₁₇ , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ ; R ₇ is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -C _0-8 alkyl-SF ₅ , -C _0-8 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -C _0-8 alkyl-N═S(O)R ₁₃ R ₁₄ , -C _0-8 alkyl-N═SR ₁₃ R ₁₄ , -C _0-8 alkyl-OS(O) ₂ R ₁₅ , -C _0-8 alkyl-S(O) _r R ₁₅ , -C _0-8 alkyl-OR ₁₆ , -C -C _0-8 alkyl-C(O)OR ₁₆ , -C _0-8 alkyl-C(O)SR ₁₆ , -C _0-8 alkyl-SC(O)R ₁₇ , -C _0-8 alkyl-C(O)R ₁₇ , -C _0-8 alkyl-OC(O)R ₁₇ , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ ; Each R ₈ is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, cyano-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -Co _0-8 alkyl-SF ₅ , _{-Co 0-8 alkyl} -S(O)(═NR ₁₂ )R ₁₃ , -Co _0-8 alkyl-N═S(O)R ₁₃ R ₁₄ , -Co _0-8 alkyl-N═SR ₁₃ R ₁₄ , -Co _0-8 alkyl-OS(O) ₂ R ₁₅ , -Co _0-8 alkyl-S(O) _r R ₁₅ 18 )R ₁₇ , -C _0-8 alkyl-C( _{═NR 18 )} R ₁₇ , -C _0-8 alkyl-N ₍ R ₁₈ )-C _{( ═NR 19} )R _{17 ,} -C _0-8 alkyl-C ₍ O _{) NR 18 R 19 and -C 0-8} alkyl- _N ( _{R 18 ) -C} (O _{) R 17} ; R _9a , R _9b and R _9c are each independently selected from hydrogen, cyano, C _1-10 alkyl, C _2-10 alkenyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -Co _0-8 alkyl-S(O) _r R ₁₅ , -Co _0-8 alkyl-OR ₁₆ , -Co _0-8 alkyl-C(O)OR ₁₆ , -Co _0-8 alkyl-C(O)SR ₁₆ , -Co _0-8 alkyl-C(O)R ₁₇ , -Co _0-8 alkyl-OC(O)R ₁₇ , -Co _0-8 alkyl-NR ₁₈ R ₁₉ , -Co _0-8 alkyl-C(O)NR ₁₈ R ₁₉ and -Co _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ , the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, _3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, ＝O, ＝S, -Co _-8 alkyl-SF ₅ , -Co _-8 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -Co _-8 alkyl-N＝S(O)R ₁₃ R ₁₄ , -Co _-8 alkyl-N＝SR ₁₃ R ₁₄ , -Co _-8 alkyl-OS(O) ₂ R ₁₅ , -Co _-8 alkyl-S(O) _r R ₁₅ 18 )R ₁₇ , -C _0-8 alkyl-C( _{═NR 18 )} R ₁₇ , -C _0-8 alkyl-N ₍ R ₁₈ )-C _{( ═NR 19} )R _{17 ,} -C _0-8 alkyl-C ₍ O _{) NR 18 R 19 and -C 0-8} alkyl- _N ( _{R 18 ) -C} (O _{) R} substituted by a substituent of ₁₇ ; R _10a and R _10b are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -Co _0-8 alkyl-SF ₅ , -Co _0-8 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -Co _0-8 alkyl-N═S(O)R ₁₃ R ₁₄ , -Co _0-8 alkyl-N═SR ₁₃ R ₁₄ , -Co _0-8 alkyl-OS(O) ₂ R ₁₅ , -Co _0-8 alkyl-S(O) _r R ₁₅ , -Co _0-8 alkyl-OR ₁₆ , -Co _0-8 alkyl-C(O)OR ₁₆ , -C _0-8 alkyl-C(O)SR ₁₆ , -C _0-8 alkyl-SC(O)R ₁₇ , -C _0-8 alkyl-C(O)R ₁₇ , -C _0-8 alkyl-OC(O)R ₁₇ , -C _0-8 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ , and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ , the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, _3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, ＝O, ＝S, _{-Co 0-8 alkyl} -SF ₅ , -Co _0-8 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -Co _0-8 alkyl-N＝S(O)R ₁₃ R ₁₄ , -Co _0-8 alkyl-N＝SR ₁₃ R ₁₄ , -Co _0-8 alkyl-OS(O) ₂ R ₁₅ , -Co _0-8 alkyl-S(O) _r R ₁₅ , -Co ₁₈ )R ₁₇ , -Co _0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -Co _0-8 alkyl-N ₍ R ₁₈ )-C(═NR ₁₉ )R _{17 , -Co 0-8} alkyl-C _{( O ) NR 18 R 19 and -Co 0-8 alkyl - N ( R 18} )-C ₍ O _{) R} substituted by a substituent of ₁₇ ; R _11a and R _11b are each independently selected from hydrogen, deuterium, hydroxyl, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C _1-10 alkanoyl, and the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, hydroxyl, ═O, C _1-10 alkyl, C _2-10 alkenyl, C 2-10 alkynyl, C _1-10 alkylene, halogen-substituted C _1-10 alkylene, deuterium-substituted C _1-10 alkylene, _{halogen-substituted C 1-10 alkyl} , deuterium-substituted C substituted with a substituent selected _from the group consisting of a C _1-10 alkyl group, a C _1-10 alkoxy group, a C _3-12 cycloalkyl group, a C _3-12 cycloalkyloxy group, a 3-12 membered heterocyclyl group, a 3-12 membered heterocyclyloxy group, a C _6-10 aryl group, a C 6-10 aryloxy group, a 5-10 membered heteroaryl group, a _5-10 membered heteroaryloxy group, an amino group, a mono-C _1-10 alkylamino group, a di-C _1-10 alkylamino group, and a C _1-10 alkanoyl group; Alternatively, R _11a and R _11b together with the nitrogen atom to which they are directly attached form a 4-10 membered heterocyclyl or 5-10 membered heteroaryl, wherein the 4-10 membered heterocyclyl or 5-10 membered heteroaryl is optionally further substituted by one or more groups selected from deuterium, halogen, hydroxy, =O, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _1-10 alkylene, halogen-substituted C _1-10 alkylene, deuterium-substituted C _1-10 alkylene, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, _{C 1-10} alkoxy, C _3-12 cycloalkyl, C _3-12 cycloalkyloxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, C _6-10 aryl, C _6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, amino, mono-C substituted by _{C 1-10} alkylamino, diC _1-10 alkylamino and C _1-10 alkanoyl substituents; Each R ₁₂ is independently selected from hydrogen, deuterium, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-10 cycloalkyl, 3-10 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -C _0-8 alkyl-S(O) _r R ₁₅ , -C _0-8 alkyl-C(O)OR ₁₆ , -C _0-8 alkyl-C(O)R ₁₇ and -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, _halogen -substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C ₁₈ )R 19, -C _0-8 alkyl-C(═NR _{18 ) R 17} , -C _0-8 alkyl-N ₍ R ₁₈ )-C ₍ ═NR ₁₉ )R _{17 ,} -C _0-8 alkyl-C ₍ O _{) NR 18 R 19 , and -C 0-8 alkyl} -N( _{R 18} ) _-C ( _O ) _R substituted by a substituent of ₁₇ ; Each R ₁₃ and each R ₁₄ are independently selected from hydrogen, deuterium, hydroxy, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-10 cycloalkyl, 3-10 membered heterocyclyl, C _6-10 aryl and 5-10 membered heteroaryl, or, R ₁₃ and R ₁₄ together with the sulfur atom to which they are directly attached form a 3-10 membered heterocyclyl, which is optionally further substituted by one or more groups selected from deuterium, halogen, cyano, nitro, azido, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _3-10 cycloalkyl, 3-10 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, -C _0-8 alkyl-S(O) _r R ₁₅ , -C _{-C 0-8} alkyl-OR ₁₆ , -C _0-8 alkyl-C(O)OR ₁₆ , -C _0-8 alkyl-C(O)R ₁₇ , -C _0-8 alkyl-OC(O)R ₁₇ , -C _0-8 alkyl-NR ₁₈ R ₁₉ , -C _0-8 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-8 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-8 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-8 alkyl-N(R ₁₈ )-C(O)R ₁₇ ; each R ₁₅ is independently selected from hydrogen, deuterium, hydroxy, C _1-10 alkyl, C _2-10 alkenyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, and -NR ₁₈ R ₁₉ , each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, hydroxy, ═O, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _1-10 alkoxy, C _3-12 cycloalkyl, C _3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, C _6-10 aryl, C _6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, and -NR ₁₈ R ₁₉ ; each R ₁₆ is independently selected from hydrogen, deuterium, C _1-10 alkyl, C _2-10 alkenyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, and 5-10 membered heteroaryl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, hydroxy, =0, cyano, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _1-10 alkoxy, C _3-12 cycloalkyl, C _3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 _{membered heterocyclyloxy, C 6-10 aryl} , C _6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, and -NR ₁₈ R ₁₉ ; Each R ₁₇ is independently selected from hydrogen, deuterium, hydroxy, C _1-10 alkyl, C _1-10 alkoxy, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, C _3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocycloxy, C _6-10 aryl, C _6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy and -NR ₁₈ R ₁₉ , and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxy, =O, cyano, C _1-10 alkyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _1-10 alkoxy, C _3-12 cycloalkyl, C _3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocycloxy, C substituted by a substituent selected from the group consisting of C _6-10 aryl, C _6-10 aryloxy, 5-10 membered heteroaryl, 5-10 membered heteroaryloxy, and -NR ₁₈ R ₁₉ ; Each R ₁₈ and each R ₁₉ are each independently selected from hydrogen, deuterium, hydroxyl, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-10 aryl, 5-10 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C _1-10 alkanoyl, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =O, C _1-10 alkyl, C _{2-10 alkenyl, C 2-10 alkynyl} , halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _1-10 alkoxy, C _3-12 cycloalkyl, C substituted with a substituent selected from the group consisting of a _3-12 -membered cycloalkoxy group, a 3-12-membered heterocyclyl group, a _3-12 -membered heterocyclyloxy group, a C _6-10 aryl group, a C 6-10 aryloxy group, a 5-10-membered heteroaryl group, a 5-10-membered heteroaryloxy group, an amino group, a mono-C _1-10 alkylamino group, a di-C _1-10 alkylamino group, and a C _1-10 alkanoyl group; Alternatively, R ₁₈ and R ₁₉ , together with the nitrogen atom to which they are directly attached, form a 4-10 membered heterocyclyl or 5-10 membered heteroaryl, which is optionally further substituted with one or more substituents selected from deuterium, halogen, hydroxy, ═O, C _1-10 alkyl, C _2-10 alkenyl, C _2-10 alkynyl, halogen-substituted C _1-10 alkyl, deuterium-substituted C _1-10 alkyl, C _1-10 alkoxy, C _3-12 cycloalkyl, C _3-12 cycloalkoxy, 3-12 membered heterocyclyl, 3-12 membered heterocyclyloxy, C _6-10 aryl, C _6-10 aryloxy, 5-10 membered heteroaryl, _5-10 membered heteroaryloxy, amino, mono-C _1-10 alkylamino, di-C _1-10 alkylamino, and C _1-10 alkanoyl; m is 0, 1, 2, 3 or 4; n is 0, 1, 2, 3, 4, 5 or 6; o is 0, 1 or 2; and each r is independently 0, 1 or 2. The compound of formula (I) according to claim 1, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that _R1 is selected from _C3-6 cycloalkyl, _C1-4 alkyl substituted with 3-6 membered heterocyclyl and 5-8 membered heteroaryl, _R2 is selected from hydrogen, _C1-4 alkyl, _C2-4 alkenyl, _C2-4 alkynyl, C3-6 cycloalkyl and _3-6 membered heterocyclyl, or, _R1 and _R2 together with the nitrogen atom to which they are directly attached form a 4-12 membered heterocyclyl, the 4-12 membered heterocyclyl is optionally fused to a 5-10 membered heteroaryl, and the above groups are optionally further substituted with one or more selected from deuterium, halogen, cyano, _C1-4 alkyl, _C2-4 alkenyl, _C2-4 alkynyl, _C3-6 cycloalkyl, 3-6 membered heterocyclyl, _C6-8 aryl, 5-8 membered heteroaryl, =O, =S, _-C0-4 alkyl-SF ₅ , -C _0-4 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -C _0-4 alkyl-N═S(O)R ₁₃ R ₁₄ , -C _0-4 alkyl-N═SR ₁₃ R ₁₄ , -C _0-4 alkyl-OS(O) ₂ R ₁₅ , -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-SC(O)R ₁₇ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-P(O)(R ₁₇ ) ₂ , -C _{-C 0-4} alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(＝NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(＝NR ₁₉ )R ₁₇ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -C _0-4 alkyl-SF ₅ , -C _{-C 0-4} alkyl-S(O)(═NR ₁₂ )R ₁₃ , -C _0-4 alkyl-N═S(O)R ₁₃ R ₁₄ , -C _0-4 alkyl-N═SR ₁₃ R ₁₄ , -C _0-4 alkyl-OS(O) ₂ R ₁₅ , -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-SC(O)R ₁₇ , -C _0-4 alkyl-C(O)R ₁₇ , _{-C 0-4 alkyl} -OC(O)R ₁₇ , -C _0-4 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , _-C0-4alkyl -C(= _NR18 ) _R17 , _-C0-4alkyl -N( _R18 )-C(= _NR19 ) _R17 , _-C0-4alkyl -C(O) _NR18R19 and _-C0-4alkyl -N( _R18 )-C(O) _{R17 ;} each R ₃ and each R ₄ are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -Co _0-4 alkyl-SF ₅ , -Co _0-4 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -Co _0-4 alkyl-N═S(O)R ₁₃ R ₁₄ , -Co _0-4 alkyl-N═SR ₁₃ R ₁₄ , -Co _0-4 alkyl-OS(O) ₂ R ₁₅ , -Co _0-4 alkyl-S(O) _r R ₁₅ , -Co _0-4 alkyl-OR ₁₆ , -Co _0-4 alkyl-C(O)OR ₁₆ , -Co -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-SC(O)R ₁₇ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ , or R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 membered cycloalkyl or 4-6 membered heterocyclyl, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -Co _0-4 alkyl-SF ₅ , -Co _0-4 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -Co _0-4 alkyl-N＝S(O)R ₁₃ R ₁₄ , -Co _{0-4 alkyl} -N＝SR ₁₃ R ₁₄ , -Co _0-4 alkyl-OS(O) ₂ R ₁₅ , -Co _0-4 alkyl-S(O) _r R ₁₅ 18 )R ₁₇ , -C _0-4 alkyl-C( _{═NR 18} )R ₁₇ , _{-C 0-4 alkyl} -N ₍ R ₁₈ )-C ₍ ═NR _{19 )R 17 , -C 0-4 alkyl - C ( O} ) _{NR 18 R 19 and -C 0-4 alkyl - N} ( _{R 18 )} -C(O) _R substituted by a substituent of ₁₇ ; R ₅ is selected from -NR _11a R _11b , C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-8 aryl and 5-8 membered heteroaryl, the above groups independently optionally further substituted by one or more selected from deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, C _2-4 alkenyl, C _1-4 alkylene, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, ＝O, ＝S, -C _0-4 alkyl-SF ₅ , -C _0-4 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -C _0-4 alkyl-N＝S(O)R ₁₃ R ₁₄ , -C _0-4 alkyl-N＝SR ₁₃ R ₁₄ , -C _0-4 alkyl-OS(O) ₂ R ₁₅ , -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-SC(O)R ₁₇ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ are substituted independently by one or more substituents selected from deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C 2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -C _0-4 alkyl-SF ₅ , -C _0-4 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -C _0-4 alkyl-N＝S(O)R ₁₃ R ₁₄ , -C _0-4 alkyl-N＝SR ₁₃ R ₁₄ , -C _{-C 0-4} alkyl-OS(O) ₂ R ₁₅ , -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-SC(O)R ₁₇ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C substituted by a substituent selected from -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ ; Each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -C _0-4 alkyl-SF ₅ , -C _0-4 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -C _0-4 alkyl-N═S(O)R ₁₃ R ₁₄ , -C _0-4 alkyl-N═SR ₁₃ R ₁₄ , -C _0-4 alkyl-OS(O) ₂ R ₁₅ , -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-SC(O)R ₁₇ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ ; R ₇ is selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -C _0-4 alkyl-SF ₅ , -C _0-4 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -C _0-4 alkyl-N═S(O)R ₁₃ R ₁₄ , -C _0-4 alkyl-N═SR ₁₃ R ₁₄ , -C _0-4 alkyl-OS(O) ₂ R ₁₅ , -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-SC(O)R ₁₇ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ ; each R ₈ is independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _{3- 6} cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -Co _0-4 alkyl-SF ₅ , -Co _0-4 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -Co _0-4 alkyl-N＝S(O)R ₁₃ R ₁₄ , -Co _0-4 alkyl-N＝SR ₁₃ R ₁₄ , -Co _0-4 alkyl-OS(O) ₂ R ₁₅ , -Co _0-4 alkyl-S(O) _r R ₁₅ , -Co _0-4 alkyl-OR ₁₆ , -Co _-4 alkyl-C(O)OR ₁₆ , -Co _-4 alkyl-C(O)SR ₁₆ , -Co _-4 alkyl-SC(O)R ₁₇ , -Co _-4 alkyl-C(O)R ₁₇ , -Co _-4 alkyl-OC(O)R ₁₇ , -Co _-4 alkyl-P(O)(R ₁₇ ) ₂ , -Co _-4 alkyl-NR ₁₈ R ₁₉ , -Co _-4 alkyl-C(═NR ₁₈ )R ₁₇ , -Co _-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -Co _-4 alkyl-C(O)NR ₁₈ R ₁₉ and -Co _-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ ; R _11a and R _11b are each independently selected from hydrogen, deuterium, hydroxyl, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C _1-10 alkanoyl, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, ═O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _{1-4 alkylene, halogen-substituted C 1-4 alkyl} , deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C substituted by _a C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino and C _1-4 alkanoyl substituents; Alternatively, R _11a and R _11b together with the nitrogen atom to which they are directly attached form a 4-6 membered heterocyclyl or 5-8 membered heteroaryl, wherein the 4-6 membered heterocyclyl or 5-8 membered heteroaryl is optionally further substituted by one or more groups selected from deuterium, halogen, hydroxy, =O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino and C substituted with _1-4 alkanoyl substituents; wherein R ₁₂ , R ₁₃ , R ₁₄ , R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as described in claim 1. The compound of formula (I) according to claim 1, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that R _9a , R _9b and R _9c are each independently selected from hydrogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _{3- 6} cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _{18 )} -C(O)R ₁₇ , wherein the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, _5-8 membered heteroaryl, ＝O, ＝S, -C _0-4 alkyl-SF ₅ , -C _0-4 alkyl-S(O)(＝NR ₁₂ )R ₁₃ , -C _0-4 alkyl-N＝S(O)R ₁₃ R ₁₄ , -C _0-4 alkyl-N＝SR ₁₃ R ₁₄ , -C _0-4 alkyl-OS(O) ₂ R ₁₅ , -C _{-C 0-4} alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-SC(O)R ₁₇ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C 0-4 alkyl substituted by a substituent of _0-4- alkyl-N(R ₁₈ )-C(O)R ₁₇ ; R _10a and R _10b are each independently selected from hydrogen, deuterium, halogen, cyano, nitro, azido, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -Co _0-4 alkyl-SF ₅ , -Co _0-4 alkyl-S(O)(═NR ₁₂ )R ₁₃ , -Co _0-4 alkyl-N═S(O)R ₁₃ R ₁₄ , -Co _0-4 alkyl-N═SR ₁₃ R ₁₄ , -Co _0-4 alkyl-OS(O) ₂ R ₁₅ , -Co _0-4 alkyl-S(O) _r R ₁₅ , -Co _0-4 alkyl-OR ₁₆ , -Co _0-4 alkyl-C(O)OR ₁₆ , -Co -C _0-4 alkyl-C(O)SR ₁₆ , -C _0-4 alkyl-SC(O)R ₁₇ , -C _0-4 alkyl-C(O)R ₁₇ , _{-C 0-4 alkyl} -OC(O)R ₁₇ , -C _0-4 alkyl-P(O)(R ₁₇ ) ₂ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ , the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, nitro, azido, C _{1- 4-} membered heteroaryl, ═O, ═S, —C _{0-4- alkyl} -SF 5 , —C _{0-4- alkyl} -S(O)(═NR ₁₂ )R 13 , —C 0-4-alkyl-N═S(O)R ₁₃ R 14 , —C _0-4- alkyl-N═SR ₁₃ R ₁₄ , —C _0-4- alkyl-OS(O) ₂ R ₁₅ , —C _0-4- alkyl-S(O) _{r R 15} , —C _{0-4 -} alkyl-OR ₁₆ , —C _{0-4 -alkyl-C(O)OR 16 , —C 0-4- alkyl - C ( O ) SR 18} )R ₁₉ , -C _0-4 alkyl-C ₍ ═NR ₁₈ )R _{17 ,} -C _0-4 alkyl-C ₍ O _{) NR 18 R 19 , and -C 0-4 alkyl - N} ( _{R 18} ) _-C (O _{) R 17 ;} wherein R ₁₂ , R ₁₃ , R ₁₄ , R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as described in claim 1; Preferably, R _9a , R _9b and R _9c are each independently selected from hydrogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O) _{R 17} , and the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _{17 、 -P ( O} ) ₍ R _{17 )} 2 、 _{-NR 18} R _{19 、} -C ₍ ＝NR _{18 ) R 17 、 -N ( R 18 ) -C ( ＝ NR 19 )} )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; R _10a and R _10b are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -S(O)(═NR ₁₂ )R ₁₃ , -N═S(O)R ₁₃ R 14 , -N═SR ₁₃ R ₁₄ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O) _{R 17 ,} -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(═NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ , the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ , -S(O)(═NR ₁₂ )R ₁₃ , -N═S(O)R ₁₃ R ₁₄ , -N═SR ₁₃ R ₁₄ , -OS(O) ₂ R _{R 15} , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(═NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; wherein R ₁₂ , R ₁₃ , R ₁₄ , R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as described in claim 1; More preferably, R _9a , R _9b and R _9c are each independently selected from hydrogen and C _1-4 alkyl, which are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl and 3-6 membered heterocyclyl; R _10a and R _10b are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl and C _3-6 cycloalkyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium _- substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S and -SF ₅ . The compound of formula (I) according to claim 1, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R ₁₂ is independently selected from hydrogen, deuterium, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)R ₁₇ and -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _{-C 0-4} alkyl-N(R ₁₈ )-C(＝NR 19 )R 17 ; -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(＝NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(＝NR ₁₉ )R ₁₇ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ ; Each R ₁₃ and each R ₁₄ are independently selected from hydrogen, deuterium, hydroxy, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl and 5-8 membered heteroaryl, or, R ₁₃ and R ₁₄ together with the sulfur atom to which they are directly attached form a 3-6 membered heterocyclyl, which is optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -C _0-4 alkyl-S(O) _r R ₁₅ , -C _0-4 alkyl-OR ₁₆ , -C -C _0-4 alkyl-C(O)OR ₁₆ , -C _0-4 alkyl-C(O)R ₁₇ , -C _0-4 alkyl-OC(O)R ₁₇ , -C _0-4 alkyl-NR ₁₈ R ₁₉ , -C _0-4 alkyl-C(═NR ₁₈ )R ₁₇ , -C _0-4 alkyl-N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C _0-4 alkyl-C(O)NR ₁₈ R ₁₉ and -C _0-4 alkyl-N(R ₁₈ )-C(O)R ₁₇ ; each R ₁₅ is independently selected from hydrogen, deuterium, hydroxy, C _1-4 alkyl, C _2-4 alkenyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, and -NR ₁₈ R ₁₉ , each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, hydroxy, ═O, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 _membered heterocyclyloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, and -NR ₁₈ R ₁₉ ; each R ₁₆ is independently selected from hydrogen, deuterium, C _1-4 alkyl, C _2-4 alkenyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, and 5-8 membered heteroaryl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, hydroxy, =0, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, and -NR ₁₈ R ₁₉ ; Each R ₁₇ is independently selected from hydrogen, deuterium, hydroxy, C _1-4 alkyl, C _1-4 alkoxy, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, C _3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocycloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy and -NR ₁₈ R ₁₉ , and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxy, =O, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted _{C 1-4 alkyl} , C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocycloxy, C _6-8 aryl _, C substituted by _{a 6-8} membered aryloxy group, a 5-8 membered heteroaryl group, a 5-8 membered heteroaryloxy group, and a substituent selected from -NR ₁₈ R ₁₉ ; Each R ₁₈ and each R ₁₉ are independently selected from hydrogen, deuterium, hydroxyl, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C _1-10 alkanoyl, the above groups are independently optionally further substituted by one or more deuterium, halogen, hydroxyl, =0, C _1-4 alkyl, C _{2-4 alkenyl, C 2-4 alkynyl} , halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C substituted by a C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino and C _1-4 alkanoyl substituents _; Alternatively, R ₁₈ and R ₁₉ , together with the nitrogen atom to which they are directly attached, form a 4-6 membered heterocyclyl or 5-8 membered heteroaryl, which is optionally further substituted with one or more substituents selected from deuterium, halogen, hydroxy, ═O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkoxy, 3-6 membered heterocyclyl, _3-6 membered heterocyclyloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino, and C _1-4 alkanoyl; and each r is independently 0, 1 or 2. The compound of formula (I) according to claim 1, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that the compound of formula (I) is a compound of formula (IIa), formula (IIb), formula (IIc), formula (IId), formula (IIe) or formula (IIf):
Wherein, each ring A is independently selected from the following structures:
each R ₁ is independently selected from C _3-6 cycloalkyl, C _1-4 alkyl substituted with 3-6 membered heterocyclyl and 5-8 membered heteroaryl, each R ₂ is independently selected from hydrogen, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl and _3-6 membered heterocyclyl, or, R ₁ and R ₂ together with the nitrogen atom to which they are directly attached form a 4-12 membered heterocyclyl, said 4-12 membered heterocyclyl being optionally fused to a 5-10 membered heteroaryl, which is optionally further substituted with one or more radicals selected from deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -S(O)(=NR ₁₂ )R _{13 18} )R ₁₇ , -C(＝NR ₁₈ ) _{R 17} , -C(＝NR _{19 )} R _{17 ,} -C(O) _{NR 18} R _{19 and} -N( _{R 18 )} -C(O) _{R 17 are} optionally substituted _{by one or more} substituents selected from deuterium, _{halogen , cyano , C 1-4} membered alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -S(O)(＝NR ₁₂ )R ₁₃ , -N＝S(O)R ₁₃ R ₁₄ , -N＝SR ₁₃ R ₁₄ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(═NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R ₃ and each R ₄ are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -S(O)(═NR ₁₂ )R ₁₃ , -N═S(O)R ₁₃ R ₁₄ , -N═SR ₁₃ R ₁₄ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R _{R 19} , -C(＝NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(＝NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(＝CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, the above groups being independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -S(O)(＝NR ₁₂ )R _{18 ) -C ( ═NR 19 ) R 17} , -C ₍ O _{) NR 18 R 19 and -N ( R 18 ) -C ( O ) R 17 ;} each R ₅ is independently selected from -NR _11a R _11b , C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-8 aryl or 5-8 membered heteroaryl, the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _1-4 alkylene, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -S(O)(＝NR ₁₂ )R ₁₃ , -N＝S(O)R ₁₃ R ₁₄ , -N＝SR ₁₃ R ₁₄ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ 17 、-C(O)OR ₁₆ 、-C(O)SR ₁₆ 、-SC(O)R ₁₇ 、-C(O)R ₁₇ 、-OC(O)R ₁₇ 、-P(O)(R ₁₇ ) ₂ 、-NR ₁₈ R ₁₉ 、-C(＝NR ₁₈ )R ₁₇ 、-N(R ₁₈ )-C(＝NR ₁₉ )R ₁₇ 、-C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ substituents, the above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene, C ₁₇ 、-P(O)(R 17 ) 2 、-NR ₁₈ R ₁₉ 、-C(＝ _{NR 18} )R ₁₇ 、-N(R ₁₈ )R ₁₈ 、-C(＝NR ₁₈ ) _{R 18 、} -N ₍ R ₁₈ )R _{18 、} -C _{( ＝NR 18 ) R 18 、 -N (} R _{18 ) R 18} )-C(═NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -S(O)(═NR ₁₂ )R ₁₃ , -N═S(O)R ₁₃ R ₁₄ , -N═SR ₁₃ R 14 , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O) _{R 17 ,} -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(＝NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(＝NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -S(O)(═NR ₁₂ )R ₁₃ , -N═S(O)R ₁₃ R ₁₄ , -N═SR ₁₃ R 14 , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O) _{R 17 ,} -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(＝NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(＝NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R ₈ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -S(O)(═NR ₁₂ )R ₁₃ , -N═S(O)R ₁₃ R ₁₄ , -N═SR ₁₃ R ₁₄ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(＝NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(＝NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _11a and each R _11b are independently selected from hydrogen, deuterium, hydroxyl, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C _1-10 alkanoyl, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =0, C _1-4 alkyl, C 2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene _{, halogen-substituted C 1-4 alkyl} , deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C substituted with a C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino and C _1-4 alkanoyl substituents; Alternatively, R _11a and R _11b together with the nitrogen atom to which they are directly attached form a 4-6 membered heterocyclyl, which is optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, hydroxy, ═O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen _{-substituted C 1-4 alkylene} , deuterium-substituted C _1-4 alkylene, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C 6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino, and C _1-4 alkanoyl; wherein R ₁₂ , R ₁₃ , R ₁₄ , R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r, m, n and o are as described in claim 1. The compound of formula (I) according to claim 1, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that the compound of formula (I) is a compound of formula (IIIa), formula (IIIb), formula (IIIc), formula (IIId), formula (IIIe) or formula (IIIf):

Wherein, each ring A is independently selected from the following structures:
Each R ₁ is independently selected from C _3-6 cycloalkyl, 3-6 membered heterocyclyl and C _1-4 alkyl substituted with 5-8 membered heteroaryl, each R ₂ is independently selected from hydrogen, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl and _3-6 membered heterocyclyl, or, R ₁ and R ₂ together with the nitrogen atom to which they are directly attached form a 4-12 membered heterocyclyl, said 4-12 membered heterocyclyl optionally being fused to a 5-10 membered heteroaryl, said groups optionally being further substituted with one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , which may be further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C 2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -S(O)(＝NR ₁₂ )R ₁₃ , -N＝S(O)R ₁₃ R ₁₄ , -N＝SR ₁₃ R ₁₄ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(═NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ 18 )R ₁₇ , -C(＝NR ₁₈ )R 17 , -C(＝NR 19 )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ are substituted by a substituent selected from the group consisting of: -S(O)(＝NR ₁₂ ) _{R 13} , -N＝S(O)R 13 R ₁₄ , -N＝SR ₁₃ R ₁₄ , -OS(O) 2 R 15 , -S(O) r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR 16 , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(＝NR ₁₈ )R ₁₇ , -N(R 18 )-C(＝NR 19 )R 17 , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R ₅ is independently selected from -NR _11a R _11b , C _3-12 cycloalkyl, 3-12 membered heterocyclyl, C _6-8 aryl or 5-8 membered heteroaryl, which are independently optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _1-4 alkylene, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , which are independently optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -S(O)(＝NR ₁₂ )R ₁₃ , -N＝S(O)R ₁₃ R ₁₄ , -N＝SR ₁₃ R ₁₄ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(═NR ₁₈ )R ₁₇ , -N(R ₁₈ )-C(═NR ₁₉ )R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R _8a and each R _8b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _11a and each R _11b are independently selected from hydrogen, deuterium, hydroxyl, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C _1-10 alkanoyl, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =0, C _1-4 alkyl, C 2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene _{, halogen-substituted C 1-4 alkyl} , deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C substituted with a C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino, and C _1-4 alkanoyl substituent; Alternatively, R _11a and R _11b together with the nitrogen atom to which they are directly attached form a 4-6 membered heterocyclyl, which is optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, hydroxy, ═O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen _{-substituted C 1-4 alkylene} , deuterium-substituted C _1-4 alkylene, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C 6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino, and C _1-4 alkanoyl; wherein R ₁₂ , R ₁₃ , R ₁₄ , R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r, m and n are as described in claim 1. The compound of formula (I) according to claim 6, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that the compound of formula (I) is a compound of formula (IVa1), formula (IVb1), formula (IVc1), formula (IVd1), formula (IVe1) or formula (IVf1):
Wherein, each ring A is independently selected from the following structures:
Each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C 6-8 aryl and _3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c and the part to which they are directly attached together form a C _3-4 cycloalkyl or 3-4 membered heterocyclyl, R _5b or R _5c are otherwise defined as above, or, R _5a and R _5b and the carbon atom to which they are directly attached together form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ; Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C the group is substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ; each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R _8a and each R _8b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each s is independently 0 or 1; wherein R ₁₂ , R ₁₃ , R ₁₄ , R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r and n are as described in claim 6. The compound of formula (I) according to claim 7, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -OR ₁₆ and -NR ₁₈ R ₁₉ ; each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , which are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -OR ₁₆ and -NR ₁₈ R ₁₉ ; each R _5a and R _5b together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl group, which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, ＝O, ＝S, -SF ₅ , -OR ₁₆ , -C(O)OR ₁₆ , and -NR ₁₈ R ₁₉ ; each R _5c is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; Each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which _{they are directly attached form a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(＝CH ₂ ), which are independently optionally further substituted with one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ is substituted by a substituent; Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C ₍ ═CH ₂ ), which groups are independently optionally further substituted with one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -NR ₁₈ R ₁₉ ; wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as described in claim 7; Preferably, each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano and C _1-4 alkyl, and the above groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl and deuterium-substituted C _1-4 alkyl; each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl and -C(O)R ₁₇ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted _{C 1-4} alkyl, ═O, ═S and -OR ₁₆ ; each R _5a and R _5b together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl group, which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl and deuterium-substituted C _1-4 alkyl; Each R _5c is independently selected from hydrogen, deuterium, halogen, cyano and C _1-4 alkyl; each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl and -SR ₁₅ , or R _5d and R _5e together with the carbon atom to which they are directly attached form C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _{1-4 alkyl and deuterium-substituted C 1-4 alkyl} ; each R _5f and each R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _6-8 aryl, and C _6-8 aryl and 3-6 membered heterocyclyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ , and -OC(O)R ₁₇ ; wherein R ₁₅ , R ₁₆ and R ₁₇ are as described in claim 7; More preferably, each R _1a and each R _1b are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano and methyl, and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; each R _1c is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, and -C(O)R _17a , which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriummethyl, ═O, ═S, and hydroxy; each R _5a and R _5b together with the carbon atom to which they are directly attached form a cyclopropyl or cyclobutyl group, which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; Each R _5c is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl and isopropyl; each R _5d and each R _5e are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl and -S-CH ₃ , or R _5d and R _5e together with the carbon atom to which they are directly attached form C(=CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; Each R _5f and each R _5g are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, phenyl and The above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuteriomethyl, -OR _16a , -C(O)OR _16a and -OC(O)R _17a ; R _16a is selected from pyrimidinyl, pyridyl, phenyl, amino and dimethylamino; R _17a is selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino, The compound of formula (I) according to claim 7, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -OR ₁₆ and -NR ₁₈ R ₁₉ ; each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , which are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -OR ₁₆ and -NR ₁₈ R ₁₉ ; each R _5a and R _5b together with the carbon atom to which they are directly attached form C(═CH ₂ ), which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, ═O, ═S, —SF ₅ , —OR ₁₆ , —C(O)OR ₁₆ and —NR ₁₈ R ₁₉ ; each R _5c is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; each R _5d and each R _5e is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form a 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C ₍ ═CH ₂ ), which groups are independently optionally further substituted with one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -NR ₁₈ R ₁₉ ; wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as described in claim 7; Preferably, each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano and C _1-4 alkyl, and the above groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl and deuterium-substituted C _1-4 alkyl; each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, and -C(O)R ₁₇ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted _{C 1-4 alkyl} , ═O, ═S, and -OR ₁₆ ; Each R _5a and R _5b together with the carbon atom to which they are directly attached form C(=CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl and deuterium-substituted C _1-4 alkyl; Each R _5c is independently selected from hydrogen, deuterium, halogen, cyano and C _1-4 alkyl; each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl and -SR ₁₅ , or R _5d and R _5e together with the carbon atom to which they are directly attached form C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _{1-4 alkyl and deuterium-substituted C 1-4 alkyl} ; each R _5f and each R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _6-8 aryl, and C _6-8 aryl and 3-6 membered heterocyclyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ , and -OC(O)R ₁₇ ; wherein R ₁₅ , R ₁₆ and R ₁₇ are as described in claim 7; More preferably, each R _1a and each R _1b are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano and methyl, and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; each R _1c is independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl, and -C(O)R _17a , which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriummethyl, ═O, ═S, and hydroxy; Each R _5a and R _5b together with the carbon atom to which they are directly attached form C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; Each R _5c is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl and isopropyl; each R _5d and each R _5e are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl and -S-CH ₃ , or R _5d and R _5e together with the carbon atom to which they are directly attached form C(=CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; Each R _5f and each R _5g are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, phenyl and The above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuteriomethyl, -OR _16a , -C(O)OR _16a and -OC(O)R _17a ; R _16a is selected from pyrimidinyl, pyridyl, phenyl, amino and dimethylamino; R _17a is selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino, The compound of formula (I) according to claim 7, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -OR ₁₆ and -NR ₁₈ R ₁₉ ; each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , which are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -OR ₁₆ and -NR ₁₈ R ₁₉ ; each R _5a and R _5c together with the portion to which they are directly attached form a C _3-4 cycloalkyl group, which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, ＝O, ＝S, -SF ₅ , -OR ₁₆ , -C(O)OR ₁₆ , and -NR ₁₈ R ₁₉ ; each R _5b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; Each of R _5d and R _5e is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R substituted by a substituent of ₁₉ ; Each of R _5f and R _5g is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -NR ₁₈ R ₁₉ ; wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as described in claim 7; Preferably, each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano and C _1-4 alkyl, and the above groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl and deuterium-substituted C _1-4 alkyl; each R _1c is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl and -C(O)R ₁₇ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, ═O, ═S and -OR ₁₆ ; Each R _5a and R _5c together with the part to which they are directly attached form a C _3-4 cycloalkyl group, which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl and deuterium-substituted C _1-4 alkyl; Each R _5b is independently selected from hydrogen, deuterium, halogen, cyano and C _1-4 alkyl; each of R _5d and R _5e is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl and -SR ₁₅ , or R _5d and R _5e together with the carbon atom to which they are directly attached form C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl and deuterium-substituted C _1-4 alkyl; each R _5f and R _5g is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _6-8 aryl and _{C 6-8} aryl and 3-6 membered heterocyclyl, and the above groups are independently optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -OC(O)R ₁₇ ; wherein R ₁₅ , R ₁₆ and R ₁₇ are as described in claim 7; More preferably, each R _1a and each R _1b are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano and methyl, and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; each R _1c is independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl, and -C(O)R _17a , which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriummethyl, ═O, ═S, and hydroxy; each R _5a and R _5c together with the moiety to which they are directly attached form a cyclopropyl or cyclobutyl group, which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; Each R _5b is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl and isopropyl; each R _5d and each R _5e are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl and -S-CH ₃ , or R _5d and R _5e together with the carbon atom to which they are directly attached form C(=CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl and trideuteriomethyl; Each R _5f and each R _5g are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, phenyl and The above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, trifluoromethyl, trideuteriomethyl, -OR _16a , -C(O)OR _16a and -OC(O)R _17a ; R _16a is selected from pyrimidinyl, pyridyl, phenyl, amino and dimethylamino; R _17a is selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino, The compound of formula (I) according to claim 7, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that in the compound of formula (IVa1), R _1a and R _1b are each independently selected from deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; R _1c is selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -NR ₁₈ R ₁₉ and -C(O)R ₁₇ , which are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, _{C 2-4 alkynyl} , C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, =S, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ ; R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _{6-8 aryl, C 6-8 aryl} and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; R _5d and R _5e are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), the above groups being independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a _3-6 -membered cycloalkyl group, a 3-6-membered heterocyclyl group, -OR ₁₆ , -NR ₁₈ R ₁₉ and -C(O)OR ₁₆ substituent; R _5f and R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), the above groups being independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from the group consisting of a _3-6 -membered cycloalkyl group, a 3-6-membered heterocyclyl group, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -NR ₁₈ R ₁₉ ; wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as described in claim 7; Preferably, R _1a and R _1b are each independently selected from deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl and 3-6 membered heterocyclyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; R _1c is selected from hydrogen, deuterium, cyano, C _1-4 alkyl and -C(O)R ₁₇ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, ═O, ═S and -OR ₁₆ ; R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl and C _3-6 cycloalkyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; R _5d and R _5e are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -C(O)OR ₁₆ ; R _5f and R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5f and R _5g together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -NR ₁₈ R ₁₉ ; wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as described in claim 7; More preferably, R _1a and R _1b are each independently selected from deuterium, fluorine and chlorine; R _1c is selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl and -C(O)R _17a , which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriummethyl, ═O, ═S and hydroxy; R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, C _1-4 alkyl and C _3-6 cycloalkyl, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, hydroxyl and amino; R _5d and R _5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH ₃ , phenyl and The above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, -OR _16a and -C(O)OR _16a ; R _5f and R _5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH ₃ , phenyl and Alternatively, R _5f and R _5g together with the carbon atom to which they are directly attached form a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, -OR _16a , -C(O)OR _16a and -OC(O)R _17a ; R _16a is selected from pyrimidinyl, pyridyl, phenyl, amino and dimethylamino; R _17a is selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino, The compound of formula (I), its stereoisomer or pharmaceutically acceptable salt thereof according to claim 7, characterized in that, in the compound of formula (IVa1), R _1a and R _1b are each independently hydrogen; R _1c is -C(O)R ₁₇ , which is optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, _{C 1-4} alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -OR ₁₆ and -NR ₁₈ R ₁₉ ; R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _{6-8 aryl, C 6-8 aryl} and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; R _5d and R _5e are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ; R _5f and R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), the above groups being independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ; wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as described in claim 7; Preferably, R _1a and R _1b are each independently hydrogen; R _1c is -C(O)R ₁₇ , which is optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, ═O, ═S, and -OR _{16 ;} R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl and C _3-6 cycloalkyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; R _5d and R _5e are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -C(O)OR ₁₆ ; R _5f and R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5f and R _5g together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -NR ₁₈ R ₁₉ ; wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as described in claim 7; More preferably, R _1a and R _1b are each independently hydrogen; R _1c is -C(O)R _17a , which is optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, ═O, ═S, and hydroxy; R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, C _1-4 alkyl and C _3-6 cycloalkyl, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, hydroxyl and amino; R _5d and R _5e are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH ₃ , phenyl and The above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, -OR _16a and -C(O)OR _16a ; R _5f and R _5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH ₃ , phenyl and Alternatively, R _5f and R _5g together with the carbon atom to which they are directly attached form a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, -OR _16a , -C(O)OR _16a and -OC(O)R _17a ; R _16a is selected from pyrimidinyl, pyridyl, phenyl, amino and dimethylamino; R _17a is selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino, The compound of formula (I), its stereoisomer or pharmaceutically acceptable salt according to claim 7, characterized in that, in the compound of formula (IVa1), R _1a and R _1b are each independently hydrogen; R _1c is hydrogen; R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _{6-8 aryl, C 6-8 aryl} and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; R _5d and R _5e are each independently selected from hydrogen, C _1-4 alkyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl and -S(O) _r R ₁₅ , the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; R _5f and R _5g are each independently selected from hydrogen, C _1-4 alkyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl and -S(O) _r R ₁₅ , the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; provided that R _5d and R _5f are not H at the same time; wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as described in claim 7; Preferably, R _1a and R _1b are each independently hydrogen; R _1c is hydrogen; R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl and C _3-6 cycloalkyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; R _5d and R _5e are each independently selected from hydrogen, C _6-8 aryl and 3-6 membered heterocyclyl, and -S-CH ₃ , wherein the above groups are independently optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -C(O)OR ₁₆ ; R _5f and R _5g are each independently selected from hydrogen, C _1-4 alkyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, and -S-CH ₃ , wherein the above groups are independently optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -NR ₁₈ R ₁₉ ; provided that R _5d and R _5f are not H at the same time; wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as described in claim 7; More preferably, R _1a and R _1b are each independently hydrogen; R _1c is hydrogen; R _5a , R _5b and R _5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl and cyclobutyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, hydroxyl and amino; R _5d and R _5e are each independently selected from hydrogen or -S-CH ₃ ; R _5f and R _5g are each independently selected from hydrogen, -CH ₂ -OC(O)R _17a and The above groups are independently optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl and trideuteriomethyl; provided that R _5d and R _5f are not H at the same time; R _17a is selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino, The compound of formula (I) according to claim 7, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that in the compound of formula (IVb1), formula (IVc1), formula (IVd1), formula (IVe1) or formula (IVf1), each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, _{C 2-4} alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium _{-substituted C 1-4 alkyl, C 2-4 alkenyl ,} C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C substituted by a _6-8 membered aryl group, a 5-8 membered heteroaryl group, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ; Each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -NR ₁₈ R ₁₉ and -C(O)R ₁₇ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _5a , each R _5b and each R _5c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR _{18 R 19} , and the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C substituted by a _6-8 membered aryl group, a 5-8 membered heteroaryl group, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ; Each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ; Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ; wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as described in claim 7; Preferably, each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl and 3-6 membered heterocyclyl, and the above groups are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, _{C 3-6} cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl and -C(O)R ₁₇ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted _{C 1-4} alkyl, ═O, ═S and -OR ₁₆ ; each R _5a , each R _5b , and each R _5c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, and C _3-6 cycloalkyl, which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , and -NR ₁₈ R _{19 ;} each R _5d and each R _5e is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -C(O)OR ₁₆ ; Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)OR ₁₆ , -OC(O)R ₁₇ and -NR ₁₈ R substituted by a substituent of ₁₉ ; wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ and r are as described in claim 7; More preferably, each R _1a and each R _1b are independently selected from hydrogen, deuterium, fluorine and chlorine; each R _1c is independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl, and -C(O)R _17a , which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriummethyl, ═O, ═S, and hydroxy; each R _5a , each R _5b , and each R _5c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, C _1-4 alkyl, and C _3-6 cycloalkyl, each of which is independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, hydroxyl, and amino; Each R _5d and each R _5e are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH ₃ , phenyl and The above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, -OR _16a and -C(O)OR _16a ; Each R _5f and each R _5g are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, -S-CH ₃ , phenyl and Alternatively, R _5f and R _5g together with the carbon atom to which they are directly attached form a cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, -OR _16a , -C(O)OR _16a and -OC(O)R _17a ; R _16a is selected from pyrimidinyl, pyridyl, phenyl, amino and dimethylamino; R _17a is selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino, The compound of formula (I) according to claim 6, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that the compound of formula (I) is a compound of formula (IVa2), formula (IVb2), formula (IVc2), formula (IVd2), formula (IVe2) or formula (IVf2):

Wherein, each ring A is independently selected from the following structures:
each R _1a , each R _1b , and each R _1c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ , and -NR ₁₈ R ₁₉ , which are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C 6-8 aryl and _3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c and the part to which they are directly attached together form a C _3-4 cycloalkyl or 3-4 membered heterocyclyl, R _5b or R _5c are otherwise defined as above, or, R _5a and R _5b and the carbon atom to which they are directly attached together form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ; Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ; each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R _8a and each R _8b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each s is independently 0 or 1; wherein R ₁₂ , R ₁₃ , R ₁₄ , R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r and n are as described in claim 6. The compound of formula (I) according to claim 15, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R _1a , each R _1b and each R _1c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, -OR ₁₆ and -NR ₁₈ R ₁₉ ; wherein R ₁₆ , R ₁₈ and R ₁₉ are as described in claim 15; Preferably, each R _1a , each R _1b , and each R _1c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino, and dimethylamino, and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino, and dimethylamino; More preferably, each R _1a , each R _1b and each R _1c are each independently hydrogen. The compound of formula (I) according to claim 15, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c together with the part to which they are directly attached form a C _{3-4 cycloalkyl} or 3-4 membered heterocyclyl, R _5b or R _5c is another definition as described above, or, R _5a and R _5b together with the carbon atom to which they are directly attached form C(＝CH ₂ ), R _5c is defined as described above, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen, C substituted by a C _1-4 alkyl group, a deuterium-substituted C _1-4 alkyl group, a C _3-6 cycloalkyl group, a 3-6 membered heterocyclic group, -OR ₁₆ and -NR ₁₈ R ₁₉ substituent; each R _5d and each R _5e are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5d and R _5e, together with the carbon atom to which they are directly attached, form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R _5f and each R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5f and R _5g , together with the carbon atom to which they are directly attached, form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as described in claim 15; Preferably, each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino; or, R _5a and one of R _5b or R _5c together with the part to which they are directly attached form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine or azetidinyl group, R _5b or R _5c are also defined as above; or, R _5a and R _5b together with the carbon atom to which they are directly attached form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; each R _5d and each R _5e is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxy, amino and dimethylamino; or, R _5d and R _5e, taken together with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino; each R _5f and each R _5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxy, amino and dimethylamino; or, R _5f and R _5g , taken together with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino; More preferably, each R _5a , each R _5b and each R _5c are each independently selected from hydrogen, deuterium and fluorine; each R _5d and each R _5e are each independently hydrogen; Each R _5f and each R _5g are each independently hydrogen. The compound of formula (I) according to claim 6, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that the compound of formula (I) is a compound of formula (IVa3), formula (IVb3), formula (IVc3), formula (IVd3), formula (IVe3) or formula (IVf3):
Wherein, each ring A is independently selected from the following structures:
Each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C 6-8 aryl and _3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c and the part to which they are directly attached together form a C _3-4 cycloalkyl or 3-4 membered heterocyclyl, R _5b or R _5c are otherwise defined as above, or, R _5a and R _5b and the carbon atom to which they are directly attached together form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ; Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ; each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R _8a and each R _8b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each s is independently 0 or 1; each t is independently 0, 1 or 2; wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r and n are as described in claim 6. The compound of formula (I) according to claim 18, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, -OR ₁₆ and -NR ₁₈ R ₁₉ ; each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, -OR ₁₆ and -NR ₁₈ R ₁₉ ; wherein R ₁₆ , R ₁₈ and R ₁₉ are as described in claim 18; Preferably, each R _1a and each R _1b are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino, and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino; Each R _1c is independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino, which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino. The compound of formula (I) according to claim 18, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c together with the part to which they are directly attached form a C _{3-4 cycloalkyl} or 3-4 membered heterocyclyl, R _5b or R _5c is another definition as described above, or, R _5a and R _5b together with the carbon atom to which they are directly attached form C(＝CH ₂ ), R _5c is defined as described above, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen, C substituted by a C _1-4 alkyl group, a deuterium-substituted C _1-4 alkyl group, a C _3-6 cycloalkyl group, a 3-6 membered heterocyclic group, -OR ₁₆ and -NR ₁₈ R ₁₉ substituent; each R _5d and each R _5e are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5d and R _5e, together with the carbon atom to which they are directly attached, form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R _5f and each R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5f and R _5g , together with the carbon atom to which they are directly attached, form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as described in claim 18; Preferably, each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino; or, R _5a and one of R _5b or R _5c together with the part to which they are directly attached form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine or azetidinyl group, R _5b or R _5c are also defined as above; or, R _5a and R _5b together with the carbon atom to which they are directly attached form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; each R _5d and each R _5e is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxy, amino and dimethylamino; or, R _5d and R _5e, taken together with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino; Each R _5f and each R _5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxy, amino and dimethylamino; or, R _5f and R _5g , together with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino. The compound of formula (I) according to claim 6, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that the compound of formula (I) is a compound of formula (IVa4), formula (IVb4), formula (IVc4), formula (IVd4), formula (IVe4) or formula (IVf4):

Wherein, each ring A is independently selected from the following structures:
each R _1a is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , the above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R _1b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , the above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C 6-8 aryl and _3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c and the part to which they are directly attached together form a C _3-4 cycloalkyl or 3-4 membered heterocyclyl, R _5b or R _5c are otherwise defined as above, or, R _5a and R _5b and the carbon atom to which they are directly attached together form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ; Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ; each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R _8a and each R _8b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each s is independently 0 or 1; wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r and n are as described in claim 6. The compound of formula (I) according to claim 21, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R _1a is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, -OR ₁₆ and -NR ₁₈ R ₁₉ ; each R _1b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , which are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, -OR ₁₆ and -NR ₁₈ R ₁₉ ; each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, -OR ₁₆ and -NR ₁₈ R ₁₉ ; wherein R ₁₆ , R ₁₈ and R ₁₉ are as described in claim 21; Preferably, each R _1a is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino, and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino; each R _1b is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino, which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; Each R _1c is independently selected from hydrogen, deuterium, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino, which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino. The compound of formula (I) according to claim 21, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c together with the part to which they are directly attached form a C _{3-4 cycloalkyl} or 3-4 membered heterocyclyl, R _5b or R _5c is another definition as described above, or, R _5a and R _5b together with the carbon atom to which they are directly attached form C(＝CH ₂ ), R _5c is defined as described above, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen, C substituted by a C _1-4 alkyl group, a deuterium-substituted C _1-4 alkyl group, a C _3-6 cycloalkyl group, a 3-6 membered heterocyclic group, -OR ₁₆ and -NR ₁₈ R ₁₉ substituent; each R _5d and each R _5e are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5d and R _5e, together with the carbon atom to which they are directly attached, form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R _5f and each R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5f and R _5g , together with the carbon atom to which they are directly attached, form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as described in claim 21; Preferably, each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino; or, R _5a and one of R _5b or R _5c together with the part to which they are directly attached form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine or azetidinyl group, R _5b or R _5c are also defined as above; or, R _5a and R _5b together with the carbon atom to which they are directly attached form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; each R _5d and each R _5e is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxy, amino and dimethylamino; or, R _5d and R _5e, taken together with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino; each R _5f and each R _5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxy, amino and dimethylamino; or, R _5f and R _5g , taken together with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino; More preferably, each R _5a , each R _5b and each R _5c are each independently selected from hydrogen, deuterium and fluorine; each R _5d and each R _5e are each independently hydrogen; Each R _5f and each R _5g are each independently hydrogen. The compound of formula (I) according to claim 6, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that the compound of formula (I) is a compound of formula (IVa5), formula (IVb5), formula (IVc5), formula (IVd5), formula (IVe5) or formula (IVf5):

Wherein, each ring A is independently selected from the following structures:
each R _1a is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -NR ₁₈ R ₁₉ , the above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R _1b and each R _1c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ , -C(O)NR ₁₈ R ₁₉ and -NR ₁₈ R ₁₉ , the above groups are optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C 6-8 aryl and _3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _r R ₁₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c and the part to which they are directly attached together form a C _3-4 cycloalkyl or 3-4 membered heterocyclyl, R _5b or R _5c are otherwise defined as above, or, R _5a and R _5b and the carbon atom to which they are directly attached together form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ＝O, ＝S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _5d and each R _5e are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5d and R _5e together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ; Each R _5f and each R _5g are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C 6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, 5-8 membered heteroaryl, -SF ₅ , -S(O) _{r R 15} , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5f and R _5g together with the carbon atom to which they are directly attached form _{a C 3-4 cycloalkyl} , 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C substituted by a substituent selected from: _3-6 membered cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, —SF ₅ , —OS(O) ₂ R ₁₅ , —S(O) _r R ₁₅ , —OR ₁₆ , —C(O)OR ₁₆ , —C(O)SR ₁₆ , —SC(O)R ₁₇ , —C(O)R ₁₇ , —OC(O)R ₁₇ , —P(O)(R ₁₇ ) ₂ , —NR ₁₈ R ₁₉ , —C(O)NR ₁₈ R ₁₉ and —N(R ₁₈ )-C(O)R ₁₇ ; each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R _8a and each R _8b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each s is independently 0 or 1; wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r and n are as described in claim 6. The compound of formula (I) according to claim 24, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R _1a is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)NR ₁₈ R ₁₉ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, -OR ₁₆ and -NR ₁₈ R ₁₉ ; each R _1b and each R _1c are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)NR ₁₈ R ₁₉ and -NR ₁₈ R ₁₉ , which are optionally further substituted by one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, =O, -OR ₁₆ and -NR ₁₈ R ₁₉ ; wherein R ₁₆ , R ₁₈ and R ₁₉ are as described in claim 24; Preferably, each R _1a is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, -C(O)NR ₁₈ R ₁₉ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino; each R _1b and each R _1c are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, -C(O)NR ₁₈ R ₁₉ and -NR ₁₈ R ₁₉ , which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; R ₁₈ and R ₁₉ are each independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine and azetidinyl. The compound of formula (I) according to claim 24, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R _5a and one of R _5b or R _5c together with the part to which they are directly attached form a C _{3-4 cycloalkyl} or 3-4 membered heterocyclyl, R _5b or R _5c is another definition as described above, or, R _5a and R _5b together with the carbon atom to which they are directly attached form C(＝CH ₂ ), R _5c is defined as described above, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen, C substituted by a C _1-4 alkyl group, a deuterium-substituted C _1-4 alkyl group, a C _3-6 cycloalkyl group, a 3-6 membered heterocyclic group, -OR ₁₆ and -NR ₁₈ R ₁₉ substituent; each R _5d and each R _5e are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5d and R _5e, together with the carbon atom to which they are directly attached, form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R _5f and each R _5g are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, C _6-8 aryl and 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; or, R _5f and R _5g , together with the carbon atom to which they are directly attached, form a C _3-4 cycloalkyl, 3-4 membered heterocyclyl or C(═CH ₂ ), which groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as described in claim 24; Preferably, each R _5a , each R _5b and each R _5c are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxyl, amino and dimethylamino; or, R _5a and one of R _5b or R _5c together with the part to which they are directly attached form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine or azetidinyl group, R _5b or R _5c are also defined as above; or, R _5a and R _5b together with the carbon atom to which they are directly attached form C(═CH ₂ ), R _5c is as defined above, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino and dimethylamino; each R _5d and each R _5e is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxy, amino and dimethylamino; or, R _5d and R _5e, taken together with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino; Each R _5f and each R _5g are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, phenyl, hydroxy, amino and dimethylamino; or, R _5f and R _5g , together with the carbon atom to which they are directly attached, form a cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl or C(═CH ₂ ), which are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxy, amino and dimethylamino. The compound of formula (I) according to claim 6, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , or R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(＝CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C 2-4 alkynyl, C _3-6 cycloalkyl _; wherein R ₁₆ , R ₁₈ and R ₁₉ are as described in claim 6; Preferably, each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino; or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(=CH ₂ ), C(O), cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine or azetidinyl group, and the above groups are independently optionally further substituted by one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl and cyclobutyl. The compound of formula (I) according to claim 6, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that the compound of formula (I) is a compound of formula (IVa6), formula (IVb6), formula (IVc6), formula (IVd6), formula (IVe6) or formula (IVf6):

Wherein, each ring A is independently selected from the following structures:
Each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R _8a and each R _8b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _11a and each R _11b are independently selected from hydrogen, deuterium, hydroxyl, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, sulfinyl, sulfonyl, methylsulfonyl, isopropylsulfonyl, cyclopropylsulfonyl, p-toluenesulfonyl, aminosulfonyl, dimethylaminosulfonyl and C _1-10 alkanoyl, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =0, C _1-4 alkyl, C 2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene _{, halogen-substituted C 1-4 alkyl} , deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C substituted with a C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C _6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino, and C _1-4 alkanoyl substituent; Alternatively, R _11a and R _11b together with the nitrogen atom to which they are directly attached form a 4-6 membered heterocyclyl, which is optionally further substituted with one or more substituents selected from the group consisting of deuterium, halogen, hydroxy, ═O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen _{-substituted C 1-4 alkylene} , deuterium-substituted C _1-4 alkylene, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkoxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C 6-8 aryloxy, 5-8 membered heteroaryl, 5-8 membered heteroaryloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino, and C _1-4 alkanoyl; wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r and n are as described in claim 6. The compound of formula (I) according to claim 28, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; each R _1c is independently selected from hydrogen, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl and -C(O)R ₁₇ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as described in claim 28; Preferably, each R _1a and each R _1b are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino, and the above groups are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, hydroxyl, amino and dimethylamino; each R _1c is independently selected from hydrogen, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, and -C(O)R _17a , which are optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, amino, and dimethylamino; R _17a is selected from cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino, dimethylamino, The compound of formula (I) according to claim 28, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R ₃ and each R ₄ together with the carbon atom to which they are directly attached form a C(=CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclic group, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl _; Preferably, each R ₃ and each R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine or azetidinyl group, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl and cyclobutyl. The compound of formula (I) according to claim 28, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R _11a and each R _11b are independently selected from hydrogen, hydroxyl, C _1-4 alkyl, C _3-6 cycloalkyl and -6-membered heterocyclyl, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, halogen, hydroxyl, =O, C _1-4 alkyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, 3-6-membered heterocyclyl, 3-6-membered heterocyclyloxy, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino and C _1-4 alkanoyl; Alternatively, R _11a and R _11b together with the nitrogen atom to which they are directly attached form a 4-6 membered heterocyclic group, which is optionally further substituted with one or more substituents selected from deuterium, halogen, hydroxy, ═O, C _1-4 alkyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene, halogen-substituted C _{1-4 alkyl} , deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C 3-6 cycloalkoxy, 3-6 membered heterocyclic group, 3-6 membered heterocyclic group, amino, mono-C _1-4 alkylamino, di-C _1-4 alkylamino and C _1-4 alkanoyl; Preferably, each R _11a and each R _11b are each independently selected from hydrogen, hydroxy, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine and azetidinyl, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, hydroxy, =0, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuterium, methylene, monofluoromethylene, difluoromethylene, methoxy, cyclopropyl, cyclobutyl, oxirane, oxetane, aziridine, azetidinyl, amino and dimethylamino; Alternatively, R _11a and R _11b together with the nitrogen atom to which they are directly attached form an oxirane, oxetanyl, oxolanyl, oxhexyl, aziridine, azetidinyl, azetyl, azetyl, azetyl or azetyl group. The above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine, hydroxyl, =0, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, methylene, monofluoromethylene, difluoromethylene, methoxy, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, amino and dimethylamino. The compound of formula (I) according to claim 6, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that the compound of formula (I) is a compound of formula (IVa7), formula (IVb7), formula (IVc7), formula (IVd7), formula (IVe7) or formula (IVf7):

Wherein, each ring A is independently selected from the following structures:
Each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _1c is independently selected from hydrogen, deuterium, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ , -C(O)R ₁₇ and -NR ₁₈ R ₁₉ , wherein the above groups are optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, =O, =S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R ₃ and each R ₄ are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ , or, R ₃ and R ₄ together with the carbon atom to which they are directly attached form a C(═CH ₂ ), C(O), C _3-6 cycloalkyl or 4-6 membered heterocyclyl, which groups are independently optionally further substituted by one or more groups selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, ═O, ═S, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R ₆ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; each R _8a and each R _8b is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -SF ₅ , -OS(O) ₂ R ₁₅ , -S(O) _r R ₁₅ , -OR ₁₆ , -C(O)OR ₁₆ , -C(O)SR ₁₆ , -SC(O)R ₁₇ , -C(O)R ₁₇ , -OC(O)R ₁₇ , -P(O)(R ₁₇ ) ₂ , -NR ₁₈ R ₁₉ , -C(O)NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; Each R _11a is independently selected from hydrogen, deuterium, hydroxyl, C _1-4 alkyl, C _1-4 alkylene, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl and 5-8 membered heteroaryl, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, C _3-6 cycloalkyloxy, _3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C substituted by _{a 6-8} membered aryloxy group, a 5-8 membered heteroaryl group, a 5-8 membered heteroaryloxy group, an amino group, a mono-C _1-4 alkylamino group, a di-C _1-4 alkylamino group, and a C _1-4 alkanoyl group; Each R _11b is independently selected from hydrogen, deuterium, hydroxyl, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl and 5-8 membered heteroaryl, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, _{C 3-6} cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C substituted by _{a 6-8} membered aryloxy group, a 5-8 membered heteroaryl group, a 5-8 membered heteroaryloxy group, an amino group, a mono-C _1-4 alkylamino group, a di-C _1-4 alkylamino group, and a C _1-4 alkanoyl group; Each R _11c is independently selected from hydrogen, deuterium, hydroxyl, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl and 5-8 membered heteroaryl, and the above groups are independently optionally further substituted by one or more selected from deuterium, halogen, hydroxyl, =O, C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _1-4 alkylene, halogen-substituted C _1-4 alkylene, deuterium-substituted C _1-4 alkylene, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _1-4 alkoxy, C _3-6 cycloalkyl, _{C 3-6} cycloalkyloxy, 3-6 membered heterocyclyl, 3-6 membered heterocyclyloxy, C _6-8 aryl, C substituted by _{a 6-8} membered aryloxy group, a 5-8 membered heteroaryl group, a 5-8 membered heteroaryloxy group, an amino group, a mono-C _1-4 alkylamino group, a di-C _1-4 alkylamino group, and a C _1-4 alkanoyl group; wherein R ₁₅ , R ₁₆ , R ₁₇ , R ₁₈ , R ₁₉ , r and n are as described in claim 6. The compound of formula (I) according to claim 32, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R _1a and each R _1b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ , and the above groups are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; each R _1c is independently selected from hydrogen, C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl and -C(O)R ₁₇ , which are optionally further substituted with one or more substituents selected from deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, C _6-8 aryl, 5-8 membered heteroaryl, -OR ₁₆ and -NR ₁₈ R ₁₉ ; wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as described in claim 28; Preferably, each R _1a and each R _1b are independently hydrogen; Each R _1c is independently hydrogen. The compound of formula (I) according to claim 32, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R ₃ and each R ₄ are independently hydrogen or deuterium. The compound of formula (I) according to claim 32, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R _11a is independently selected from hydrogen, deuterium, hydroxyl, methyl, ethyl and methylene, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine or hydroxyl; Each R _11b is independently selected from hydrogen, deuterium, hydroxyl, methyl and ethyl, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine or hydroxyl; Each R _11c is independently selected from hydrogen, deuterium, hydroxy, methyl, ethyl and methylene, and the above groups are independently optionally further substituted with one or more substituents selected from deuterium, fluorine, chlorine or hydroxy. The compound of formula (I) according to claim 6, its stereoisomer or a pharmaceutically acceptable salt thereof, characterized in that each Each is independently selected from the following structures:
each R _6a , each R _6b , each R _6c and each R _6d are each independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ and -NR ₁₈ R ₁₉ ; wherein R ₁₆ , R ₁₈ and R ₁₉ are as described in claim 6; Preferably, each Each is independently selected from the following structures:
Each R _6a , each R _6b , each R _6c and each R _6d are each independently selected from hydrogen, deuterium, fluorine, chlorine, bromine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy, amino, monomethylamino and dimethylamino. The compound of formula (I) according to claim 6, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R ₇ is independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, _3-6 membered heterocyclyl, -OR ₁₆ , -OC(O)R ₁₇ , -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as described in claim 6; Preferably, each R ₇ is independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, hydroxy, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy, amino, monomethylamino and dimethylamino. The compound of formula (I) according to claim 6, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that each R _8a and each R _8b are independently selected from hydrogen, deuterium, halogen, cyano, C _1-4 alkyl, halogen-substituted C _1-4 alkyl, deuterium-substituted C _1-4 alkyl, cyano-substituted C _1-4 alkyl, C _2-4 alkenyl, C _2-4 alkynyl, C _3-6 cycloalkyl, 3-6 membered heterocyclyl, -SF ₅ , -OR ₁₆ , -NR ₁₈ R ₁₉ and -N(R ₁₈ )-C(O)R ₁₇ ; wherein R ₁₆ , R ₁₇ , R ₁₈ and R ₁₉ are as described in claim 6; Preferably, each R _8a and each R _8b are each independently selected from hydrogen, deuterium, fluorine, chlorine, cyano, methyl, ethyl, n-propyl, isopropyl, trifluoromethyl, trideuteriomethyl, cyano-substituted methyl, vinyl, ethynyl, cyclopropyl, cyclobutyl, oxirane, oxetanyl, aziridine, azetidinyl, -SF ₅ , hydroxyl, methoxy, ethoxy, n-propoxy, isopropoxy, cyclopropyloxy, amino, monomethylamino and dimethylamino. The compound of formula (I) according to claim 1, its stereoisomer or pharmaceutically acceptable salt thereof, characterized in that it is selected from the following compounds:


A pharmaceutical composition comprising a compound of formula (I) according to any one of claims 1 to 39, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Use of a compound of formula (I) according to any one of claims 1 to 39, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating KRAS-related tumors. The use according to claim 41, characterized in that the KRAS-related tumor is a tumor associated with wild-type KRAS, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D or KRAS Q61H; preferably, the tumor is cancer. The use according to claim 41 is characterized in that the tumor is adenoma, lymphoma, mesothelioma, lung cancer, esophageal cancer, gastric cancer, pancreatic cancer, liver cancer, bile duct cancer, gallbladder cancer, ampullary cancer, small intestine cancer, colorectal cancer, kidney cancer, testicular cancer, blood cancer, hemangioma, myeloma, chondroma, skull cancer, brain cancer, glioma, uterine cancer, vulvar cancer, vaginal cancer, fallopian tube cancer, bladder cancer, urethra cancer, prostate cancer, adrenal tumor, sarcoma, myxoma, rhabdomyoma, fibroma, lipoma, bronchogenic carcinoma, Hodgkin's disease, malignant melanoma, basal cell carcinoma, squamous cell carcinoma, chondrodysplasia, psoriasis or neuroblastoma. A compound of formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 39, for use in treating tumors associated with wild-type KRAS, KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12R, KRAS G12S, KRAS G12V, KRAS G13D or KRAS Q61H.